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ABSTRACT 
Background and aims 
Early detection of oesophageal cancer is the most effective strategy to improve its 
outcome. The thesis explores the metabolic characteristics of oesophageal tumours as 
compared to normal tissue from same patients as well as that from healthy individuals. 
The aim is to characterise the basic metabolic profile of oesophageal cancer, detect 
possible evidence of field cancerization and to characterise effect of chemotherapy on 
oesophageal cancer tissue. The clinical benefit is to develop a non-invasive early test to 
be translated to the bed side/laboratory practice for screening, diagnosis and prediction of 
response to chemotherapy for patients with oesophageal tumours.    
Methods 
Using 1H Magic Angle Spinning – Nuclear Magnetic Resonance (MAS-NMR) 
spectroscopy of intact tissue, we generated metabolic profiles of tumour tissue, proximal 
histologically normal mucosa from cancer patients (PHINOM) and mucosa from a 
control group.  Using multivariate regression and receiver-operator characteristic analysis 
we were able to identify a panel of metabolites discriminating malignant and 
histologically-normal tissues from cancer patients from that of controls.   
Results 
While 26% and 12% of the spectral profile regions were uniquely discriminating tumour 
or control tissue respectively, 5% of the profile exhibited a significant progressive change 
in signal intensity from controls to PHINOM to tumour. Regions identified were assigned 
to phosphocholine, glutamate, myo-inositol, adenosine-containing compounds, uridine-
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containing compounds and inosine. In particular, the phosphocholine to glutamate 
metabolite ratio in histologically-normal tissue signified the presence of oesophageal 
cancer (n=123, AUC 0.84, p<0.001). Metabolites that were found to be significantly 
altered in correlation to response to chemotherapy are lysine, glutathione, creatine, 
taurine, uracil and tyrosine 
 
Conclusion 
The results of the study enable better understanding of the metabolic perturbations in 
oesophageal and cancer. The findings support the hypothesis that field effects are present 
in oesophageal cancer, even in the absence of Barrett’s oesophagus. This indicates that 
metabolic profiling of tissue can potentially play a role in the surveillance of cancer 
especially in high risk groups. It also shows the potential of using this methodology to 
study the prediction of response to chemotherapy. This helps aiding the clinical decision 
making process and the implementation of personalized treatment protocols for different 
patients according to their disease extent and potential for response to chemotherapeutics.  
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1.1 Cancer cell metabolism 
In spite of the significant advancements made in cell biology and the molecular biology 
of cancer over the past decades, cancer cell metabolism remains one of the least explored 
and forgotten areas of cancer biology and cancer therapy. Recently, increasing evidence 
has shown the potential role of cancer cell metabolism and its controlling factors for 
cancer development, progression and treatment. Objective evaluation of the data in this 
area is essential despite being in an early experimental and clinical stage. Attempts on 
this evaluation have been made possible by the introduction and extensive use of new 
methods and accurate techniques for the study of cell ultra structure, genomic, proteomic, 
transcriptomic and metabonomic cell mechanistics 1. The study of metabolic, m-RNA 
(messenger RNA), lysosomes, cell surface receptors, mitochondrial DNA (mt-DNA) as 
well as mitochondrial metabolism significantly advanced knowledge of cancer cell 
metabolism. Various new methods were developed to look at these variables from 
different aspects have been devised, most prominently advances in genomics, proteomics 
and metabonomics 2-9. Amongst those, metabonomics which is defined as “The 
quantitative measurement of the time-related multi-parametric metabolic response of 
living systems to patho-physiological stimuli or genetic modification”10. Metabonomics 
complements and enhances the information provided by genomics and proteomics 11 and 
has already shown promise in identifying metabolite-based biomarkers in ovarian, brain 
and liver cancers 12-14.  
It has been shown that there is a strong relationship between cancer cell metabolism and 
cancer cell structure, thus, the early detection of metabolic, and genetic abnormalities will 
be of value in predicting the outcome of cancer therapies (hormone therapy, 
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chemotherapy, cell differentiation therapy, cytokine therapy, gene and antisense therapy). 
Electron and proton transport across cell membranes, ion, and proton pumps (H+, K+, 
ATP ase), Calcium Ca2+ channels, oxidative phosphorylation involving ATP synthesis 
and some enzymes of tricarboxylic acid (Krebs cycle), metabolic oxidative stress and, 
antioxidants were shown to have considerable potential for providing biomarker pathway 
pools where direct significance to novel therapy development can be explored 15,16. 
Recent proteomic data have shown alterations of metabolic pathways in colonic cancer, 
these included glycolysis, gluconeogenesis, tricarboxylic acid cycle and purine / 
pyrimidine metabolism 17.  This was complemented by metabonomic data from 1H NMR 
spectroscopy studies showing significant increases in taurine, choline-containing 
compounds and lipid resonances in malignant colonic mucosa 18. These metabolic 
pathway changes subsequently change tissue metabolic profiles, which can potentially be 
detected and explored as potential biomarkers for cancer detection, staging, and can help 
tailoring treatment to patients according to their predicted prognosis 19. 
 
1.1.1 Mitochondrial metabolism and cancer 
Recent evidence strongly suggests that mitochondria, the power plants of cells producing 
energy needed for vital structural and functional maintenance, play an additional 
important role in cancer cell growth and proliferation. Under electron microscopy, 
mitochondria have two membranes, an outer smooth membrane and an inner membrane 
with multiple introflexions known as cristae. The inner compartment contains the matrix, 
a gel-like substance which is approximately 50% protein. The inner mitochondrial 
membrane contains the respiratory chain proteins which consist of electron transport, 
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succinate and NADH dehydrogenase activity, oxidative phosphorylation, or translocation 
phospholipid synthesis, and ATPase activity. The outer membrane and the protein-rich 
mitochondrial matrix contain the enzyme of the Krebs cycle fatty acid oxidation, 
elongation of fatty acids, and synthesis of phospholipids. The normal mitochondria 
membrane is impermeable to protons 20. Mitochondria are under the control of two 
genomes, their own (mt-DNA), and that of nuclear DNA, (n- DNA). This symbiosis 
allows mammalian cells to produce energy more efficiently via catabolism of glucose by 
an electron-proton transfer, and oxidative-phosphorylation reactions taking place in the 
tricarboxylic acid cycle (Krebs cycle). This produces ATP, lactic and pyruvic acid, and is 
essential for cell growth and survival. Molecular studies showed that human mt-DNA is a 
16,569-nucleotide pair, a closed circular molecule (compared to linear stranded double 
helix nuclear DNA), that codes for essential genes of oxidative phosphorylation plus the 
structural rRNA (ribosomal RNA) and tRNA (transfer RNA) necessary for their 
expression. Mt-DNA is maternally inherited, and thought to be of separate evolutionary 
origin, being derived from the circular genomes of the bacteria that were engulfed by the 
early ancestors of today's eukaryotic cells. Recent research has been centred on exploring 
the potential role of mitochondrial metabolism and mt-DNA in carcinogenesis, and in 
novel anticancer drugs development. For instance, it has been suggested that by reducing 
or suppressing the mitochondrial ATP production, which plays an important role in cell 
cycle progression, it would be possible to inhibit the cell cycle at the transition from G1 
to S and G2 to M phase; both are important checkpoints of cell cycle progression and cell 
growth. Electron microscopic studies revealed that cancer cells contain fewer 
mitochondria than normal cells, which also exhibit several perturbances as damaged 
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cristae and disrupted inner membrane. Such abnormalities could explain the role of 
mitochondria in carcinogenesis when carcinogens interact with mt-DNA as well as 
protein synthesis leading to dysfunctions of the respiratory chain and oxidative phos-
phorylation. In addition, it could point to a potential role of mitochondria in acquired 
resistance to chemotherapeutics. Therefore, mitochondria can become a central target for 
new cancer therapeutics which can fight carcinogenesis as well as facilitate response to 
other chemotherapeutics; for example, Rhodacyanine MKT-077 was found to have a 
selective cytotoxic damage in the mitochondrial ultra structure of carcinoma cells but not 
in similarly treated normal epithelial cells 1.  
 
1.1.2 Carbohydrate metabolism 
1.1.2.1  Glycolysis    
This is the process of metabolism of the glucose molecule and eventually converting it 
into two molecules of pyruvate. It is a set of reactions that occur in the cytosol. The most 
common type of glycolysis is the Embden-Meyerhof pathway (Figure 1.) 21. Glycolysis 
has three control elements: The first reaction is a control element, the conversion of 
glucose to glucose 6-phosphate catalysed by the enzyme hexokinase. This enzyme binds 
to the outer membrane of the mitochondrion. Hexokinase reduces the ATP to ADP and 
produces glucose 6-phosphate. Meanwhile, ADP enters the mitochondrion again and 
becomes an acceptor for phosphoryl groups. The second important step is the conversion 
of fructose 6-phosphate to fructose 1,6-bisphosphate catalysed by phosphofructokinase, 
which is the most important control element in glycolysis. Unlike the other control 
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elements hexokinase and pyruvate kinase, this is the only unique irreversible step in 
glycolysis (i.e. it catalyses the reaction of molecules that are strictly glycolytic 
intermediates). The third irreversible step in glycolysis is the reaction 
phosphoenolpyruvate–pyruvate, catalysed by pyruvate kinase. At the end of glycolysis, 
pyruvate is subject to four different metabolic fates. Under anaerobic conditions, 
pyruvate is reversibly converted into lactate; a second fate is to be transaminated into the 
amino acids alanine, valine and leucine. A third fate is to be carboxylated inside 
mitochondria into oxaloacetate, an intermediate of the citric acid cycle. And last but not 
least, is its conversion into acetyl-CoA inside mitochondria. This molecule can be the 
supplier of two-carbon fragments needed for the synthesis of lipids or it can enter the 
citric acid cycle if there is a need for ATP 22. 
 
1.1.2.2 The citric acid cycle 
The citric acid cycle, also called the tricarboxylic acid cycle or Krebs cycle, occurring in 
the mitochondria, is the final common pathway for the oxidation of glucose and other 
fuel molecules. Some intermediates can also be transaminated into amino acids. The first 
step in the cycle is the condensing of acetyl-CoA with oxaloacetate, thus generating a six-
carbon molecule: citrate. In the following steps citrate is again converted into 
oxaloacetate. The energy yield from the several steps is 3 NADH, 1 FADH and 1 GTP 
per molecule of pyruvate. The NADH and FADH molecules transfer their electrons to 
oxygen in the electron-transport chain to generate 3 ATP per NADH and 2 ATP per 
FADH. This is necessary for the continuity of the cycle, since a constant supply of the 
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electron acceptors NAD + and FAD+ is required for the cycle to proceed. Hence, the 
citric acid cycle is obligatorily aerobic 22.  
 
1.1.2.3 Pentose phosphate pathway 
This is a pathway that starts with some intermediates of glycolysis with the ability to 
produce NADPH, which serves as an electron donor in reductive biosynthesis. It takes 
place in the cytosol also, and is largely involved in the de novo synthesis of nucleic acids 
and therefore cell proliferation in vitro and in vivo 22. 
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Figure 1. Glycolysis 
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1.1.2.4 Glucose uptake in tumour cells 
‘Aerobic glycolysis’, uniquely observed in cancer, is the conversion of glucose to lactic 
acid in the presence of oxygen. This is known as the ‘Warburg effect’ 23. In 1926, Otto 
Warburg postulated that cancer cells originate due to a transition from aerobic energy 
metabolism of normal cells to an anaerobic metabolism with high anaerobic glycolysis 
and high lactic acid synthesis following injury to the cell respiratory system 24. However, 
radioisotopic studies done subsequently, revealed that cancer cells have the same ability 
to convert glucose (and fatty acids) to CO2 as normal cells do; therefore, high glycolysis 
and lactic acid production alone, cannot explain the origin of cancer cells 25,26. Although 
these studies defied the ‘Warburg hypothesis’, the experimental and clinical observation 
of increased glycolysis in tumours even in the presence of oxygen have been repeatedly 
reported 27. 
A normal cell derives most of its energy from oxidative phosphorylation, so the fact that, 
in a rapidly growing tumour cell, the citric acid cycle shows minor activity and the cell 
depends on glycolysis for more than half of its energy needs indicates a very important 
metabolic difference between a normal and a malignant cell 28. Besides producing of 
energy, glycolytic intermediates are also involved in two other features of growing 
tumours: enhanced DNA/RNA synthesis by means of the pentose phosphate pathway and 
the synthesis of lipids (out of fructose 1,6-bisphosphate), essential for membrane 
synthesis. The glycolytic capacity of a given tumour is now generally assumed to be 
characteristic of its state of differentiation 22,29,30. 
Singh et al. suggested that the promoting force for this increased glycolytic flux is the 
phosphorylation of glucose, the first reaction of the glycolytic pathway 31. This step is 
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catalysed by hexokinase and it is this enzyme that shows an increased activity in tumour 
cells 32,33. At least two factors contribute to this increased activity of hexokinase. One is 
the difference in binding to the outer membrane of the mitochondrion, the other is the 
overproduction of this enzyme in malignant cells compared to normal cells. That group 
also studied hexokinase in liver cells and found that the percentage of membrane-bound 
enzyme activity increases with the grade of malignancy, varying from about 30% of the 
total activity in normal liver cells to about 70% in dedifferentiated tumour cells 33. 
Another variable is p53, in normal cells, p53 acts as a cell-cycle checkpoint protein, thus 
halting the cell in Gl phase in the event of DNA damage. In one of the published 
experiments 34, there appeared to be a positive regulatory effect of mutated p53 (two 
point mutations in its cDNA were demonstrated) on the hexokinase pro-motor. In the AS-
30D hepatoma cells, p53 was highly abundant in its mutated form, with a longer half-life 
than wild-type p53 35. This could be the key to a possible link between loss of cell-cycle 
control in rapidly growing tumour cells and their propensity to catabolise glucose at high 
rates, one of the commonest biochemical signatures of cancer cells 22. 
 
1.1.2.5 Fluorodeoxyglucose and Positron Emission Tomography scanning 
The glucose analogue deoxyglucose, which has one oxygen atom less than the glucose 
molecule, is transported into the cell in the same way as glucose. Once it has reached the 
cytosol, it is phosphorylated to deoxyglucose 6-phosphate by the enzyme hexokinase, just 
like normal glucose. The next reaction in glycolysis, producing deoxyfructose 6-
phosphate, in effect a rearrangement of the carbonyl group from the C-1 to the C-2 
position in the ring structure, is not possible because this would require an oxygen atom 
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at the C-2 position. Thus, deoxyglucose 6-phosphate is trapped in the cell, as the reverse 
reaction to deoxyglucose does not take place because of the low concentration of glucose 
6-phosphatase in tumour cells. When labelled with 18F, PET can reveal this molecule. 
Hence, a high uptake of 18Ffluorodeoxyglucose (FdGlc) reflects an increased glucose 
metabolism in, for example, tumour cells 22. FdGlc PET is recognized to be an accurate, 
non-invasive tool for imaging, specific diagnosis and staging of a wide range of different 
tumours 37. Furthermore, it is even thought to be useful in the evaluation of cancer 
prognosis and efficacy of anticancer therapy 38; FdGlc PET measures the metabolic 
activity reflecting the inhibition of proliferative activity caused by anticancer therapy 39. 
Crippa et al. demonstrated that standardised uptake value of FdGlc was correlated with 
prognostic factors such as histopathological grading and p53 expression 40. 
Measuring metabolic activity in tumours has attracted special attention, especially since 
clinical studies on gliomas and lymphomas have shown that hypermetabolic tumours 
usually have a poorer prognosis than hypometabolic ones 41. However, a number of 
factors in scintigraphic tumour metabolic activity measuring should be taken into 
account. First, tumour inhomogeneity hampers the assessment of the real metabolic status 
of the tumour as a combination of activities of tumour cells; normal cells, matrix and 
premalignant cells are measured rather than pure tumour activity. Second, Kubota et al. 
42,43
 reported on that both invading macrophages and granulation tissue formed by the 
inflammatory reaction induced by tumours, showed a higher uptake of FdGlc than did 
viable tumour cells. Third, there is hardly any literature on the time period needed to 
lapse before the start of the scintigraphic examination. FdG1c uptake with time is most 
likely dependent on local parameters, such as mitotic activity and growth rate. Also early 
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uptake by inflammatory cells may falsify a positive result. Despite the increasing clinical 
use of FdGlc PET that has proved to be of great value in solving individual clinical 
problems, the issue of quantification remains unresolved.22.  
 
1.1.3 Amino acid metabolism 
Glutamine metabolism (Figure 2.) in cancer cells has long been reported to exceed the 
use of other nonessential amino acids 44,45. Glutamine is the most abundant free amino 
acid in the body 46 and plays a key role in intermediary metabolism for rapidly dividing 
cells such as enterocytes and cells of the immune system. Glutamine has been shown to 
be an unusually good substrate for oxidation by tumour cell mitochondria; predictably, 
tumour glutaminase activity is relatively high. Phosphate-dependent glutaminase converts 
glutamine to glutamate and ammonia and is the first step in a series of reactions that 
generate the metabolic intermediates required for cell growth. Glutaminase activity 
increases proportionally with tumour glutamine consumption and growth rates, and the 
low intracellular glutamine concentrations have been attributed, in part, to an increase in 
the activities of glutamine-using nucleotide biosynthetic enzymes and glutaminase. 
Physiologic concentrations of circulating glutamine are essential for optimal growth of 
malignant cells in culture. The tumour acts as a "glutamine trap". Malignant cells 
transport glutamine across their plasma cell membrane at a faster rate than do their non-
malignant counterparts. For example, human hepatoma cells consume glutamine at a rate 
five- to tenfold faster than do normal hepatocytes 47. Because solid tumours are poorly 
vascularized, it has been suggested that they are endowed with efficient transport systems 
to compete with the host for glutamine 47.   After glutamine enters the cytoplasm, it must 
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be transported into the mitochondria before it is hydrolyzed by phosphate-dependent 
glutaminase. In the majority of patients with cancer, glutamine depletion develops with 
time, both from the disease process itself and from the catabolic effects of antineoplastic 
therapies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Glutamine metabolism 
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CoA, malonyl-CoA, and nicotinamide adenine dinucleotide phosphate (NADPH) 48. In 
the liver and adipose tissue, FAS helps storage of energy derived from carbohydrate 
metabolism as triglycerides. In contrast, human cancer cells do not store significant 
amounts of triglycerides but esterify fatty acids to phospholipids, such as 
phophatidylcholine (Figure 3.) 48,49.  
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Simplified overview of tumour lipid metabolism. ACC = acetyl-CoA carboxylase; 
CDP = cytidine diphosphate; FAS = fatty acid synthase. Fatty acids are activated to acyl-CoA and 
in a 2-step reaction form diacylglycerides with glycerol 3-phosphate. These diacylglycerides then 
react with CDP-choline to form phosphatidylcholine 49. 
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Many malignant tumours, including lung, colon, breast, ovarian, and prostate cancer, 
have been shown to overexpress ChoK50. ChoK phosphorylates free choline to 
phosphocholine (PCho), which represents the first step of choline metabolism. Catalyzed 
by choline-cytidyltransferase (CCT), PCho can then react with CTP (cytosine 
triphosphate) to form cytosine diphosphate-choline (CDP-choline). The 
phosphorylcholine unit of CDP-choline is then transferred to a diacylglycerol (DAG) by 
cholinephosphotransferase (CPT) to form phosphatidylcholine (PC), a major constituent 
of the mammalian cell membrane 50,51. PC can be metabolized by 3 phospholipases 
(phospholipases A2, C, and D). These phospholipases hydrolyze different bonds of PC. 
Phospholipase A2 splits PC into lyso-PC and a free fatty acid (FFA), metabolism by 
phospholipase C results in PCho and DAG, and phospholipase D generates choline and 
phosphatidic acid 51. Thus, the intracellular choline levels are determined by both the rate 
of choline uptake as well as the rate of phosphatidylcholine synthesis and degradation 52.  
Choline kinase expression has been shown to be associated with particular cell stresses as 
polycyclic aromatic hydrocarbon carcinogens or carbon tetrachloride intoxication 53,54. 
These results indicate that choline kinase is a member of an acute responsive gene family, 
although the exact role of choline kinase induction as well as of newly generated PCho in 
various cell stresses are currently not fully revealed. PCho has also been shown to act as a 
second messenger in cell growth signaling 55. Several oncogenes such as ras, src, raf, and 
mos increase choline kinase activity when expressed in mouse fibroblasts 53. Likewise, 
transfection of human mammary epithelial cells with the erbB2 oncogene has been 
reported to cause a significant increase in P-Cho levels 56,57. Choline kinase activity and 
phosphocholine levels were generally not well correlated with proliferation rates 56,58 
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suggesting that activation of choline kinase cannot be explained alone with net PC 
synthesis by proliferating cells.  
Other studies found that due to the increase in total cell mass of the proliferating cancer, 
cells need a net increase in lipid biosynthesis, especially to serve increased 
membranogenesis, i.e. proliferating tumour cells are prolific lipogenic cells 59. 
Furthermore, biochemical alterations mainly detected in poorly differentiated and rapidly 
growing tumours, are related to modifications in lipid composition (e.g. decrease in 
polyunsaturated fatty acids and/or increase in cholesterol to phospholipid ratio) with 
subsequent alterations of membrane bi-layer fluidity and enzyme activities. Yet, little is 
known about the specific alterations at the level of mechanisms of intracellular 
compartmentalization responsible for biosynthesis, trafficking and turnover of the major 
phospholipid components (PL); thus at this time there is an established role of these 
molecules as both ‘passive’ structural building blocks of cell structure and ‘active’ 
regulators of cell function. Novel approaches such as metabonomics methods opened up 
new ways to investigate biochemical alterations occurring in tumours, notably at the level 
of phospholipid and lipid metabolism 60. 
 
1.1.4.1 Magnetic Resonance Spectroscopy (MRS) imaging of tumour lipid 
metabolism 
Earlier studies on significance of choline metabolites in human tumours used mostly 31P-
MRS. However, proton MRS was used with higher success due to its better sensitivity 
(owing to its very high abundance in tissues), consequently, improved spatial resolution 
(having much more distinct sharp peaks) compared with 31P-MRS 61. In proton (1H) 
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MRS, the total choline (tCho) peak is a measure of the concentration of choline, 
phosphocholine, glycerophosphocholine, betaine, and taurine 51. tCho has been shown to 
be increased in a variety of malignant tumours, including breast cancer prostate cancer 
and brain tumours 61. Another significant metabolic abnormality observed with MRS in 
brain tumours is a reduction of the neuronal marker N-acetyl aspartate (NAA) and total 
creatine (tCr, creatine and phosphocreatine) and an increase of tCho 62. The tCho 
concentration gradually increased from normal white matter to grade II astrocytomas and 
to grade III astrocytomas. However, the tCho signal falls in glioblastoma multiforme, 
which has been attributed to possible dilution of the signal by necrotic tissue 63. 
Variations of the tCho signal caused by differences in cellular density can be corrected by 
normalizing tCho by tCr 63-65. Compared with normal prostate tissue, prostate cancer 
demonstrates decreased levels of citrate and increased levels of tCho. Production and 
secretion of citrate is an important function of the human prostate 66. Citrate is 
synthesized from oxaloacetate (OAA) and acetyl-CoA by citrate synthase. The next step 
of citrate metabolism in the Krebs cycle is the isomerization of citrate to isocitrate by the 
enzyme aconitase. However, in the prostate the activity of aconitase is low and 
consequently citrate accumulates and is eventually secreted 66. Thus, the normal prostate 
gland is characterized by "aerobic glycoloysis" due to inhibition of Krebs cycle and 
consequently inhibition of oxidative phosphorylation 67. Consequently, the choline-to-
citrate ratio has been used to detect prostate cancer with MRSI and to differentiate 
prostate cancer from benign prostate hyperplasia 68. 
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1.1.4.2 Clinical applications 
PET with radio-labeled choline has been used successfully in study of prostate cancer, as 
this tumour is frequently negative on 18F-FDG PET 69. Furthermore, urinary excretion of 
11C
-choline is markedly lower than that of 18F-FDG, which facilitates evaluation of 
primary and recurrent tumours in the pelvis 70. Choline uptake of prostate cancer has not 
turned out to be closely correlated with grading and Gleason score 61,71-73. However, 
antihormonal therapy has been shown to decrease choline uptake of newly diagnosed 
prostate cancer 73. Choline was taken up by hyperplastic prostate tissue and by various 
inflammatory lesions, including chronic and acute prostatitis, which limited the 
specificity of choline PET for detection and correct localization of cancer foci within the 
prostate 74.  
 
1.2 Field cancerization 
For a long time, it has been postulated that cancer begins with multiple cumulative 
epigenetic and genetic alterations that sequentially transform a cell or a group of cells in a 
particular organ. One could extrapolate that the early genetic events might well lead to 
clonal expansion of pre-neoplastic daughter cells forming a particular tumour field, where 
subsequent genomic changes in some of these cells drive them towards the malignant 
phenotype. The fully transformed cells are readily identified histopathologically as 
cancers owing to changes in cell morphology. However, a population of cells with early 
genetic changes (without histopathology) remain in the organ, demonstrating the concept 
of field cancerization. Identification of molecular signatures in these genetically 
transformed but histologically normal cells have potentially excellent clinical utility; 
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namely in risk assessment, early cancer detection, monitoring of tumour progression and 
definition of tumour margins 75.  
The idea of field cancerization was initially conceived by Slaughter almost a decade prior 
to introducing the term in 1953. In an earlier publication he stated that; "cancer does not 
arise as an isolated cellular phenomenon, but rather as an anaplastic tendency involving 
many cells at once" 76. The term "lateral cancerization" was subsequently used to indicate 
that the lateral spread of tumours was due to progressive transformation of cells adjacent 
to a tumour, rather than the spread and destruction of the adjacent epithelium by pre-
existing cancer cells 77. In a more extensive study where histopathologic review of 783 
oral cancer patients was done, Slaughter used the term “field cancerization” to describe 
the existence of generalized carcinogen induced early genetic changes in the epithelium 
from which multiple independent lesions occur, leading to the development of multifocal 
tumours 78.  
At that time, the demonstration of the presence of histologically abnormal cells that are 
normal looking in close proximity to malignant cells was reported; these were considered 
part of the transformed cells in the tumour field, and consequently were suggested to be 
responsible for local tumour recurrences. These observations were made in the absence of 
modern molecular techniques, when the discovery of the genetic material was emerging. 
More assuring of the veracity of these observations, recent studies using various 
sophisticated genetic analyses have provided unequivocal evidence in support of the 
work of Slaughter 79. 
However, field cancerization theories could not explain exactly how these cancer fields 
develop. Some authors suggested that a particular carcinogen could have induced 
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multiple distinct genetic alterations in different cells resulting in polyclonal pre-
neoplastic lesions in adjacent tissue from which multiple tumours develop. Others 
believed that a single genetic event occurs in a cell that then clonally expands and 
laterally spreads to replace the normal epithelium, and therefore create a large area of 
pre-neoplastic field from which multiple tumours develop. Alternatively, an early genetic 
event occurring simultaneously in a group of cells such that subsequent genetic lesions 
drive some cells towards malignancy is another postulation.  Is it also possible that some 
field changes are created during organogenesis when some altered cells proliferate to 
generate a vast area of preconditioned epithelial surface, such that subsequent genetic 
lesions in some cells result in multiple cancers? While all these theories of field 
cancerization are possible, molecular data accrued from studies of head and neck, 
oesophagus, and bladder cancers support the clonal expansion model 80-82. This model is 
believed to possibly explain how multiple tumours develop in organs such as skin, colon, 
oesophagus, stomach, bladder, cervix, and vulva that have contiguous epithelium. In spite 
of its possibility, it is less likely that the spread of monoclonal cells can explain the 
development of multiple tumours in glandular tissues like the lung, breast, ovary, 
pancreas, and prostate as these have discontinuous glandular epithelial organization, even 
when exposed to the same carcinogen. Recent molecular techniques have enabled 
detection of alterations at all genomic levels. Epigenetic gene silencing, chromosomal 
anomalies, loss of heterozygosity (LOH), DNA sequence analysis for SNP and mutation 
detection, altered gene expression (transcripts and proteins), and mitochondrial genome 
changes have all been demonstrated in both precancerous lesions and normal appearing 
cells close to tumours 82-89.  
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Another issue to consider in explanation of field cancerization is mitochondrial genome 
mutations. The mitochondria produce almost all the energy required for cellular 
physiology, and an inevitable byproduct of this reaction is the generation of reactive 
oxygen species (ROS), which can damage nucleic acids, proteins and lipids. The 
mitochondrial genome is less protected and has an inefficient repair mechanism 
compared to the nuclear genome, and yet is bathed by ROS. Therefore, it has a high 
mutation rate, and this may signal the genesis of cancer 90. It is thus likely that the modest 
mt-DNA molecule might sustain early genetic damage, and thus an even earlier 
biomarker indicative of field cancerization compared to nuclear genomic alterations that 
have been extensively studied. 
Therefore, field cancerization can be viewed as a general phenomenon of epithelial 
tumours. An important physiologic function of epithelia is their protective role that 
inevitably exposes them to environmental substances, including carcinogens that can 
create a vast area of genetically altered cancer fields. Epithelial cells frequently self 
renew and can undergo abnormal proliferation. Hyperplastic epithelia could form the 
basis of neoplastic transformation leading to the formation of the most common types of 
cancers of the human body. Molecular signatures of field cancerization have been 
documented for several epithelial tumours including those of the head and neck 91, 
oesophagus 92, stomach 93, lungs 94, skin 95, cervix 96, vulva 97, bladder 98, colon 85, breast 
87
, ovary 99, pancreas 100, and recently the prostate 101. It has even been conceptualized in 
brain and hematologic malignancies 102,103.  
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1.2.1 Field cancerization in oesophageal and gastric cancers 
Development of oesophageal cancer in Barrett’s oesophagus has repeatedly served as a 
model to study clonality and tumour progression in field cancerization. Prevo et al. used 
p53 mutation as a clonal marker to map 213 endoscopic biopsies from 58 patients; the 
study demonstrated that 50% were clonal and occupied cancer fields ranging from 1 cm 
to 9 cm 80. Other genetic observations as LOH at 9p21 (p16 locus) and 17p13 (p53 locus) 
have also been used to map fields in the oesophagus 104. In 61 patients with 404 samples, 
LOH was observed in 73% of cases. Clone sizes were heterogeneous and variable in 
terms of field perimeters; some even occupied the entire Barrett's segment 104. Epigenetic 
gene silencing of APC, CDH1, ESR1 and p16 are examples of other studies on Barrett's 
oesophagus and its predisposition to cancer development. Hypermethylation in large 
contiguous fields were observed, further confirming molecular field cancerization in 
Barrett's metaplasia 105. In a prospective study where 267 patients were followed, it was 
demonstrated that clone sizes (which is an index of clones multiplied by the length of 
Barrett's segment they occupied) with p53 LOH and ploidy, were a better predictor of 
progression towards adenocarcinoma 106. Recently, a clonal cellular diversity theory 
attempted explanation of progression of Barrett's oesophagus towards adenocarcinoma; 
this was done by applying the principles of ecology and evolution, (mutation rate, 
population size of evolving clones, rate of natural selection or clonal expansion), clonal 
diversity was a strong predictor of disease progression, even after controlling for known 
risk factors such as p53 LOH and ploidy abnormalities 107,108. This finding is an example 
of how a laboratory observation can be translated into a clinically relevant test in terms of 
disease surveillance. However, the sensitivity and specificity and more importantly the 
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economic efficiency of such a test are factors that could potentially slow development 
down that route.  
On the other hand, genetic evidence has been provided for the multicentricity of 
synchronous multiple gastric cancers. Analysis of mutation pattern in genes as APC, 
MCC and p53 genes in multiple tumours concluded that there was discordance in 
mutation patterns in these tumours 109. Therefore, pointing to the possibility that 
independent genetic events in a preconditioned epithelium may have caused these 
multiple lesions. In addition, epigenetic silencing via CpG island hypermethylation of 
LIMS1, a gene involved in cell dispersion has been demonstrated in 53% of gastric 
cancers 93. Also, C-erb amplification was observed in a subset of tumours and the normal 
mucosa close to tumour margin 110, and aneuploidy was frequent in normal mucosa at 
about 3 cm distance from the tumour margin 111.  
Therefore, field cancerization has become a well-documented process of malignant 
transformation in oesophago-gastric tumours. With technological advancement, the future 
should benefit from well designed studies aimed at identifying genetic markers and 
pathways useful in disease management. An obvious shortcoming in almost all the 
studies of field cancerization is the lack of extensive genome-wide scans that will enable 
early and important genetic changes in tumour evolution to be uncovered. Many studies 
have relied heavily on known markers associated with a particular tumour. Such selected 
tumour markers might be later acquisitions in the disease process, and will be missed in 
peri-tumoural samples or precancerous lesions. Comprehensive high-throughput analyses 
for the discovery of early and relevant genetic and functional genomic changes that 
extend across global networks and represent modular alterations of multiple targets (or 
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surrogates) of terminal histologically differentiated stages of cancer subtypes will be 
essential for early detection, risk assessment and primary chemoprevention 75. 
 
1.3 Demographics of gastric and oesophageal cancer 
The demographics of gastro-oesophageal cancer have been changing dramatically across 
the Western world over the past several decades. While incidence rates for oesophageal 
squamous cell carcinoma and distal gastric carcinoma have been declining, the trends for 
adenocarcinoma of the oesophagus and proximal stomach have been raising rapidly 112. 
In spite of a decline in incidence of gastric cancer in developed countries, it remains the 
second most cause of cancer-related deaths in the world 2.  
Approximately 876 000 persons are diagnosed with the disease and approximately 649 
000 die from it every year 113. Although surgery plays a central role in the overall 
management of operable disease, it is clear that additional therapy is required to improve 
patient outcomes. The United Kingdom Medical Research Council Adjuvant Gastric 
Infusional Chemotherapy (MAGIC) trial demonstrated a 25% reduction in the risk of 
death and a significant improvement in 5 year survival in patients given perioperative 
chemotherapy compared to those treated with surgery alone 114. 
 
1.4 Molecular basis of chemotherapeutic effect on cancer tissues 
Chemotherapy is an integral part of management protocols of oesophageal and gastric 
cancer. Accepted approaches include preoperative chemotherapy followed by surgery 
(oesophageal cancer), chemo-radiotherapy alone (oesophageal cancer) and perioperative 
chemotherapy (gastric and gastro-oesophageal adenocarcinomas). The underlying 
principles behind neoadjuvant therapy are to improve resectability by tumour 
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shrinkage/downstaging and to treat occult metastatic disease as early as possible. The 
response rate to cytotoxic therapy is about 40% in oesophago-gastric cancer. Available 
evidence suggests that a favourable histopathological response to cytotoxic therapy may 
be a useful positive predictive marker in oesophago-gastric cancer. However, the ability 
to predict tumour response in routine clinical practice is difficult and is an area of intense 
investigation.  
Chemotherapeutics used to treat oesophageal cancer include 5-fluorouracil (5-FU), 
cisplatin, carboplatin, bleomycin, mitomycin, doxorubicin, methotrexate, paclitaxel, 
vinorelbine, topotecan, and irinotecan. In chemoradiotherapy, the most frequently used 
drugs are 5-FU and cisplatin given together 115. Many trials are currently underway to 
assess efficacy of different treatment combinations for management of gastro-
oesophageal cancer (Table 1.) 
Name Design Indication 
TOGA XP or FP +/- trastuzumab Advanced gastric cancer HER2-positive 
AVAGAST XP +/- bevacizumab Metastatic gastric cancer 
REAL-3 EOX +/- panitumumab Advanced esophagogastric cancer 
FFCD 03-07 
ECX followed by FOLFIRI vs 
FOLFIRI followed by ECX 
Advanced esophagogastric cancer 
 
EXPAND XP +/- Cetuximab Advanced/Metastatic gastric cancer 
MAGIC-B 
Periperative ECX +/- 
bevacizumab 
Neo-adjuvant gastric cancer 
CLASSIC XELOX vs observation Adjuvant gastric cancer 
 
Table 1. Examples of important ongoing Phase III clinical trials, including monoclonal 
antibodies and signal transduction/tyrosine kinase inhibitors  
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In the MAGIC trial (vide supra), surrogate markers of tumour response and downstaging, 
such as smaller primary tumours (3 cm vs 5 cm), early-stage tumours (T1 and T2 vs T3 
and T4), and less advanced nodal status (N0 or N1 vs N2 or N3) were significantly more 
frequently recorded in the perioperative chemotherapy group compared to the primary 
surgery group 114. Similar results have also been demonstrated in the MRC OEO2 trial of 
surgical resection with or without preoperative chemotherapy (consisting of two cycles of 
cisplatin and 5- fluorouracil (5-FU) chemotherapy) in oesophageal cancer 116. The 
seminal study by Mandard et al 117 reported on the predictive/prognostic significance of 
histopathological response to cytotoxic therapy in oesophageal cancer specimens 
following neoadjuvant chemo-radiotherapy. It is to be noted that specimens used in that 
study were predominantly squamous cell carcinomas. Tumour regression grade (TRG) 
analysis was used as a marker of treatment response and was undertaken and scored from 
complete regression (TRG1) to absent regression (TRG5). Of 93 patients, 42% were 
TRG1–2, 20% TRG3 and 33% were TRG4–5. Tumour size, pathological lymph node 
status, TRG and oesophageal wall involvement correlated highly with disease-free 
survival. On multivariate analysis, however, only TRG (TRG1–3 vs TRG4–5) remained a 
significant (p=0.001) predictor of disease-free survival 117. Similar results for gastric 
cancer patients receiving neoadjuvant chemotherapy were demonstrated in another study 
where survival benefit was shown to be significantly improved in the group of patients 
where histopathological evidence of response to cytotoxic therapy was achieved 118.  
One of the arguments against preoperative therapy has been the risk of delaying surgery 
in those patients who do not respond to chemotherapy, in spite of the fact that current 
evidence suggests that preoperative treatment does not negatively impact on surgical 
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outcomes 114. Therefore, predictive markers of response would be of unequalled 
significance in individualizing patient treatment as it would preclassify those patients 
likely to respond to combination therapy from those likely to be non-responsive and may 
progress during therapy. 
 
1.4.1 Predictive biomarkers in oesophago-gastric cancer 
The role of predictive biomarkers has been well established in solid tumours such as in 
breast cancer (Her-2 overexpression predicts response to herceptin and oestrogen receptor 
positivity predicts tamoxifen response), chronic myeloid leukaemia (breakpoint cluster 
region–Abelson murine leukaemia oncogene (BCR–ABL) translocation predicts response 
to imatinib mesylate), lung cancer (epidermal growth factor receptor (EGFR) kinase 
domain mutations predict response to erlotinib or geftinib), brain tumours (EGFR 
mutations in the extracellular domain and response EGFR inhibitors) and colonic cancer 
(mutations in KRAS predict response to EGFR specific antibody therapy) 115.  
Conventional protocols are being used to treat gastro-oesophageal tumours based on their 
site of origin rather than taking into account their biological characteristics. Current 
clinical parameters such as TNM staging, tumour location, sex and histological subtype 
are unable to help predict non-responders to chemotherapy. Recent molecular biology 
research has confirmed that the cancerous phenotype is a sum total of genetic and 
epigenetic changes that confer selective survival advantage to clones of cells we define as 
cancer. Similarly, the ultimate response to chemotherapy is also likely to be dictated by a 
sum of the genetic make-up of tumours and the various cellular metabolic pathways they 
may initiate. Search for an ideal biomarker for prediction of response to chemotherapy 
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has been the daunting task of many research groups working on various cellular genomic 
and functional genomic levels. An ideal predictive marker should be reliable, readily 
available, and detectable by reasonably acceptable laboratory techniques.  
 
1.4.2 Chemotherapeutics used in gastric and oesophageal cancers 
Alkylating agents (cisplatin and oxaliplatin), 5-FU, capecitabine, anthracyclins and 
ionising radiation are the predominant cytotoxic agents used in the treatment of 
oesophago-gastric cancer. Induction of DNA damage in cancer cells is the main cytotoxic 
effect of systemic chemotherapy and radiotherapy. The cellular responses involved in 
mediating the cytotoxicity of these agents are complex. Predictive biomarkers have been 
investigated at a genetic level (eg, polymorphisms), transcriptional level (mRNA 
expression) or at the protein level. Cells respond to the cytotoxic effect of 
chemotherapeutics in variable ways. 
 
1.4.2.1 5-Flourouracil metabolism pathway 
5-FU belongs to the family of drugs known as antimetabolites and principally acts via 
inhibition of DNA and RNA synthesis 119,120.  The predominant mechanism for the 
cytotoxicity of 5-FU is via ‘‘thymineless death’’. Upon entering cells, 5-FU is converted 
to 5-fluorodeoxyuridine (5- FUDR) by the enzyme thymidine phosphorylase (TP). 5-
FUDR is converted to 5-fluorodeoxyuridine monophosphate (5-FdUMP) by thymidine 
kinase (TK). 5-FdUMP competes with endogenous deoxyuridine monophosphate 
(dUMP) for binding to thymidylate synthase (TS) in a complex that is stabilised by 5,10-
methylenetetrahydrofolate (CH2THF) (the enzyme methylenetetrahydrofolate reductase 
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(MTHFR) converts CH2THF to 5-methyltetrahydrofolate) (Figure 4.). Binding of 5-
FdUMP to TS depletes the thymidine nucleotide pool and hence DNA synthesis. Though 
the exact molecular mechanisms are unclear, recent studies suggest that depletion of 
dTMP leads to imbalances in the deoxynucleotide pool and accumulation of dUMP and 
dUTP which may be incorporated into the DNA 121. In addition, 5-FU is also converted to 
5- fluorouridine monophosphate (5-FUMP), by the action of orotate 
phosphoribosyltransferase (OPRT). 5-FUMP is converted to 5-fluorouridine diphosphate 
(5-FUDP) and then to 5-fluorouridine triphosphate (5-FUTP), which inhibits RNA 
synthesis.  
Capecitabine is also an anti-metabolite belonging to the fluoropyrimidine carbonate class. 
It is an orally administered precursor of 5-FU and is converted to 5-FU by 
carboxyesterase (CE), cytidine deaminase (CD) and TP (Figure 4.). The daily oral 
administration of capecitabine parallels the intravenous infusion of 5-FU in efficacy, yet 
with more patient and health care system convenience 122. S-1 is another orally available 
5-FU derivative; it combines three pharmacological agents: tegafur, a pro-drug of 5-FU; 
gimeracil, which reversibly inhibits DPD (the enzyme involved in inactivation of 5- FU); 
and potassium oxonate, which reversibly inhibits the enzyme responsible for 
phosphorylation of 5-FU (orotate phosphoribosyltransferase) thereby reducing the 
gastrointestinal side effects of 5-FU 123.  
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Figure 4. The metabolic pathway of 5-fluorouracil (5-FU). Possible predictive factors  of 
response within this pathway are shown in green. CD, cytidine deaminase; CE, 
carboxyesterase; 5-DFUR, 59-deoxy-5-fluorouridine; DPD, dihydropyrimidine dehydrogenase; 
DHFU, dihydrofluorouracil; 5-FU, 5-fluorouracil; OPRT, orotate phosphoribosyltransferase; PO, 
potassium oxonate; TK, thymidine kinase; TP, thymidine phosphorylase; TS, thymidylate 
synthase. 
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1.4.2.2 Platinum compounds 
Cisplatin and oxaliplatin are the main platinating agents used in the treatment of 
oesophageal and gastric cancer. Cytotoxicity is predominantly due to their ability to 
generate free radicals and bind to DNA and produce cross-links leading to DNA damage. 
Therefore, DNA repair capacity represents the major factor affecting the therapeutic 
efficacy in cancer cells (Figure 5). The nucleotide excision repair (NER) pathway is the 
predominant DNA repair pathway that is involved in the repair of bulky DNA-damaging 
lesions induced by platinating agents. NER is a highly conserved, versatile and robust 
DNA repair pathway that deals with a wide range of DNA lesions such as those that 
distort the DNA double helix, DNA base pairing and interfere with DNA replication and 
transcription. Two sub-pathways of NER have been described in literature: (1) the 
transcription-coupled nucleotide excision repair (TCR) pathway which targets lesions 
specifically in the transcribed strand of expressed genes; and (2) the global genome 
nucleotide excision repair (GGR) pathway which deals with lesions in the rest of the 
genome. Free radicals generated either by radiation or platinating agents may also induce 
oxidative DNA base damage that is predominantly repaired in base excision repair (BER) 
machinery. Glutathione S-transferases (GSTs) have been shown to be crucial enzymes 
involved in detoxification of platinating agents. Among the various isoforms of GSTs, 
GST pi has been shown to bind to platinum and also allows its export from the cytosol 
using an MDR energy-dependent efflux pump mechanism 115.  
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Figure 5. Pathways involved in the repair of platinating agents and ionising radiation are 
summarised here. Predictive markers within the pathways are shown in bold. AP, 
apurinic/apyrimidinic; ERCC, excision repair cross-complementing group; FEN-1, flap structure 
specific endonuclease 1; PCNA, proliferating cell nuclear antigen; RAD23B, RAD23 homolog B; 
RPA, replication protein A; RFC, replication factor C; XPA and XPC, xeroderma pigmentosum 
complementation groups A and C; XRCC1, x ray cross-complementation group 1. The TFIIH 
complex is cdk7, cyclin H, maturationassociated protein 1 (MAT1), xeroderma pigmentosum 
complementation groups B and D (XPB and XPD), p34, p44, p52 and p62. 
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1.4.2.3 Other chemotherapeutics used in gastric and oesophageal cancer treatment 
Other chemotherapeutic agents used in the treatment of oesophago-gastric cancer include 
docetaxel which is a taxane analogue that inhibits microtubule disassembly 124 and 
irinotecan which is a topoisomerase I inhibitor 125.  
 
1.4.3 Factors affecting cancer cell death and response to chemotherapy 
1.4.3.1 Apoptosis 
The mechanism by which cancer cells die is complex and may include necrosis, mitotic 
catastrophe and apoptosis (programmed cell death). It has been well documented that 
chemotherapy and irradiation initiate cell death mainly through apoptosis. There are at 
least two known pathways of apoptosis in cells: (1) the extrinsic pathway that is activated 
by interaction with death receptors on the cell surface; and (2) the intrinsic pathway 
largely mediated by the mitochondria. Chemotherapy and irradiation initiate apoptosis 
through the mitochondrial (intrinsic) pathway. However, this is tightly controlled by pro-
apoptotic and antiapoptotic factors. These factors have been considered potentially 
important predictive markers in oesophago- gastric cancer 115.  
1.4.3.2 Survivin 
Is a prominent member of the inhibitor of apoptosis (IAP) family that halts the activation 
of downstream checkpoints of apoptosis such as the caspases126. Survivin expression may 
be the reason behind resistance to cisplatin-induced apoptopsis during chemotherapy. In a 
study of 42 patients with gastric cancer the mRNA expression of surviving and its 
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relationship between expression and sensitivity of cisplatin (CDDP) was examined. 
Survivin was frequently upregulated in gastric cancer tissue and was negatively 
associated with overall survival in patients in that study 127. Another study of 51 patients 
with oesophageal squamous cell cancer receiving cisplatin and 5-FU neoadjuvant 
chemotherapy showed that survivin expression in the cancer tissue in patients who 
achieved a partial response was significantly lower than that in patients with no response 
or those with progressive disease 128. 
1.4.3.3 Bax 
A study by Kang et al. in 63 patients treated by definitive chemo-radiotherapy for locally 
advanced oesophageal cancer, examined protein expression of Bax, p53, Bcl-2 and 
galectin-3 in pre treatment biopsy specimens. Low expression of Bax was significantly 
correlated with a lack of clinical complete response. In addition the low expression of 
Bax was associated with a poor overall median survival of 8 months vs. 16 months in the 
other group 129. 
1.4.3.4 Cyclooxygenase-2 (COX-2) 
Although the molecular mechanism is not clear, COX-2 may be involved in the 
upregulation of factors that promote cell survival. High levels of COX-2 have been 
reported in oesophageal 130 and gastric cancers 131. Over-expression of COX-2 has been 
found to be associated with resistance to apoptosis. In a study of 52 patients with 
resectable oesophageal cancer following neoadjuvant chemo-radiotherapy, high COX-2 
protein expression levels seem to be significantly associated with poor prognosis and a 
poor histopathological response to chemotherapy 132. 
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1.4.3.5 Transcription factors 
1.4.3.5.1 TP53 (p53) 
TP53 (p53) is widely accepted to be an important transcription factor involved in key 
cellular activities as cell cycle regulation, apoptosis and DNA repair. Mutation of p53 is a 
hallmark of many cancers. Mutant p53 tends to be resistant to degradation and hence p53 
protein expression in tumours is considered a surrogate marker of p53 mutation and 
therefore may correlate with tumour resistance. p53 negativity has been correlated with 
good tumour response in gastric cancer 133. On the other hand, the results have been 
conflicting in oesophageal cancer. While one study suggests that p53 negativity may 
correlate positively to tumour response 134, other studies did not find any correlation 
between p53 protein expression and response to cytotoxic therapy 135,136. Also, another 
study suggests that p53 mutations may correlate with complete pathological response and 
improved survival 137. 
1.4.3.5.2 Nuclear factor kappa B 
Nuclear factor kappa B (NF-kB) protein expression was studied in 43 patients with 
oesophageal cancer (both squamous cell and adenocarcinomas) who underwent 
neoadjuvant chemo-radiotherapy. NFkB positivity correlated with lack of tumour 
response and poor overall survival 138. 
1.4.3.5.3 Hypoxia-inducible transcription factor-1 (HIF-1) 
The hypoxic microenvironment is being believed to selects cells that are capable of 
evading apoptosis and survive in the absence of normal oxygen availability. Tumour 
hypoxia is an important factor in induction of angiogenesis within tumours. Therefore, it 
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is accepted that the hypoxia-inducible transcription factor-1 (HIF-1) mediated pathway is 
critical for tumour angiogenesis 139. HIF-1 transcription factors cause the overexpression 
of several genes that control various biological processes necessary for tumourigenesis 
such as cell proliferation, apoptosis, immortalisation, migration and angiogenesis (VEGF 
expression) 139. In a recent study in gastric cancer, patients with VEGF negative tumours 
had response rates very similar to VEGF positive tumours. However, median survival in 
VEGF negative tumours was significantly longer than in VEGF positive tumours. This 
points out the prognostic significance of VEGF in gastric cancer 140.  Multiple other 
pathways have also been identified as being strong effectors of the mechanism of cellular 
resistance to chemotherapeutics, these include but not exhaustive of Multi-drug resistance 
related protein-1 (MRP-1) and multidrug resistance related gene-1, tyrosine kinases, 
messenger RNA expression levels of c-erb-B1 and c-erb-B2, EGFR protein expression, 
Caldesmon and also polymorphisms of glutathione S-transferases.  
The studies described above have focused on a single marker or a set of markers targeting 
a specific pathway or a set of pathways that may be involved in cellular response to 
cytotoxic agents. However, as emphasized before that the cancer phenotype is a sum total 
of genetic and epigenetic alterations and, therefore, the ultimate response to cytotoxic 
therapy in cancer is also likely to be dictated by these genetic and epigenetic changes 
involving perhaps several thousands of genes within the cancer genome. Recent advances 
in genomics, proteomics and metabolomics have for the first time provided tools of 
global profiling of a biological set in order to make it possible to explore these 
genome/proteome/metabolome wide marker patterns 141. 
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1.4.4 Gene expression profiling in oesophago-gastric cancer  
Gene expression profiling has been less well researched in gastric and oesophageal 
cancer as compared to other tumours as breast cancer 142. However, valuable insights 
have been given in a few recent studies in patients with oesophageal cancer treated with 
neoadjuvant chemo-radiotherapy. In one study of nineteen patients 143, approximately 400 
genes were differentially expressed between the two groups; the molecular profile 
generated by gene expression analyses of pre-treatment endoscopic biopsies was 
correlated with pathological response. Unsupervised hierarchical cluster analyses 
separated tumours into two molecular subtypes. Pathological complete response was seen 
in six of the nineteen patients (32%); five of the six patients clustered into subtype I 
suggesting that gene signatures may predict response. In addition, survival rate was less 
in molecular subtype II. Genes involved in apoptosis, calcium homeostasis, stress 
response and proliferation was differentially expressed in both groups 143; down 
regulation of epidermal differentiation complex (EDC) genes (S100A2 and SPRR3) at 
chromosome 1q21 was associated with resistance to chemotherapy. A subsequent study 
by the same group has provided further evidence that expression levels of genes mapping 
within and close to the EDC may determine sensitivity to chemo-radiotherapy 144. 
Another study in 33 oesophageal squamous cell carcinomas treated with chemo-
radiotherapy identified 57 genes that correlated with short-term survival, and 120 genes 
with long-term survival. Genes up regulated in long-term survivors were largely those 
involved in immune response, additionally, immunohistochemical staining suggested that 
the effects of chemo-radiotherapy were correlated with CD8 positive staining in long-
term survivors 145. Duong et al. were able to identify a 32-gene mathematical model that 
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could predict response to neoadjuvant chemo-radiotherapy in squamous cell carcinomas 
146
.  The most interesting gene from this study was the gene Siah2, which is known to 
induce expression of hypoxia-inducible transcription factors. Decreased expression of 
that gene was seen in patients with squamous cell carcinoma who had CT, 
endoscopy/biopsy and FDG-PET proven complete response to chemoradiotherapy 146.  
The aforementioned studies may provide preliminary data on the role of potential 
biomarkers in oesophago-gastric cancer. However, published studies are limited and 
patient numbers are too small to provide convincing evidence that this approach is 
feasible in routine clinical practice. Therefore, whether predictive markers will be 
routinely incorporated in clinical practice remains to be seen. Biomarker research is 
expensive and the data generated from these investigations are complex. It is clear that a 
concerted international effort between academia and industry is critical if practice of 
personalised medicine for our cancer patients is to be realised. 
 
1.5 Pathology and staging of oesophageal cancer 
Once diagnosis of gastric and oesophageal caner is made, the subsequent question is the 
staging of these tumours as this will dictate subsequent management protocols. The 
staging system proposed by the Union Internationale Contre le Cancre (UICC). This is 
the most widely used system for dictating management policies in oesophageal cancer 
patients (Table 2, 3.) 147.  
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T PRIMARY TUMOUR  
Tis Carcinoma in situ 
T1 Invades lamina propria or submucosa 
T2 Invades muscularis propria 
T3 Invades periesphageal tissue 
T4 Invades adjacent structures 
N REGIONAL LYMPH NODES 
N0 No regional node involvement 
N1 Regional node involvement 
N1-4 More distant node involvement 
M DISTANT METASTASIS 
M0 No distant metastasis 
M1 Distant metastasis 
Table 2. UICC TNM designations  
 
STAGE TNM DESIGNATION 
0 Tis N0 M0 
I T1 N0 M0 
IIA T2-3 N0 M0 
IIB T1-2 N1 M0 
III T3 N1 M0, T4 any N M0 
IV Any T Any N M1 
Table 3. Disease stage with corresponding TNM designation 
 
1.6 Diagnosis and multimodality management of gastro-oesophageal cancer 
The multidisciplinary management of gastric and gastro-oesophageal cancers, in 
diagnosis as well as in treatment strategies has become the standard of care now after 
results of recent randomised studies became available. The time has come for the launch 
of multimodal treatments to increase the chance of better outcome, longer survival or 
even cure. By using this team approach, all diagnostic and therapeutic disciplines, such as 
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the gastroenterologist, surgeon, oncologist, radiologist and radiotherapist, will be 
instrumental in planning the effective administration of their treatment modalities. The 
diagnostic arsenal, i.e. CT scan, endoscopic ultrasound (EUS), mini-laparoscopy, MRI 
and PET, allows improved pre- or postoperative staging 148. For endoscopically large 
tumours and tumours of the gastro-oesophageal junction in particular, CT scan of the 
abdomen/thorax and EUS are mandatory for an exact preoperative tumour and node 
metastases staging. EUS allows the differentiation between small and large tumours as 
well as staging or biopsies of mediastinal and celiac lymph nodes. In addition, mini-
laparoscopy is a valuable tool, as peritoneal carcinosis is found in about 20% to 30% of 
all gastric cancer patients at first diagnosis 149. As PET scan has also been shown to 
effectively predict clinical response in oesophageal and gastric cancer, it might 
potentially allow better allocations and adjustments for further individualized and 
optimized treatment strategies. Staging with PET may best be used either in patients with 
locally advanced disease who may benefit from curative resection, if distant metastases 
are not found, or in patients with high-grade stenosis, where EUS is not applicable 148. 
The accuracy of EUS for assessing T and N status has been reported to be 85% and 75%, 
respectively, while the sensitivity of CT for staging T and N disease has been reported to 
be about 50% and 60–87%, respectively. Thus, the combined use of all three modalities 
(CT, EUS, PET) is often needed for initial staging of oesophageal cancer 150. Most 
centres in the UK offer endoscopic surveillance for predisposing conditions as Barrett’s 
oesophagus with the aim to detect early, curable lesions. Surveillance in its current form 
is cumbersome and expensive 151. 
 56 
Depending on tumour stage, current treatment options for oesophageal and gastric cancer 
range from endoscopic mucosal resection to preoperative chemo- radiotherapy followed 
by oesophagectomy or gastrectomy and associated radical lymphadenectomy (D2 
Gastrectomy) with a curative intent is done to remove the tumour and all draining lymph 
node groups, thus achieving an R0 resection margin; this has now become the standard of 
care. This is further augmented with post operative chemotherapy and/or radiotherapy 
according to number and position of lymph nodes involved. Most of these therapeutic 
approaches are associated with substantial morbidity and mortality, as well as a long-term 
compromise in quality of life. Accurate pre-therapeutic staging by imaging techniques is 
therefore crucial in order to select the appropriate form of therapy 152. Although surgery 
remains the standard treatment for non-disseminated gastric and oesophageal cancer, a 
variety of combined modality treatments have been investigated in order to induce 
downstaging of the tumour, improve local control, treat micro-metastases, and ultimately 
improve long term survival. For example, induction chemotherapy given before surgery 
has been shown to improve outcome in subgroups of patients as reported in recent large 
prospective randomized trials such as the UK Medical Research Council (MRC) trial for 
oesophageal cancer 116 and the presentation of the first survival results of the MRC 
Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial 114.  
However, no indicators exist which can reliably predict response to chemotherapy. 
Histological grading of oesophageal tumours has been used as a prognostic indicator in 
patients treated with combined neoadjuvant therapy and surgery. It is important to 
identify non-responders so that unnecessary, potentially harmful treatment is not given to 
those who will not benefit 153,154. Many molecular markers have been proposed as 
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predictors of response e.g. P53, Ki-67, yet none with reliable significance. PET, as a 
complementary investigation to cross-sectional imaging studies has been shown, in two 
studies, to differentiate responding from non-responding tumours early in the course of 
neoadjuvant systemic chemotherapy 155,156. This is based on the fact that it is considered 
as a “metabolic” imaging study that relies on differences between tumour cell glucose 
metabolism and that of normal cells. In follow up of patients, the changes in tumour 
metabolic activity may be employed to individualize the use of chemotherapy in patients 
with oesophageal and gastric cancer10,157. 
1.7 Outcome of gastro-oesophageal tumours 
Gastro-oesophageal cancer is a highly lethal disease with a 5-year mortality >80%. Even 
after intended curative surgery, overall survival remains poor. In approximately two-
thirds of the patients local recurrences and/or distant metastases are detected within five 
years of follow-up 160. In approximately 30% of patients undergoing surgery, who were 
clinically considered to have resectable disease, radical excision with curative intent 
could not completely eliminate microscopic residuals of the disease as noted on 
pathological examination of surgical specimens 161. The shortcomings in current 
diagnosis and staging tools for gastric and oesophageal cancer indicate that the actual 
patient selection for multimodality treatment and the assessment of their outcome 
remains unreliable 162. Hence, the need for a non-invasive diagnostic test that assesses 
tumour type, behaviour, stage or even predicts histopathological response to preoperative 
therapy has been emphasized by many investigators 152. 
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1.8 Barrett’s disease 
It is defined as columnar metaplasia of normal oesophageal squamous epithelium of 
lower oesophagus due to chronic gastro-oesophageal acid reflux. It is thought to be a 
precursor to adenocarcinoma of the oesophagus. It increases risk of developing 
malignancy to 40-50 times that of normal epithelium 163. Histopathological examination 
can accurately distinguish between normal and malignant epithelium, nevertheless, it 
cannot predict the potential for malignant transformation in Barrett’s epithelium 164. 
Immuno-histochemical studies searching for detectable markers have been recently 
focusing on predicting progression from intestinal metaplasia to dysplasia and low-grade 
to high-grade dysplasia/ adenocarcinoma. Many groups have been working on projects to 
qualify tumour suppressor genes, cell adhesion molecules and apoptosis-related genes as 
potential tumour markers (Figure 6.). Current data describe high-grade dysplasia and 
adenocarcinoma as a direct outcome of continuous progression of Barrett’s oesophagus. 
However, no single marker reliably discriminates lesions that will progress from those 
that will not 157. Recent advancement in molecular profiling analysis provides new tools 
for assessing hundreds to thousands of genes, RNA, proteins or metabolites in a single 
experiment. This has led to the emergence of new sciences according to target structure 
e.g. genetics, genomic-scale mRNA expression (Transcriptomics), cell and tissue-wide 
protein expression (Proteomics), and last but not least, metabolite profiling using NMR 
spectroscopy followed by analysis using bioinformatics and pattern recognition 
techniques (Metabonomics). These new sciences individually, or rather in integration, 
enable mining for new diagnostic and therapeutic targets that can give the answer for 
many problems in the management of cancer 165. 
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Figure 6. Genetic alterations involved in the progression of Barrett’s metaplasia toward 
Barrett’s adenocarcinoma. (Alterations that occur in the early stages are usually also present in the 
advanced histologic stages. In each histologic category, the alterations are placed randomly; there is no 
hierarchical order. Slides are part of St Mary’s Hospital, London histopathology slides database) 
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Intestinalised epithelium in Barrett's oesophagus (BO) with mild 
regenerative changes. Note that a mild degree of crypt distortion, budding 
and crowding is a normal component of metaplastic epithelium in BO. 
  
Low grade dysplasia (LGD): The 
nuclei are pencil shaped, 
hyperchromatic and stratified, but 
limited to the basal half of the cell 
cytoplasm, except focally in the 
surface epithelium. There are 
minimal architecture abnormalities.  
High grade dysplasia (HGD): 
Crowded crypts with more severe 
nuclear stratification. There is 
mild architectural distortion. The 
nuclear/cytoplasmic ratio of HGD 
is markedly increased compared 
with LGD. 
 
 
High power view of HGD with intramucosal adenocarcinoma: The 
intramucosal adenocarcinoma is characterised by a proliferation of 
small irregular glands with markedly atypical nuclei infiltrating the 
lamina propria in a haphazard fashion that cannot be explained on 
the basis of involvement of preexisting crypts 
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1.9 Metabonomics 
1.9.1 Introduction 
Metabonomics is defined as “The quantitative measurement of the time-related multi-
parametric metabolic response of living systems to patho-physiological stimuli or genetic 
modification” 10. Metabonomics studies provide a quantitative description of the low-
molecular mass endogenous metabolites present in a biological sample such as urine, 
plasma or tissue. In such studies analysis is usually performed using high field 1H nuclear 
magnetic resonance (NMR) spectroscopy, which gives a "metabolite fingerprint" 166. This 
rapidly advancing science has been mostly employed in toxicology and drug 
development research in addition to cancer research in studies as early as the eighties167, 
but recently with the advent of robust mathematical models and sophisticated statistical 
techniques, various new studies employed it further in cancer investigation, especially 
early detection of cancer studies. One study on detection of early ovarian cancer indicated 
that the sera from patients with EOC and healthy postmenopausal women could be 
identified with 100% sensitivity and specificity. Results as these are yet to be augmented 
by further thorough studies applying the technique on various cancers 168. 
 
1.9.2 Theoretical basis of NMR spectroscopy 
The theoretical basis for nuclear magnetic resonance (NMR) was proposed by Pauli in 
1924 and demonstrated and further developed by Bloch and Purcell in 1946 169. The 
theory states that atomic nuclei possessing the spin property would exhibit split energy 
levels when exposed to a magnetic field and either align or oppose with this external 
field. Electromagnetic pulses in the radiofrequency range induce transitions across these 
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energy levels. The signal emitted by return of nuclei to their ground state energy levels on 
stopping the magnetic field energy decays in the interval between pulses (Free induction 
decay (FID)). This time domain signal is then converted to frequency domain by Fourier 
transformation that finally provides an NMR spectrum. Molecular characteristics that can 
be deduced from this spectrum include:  
 
a) Chemical shift: indicates nuclei’s chemical environment resulting from differences in 
electron density. The chemical shift, δ, is a relative scale in the order of 10-6, thus the 
units are in parts per million (ppm) which reflects the relative frequency of each detected 
signal 
b) Spin or scalar coupling: where electron-electron interaction between adjacent nuclei 
affect their energy states resulting in a spin state that reflects as line splitting on the NMR 
spectrum 
c) Signal intensity: is proportional to the number of nuclei present in each of the chemical 
environments within the molecules. Relative concentration of a compound (signal) can be 
calculated by comparisons to signal intensity of an internal standard of known 
concentration 
However, line width may compromise NMR spectral resolution. This may be contributed 
to by intrinsic factors in the sample or by factors related to NMR instrumentation. 
Examples of sample intrinsic factors are chemical anisotropy and dipolar coupling. The 
asymmetrical distribution of electron density within chemical bonds may sustain 
chemical anisotropic effects on chemical shifts in the spectrum; and this effect is 
exaggerated in unsaturated bonds, where the position of electrons, circulating under the 
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effect of external magnetic field, determines shielding of the nucleus to that field. Dipolar 
coupling is defined as the direct influence of the magnetic environment of one nucleus on 
another. In two adjacent nuclei, continually fluctuating static fields are experienced by 
both, and will have direct influences on each other. Chemical anisotropy and dipolar 
coupling produces no splitting in spectra of liquids, as they are in continual motion so 
that the net effect of the two states on a neighbouring nucleus averages to zero. On the 
other hand, in tissues, the limited rotational motion of molecules these processes result in 
low spectral resolution. 
 
1.9.3 Magic angle spinning (MAS) 
Over the last three decades NMR various analytic and experimental methods have been 
used, yet have only relatively recently MAS has come into use in mainstream high-
resolution NMR. This transition has been prompted by technical developments in 
instrumentation, more specifically in probe head design. Magic-angle spinning of 
(partially) fluid heterogeneous samples, a technique that has been used extensively over 
the years for solid-state materials and which demands very fast sample rotation, typically 
at 1 to 70 kilohertz. In any condensed phase, a nuclear spin experiences a great number of 
interactions. The main three interactions (dipolar, chemical shift anisotropy, quadrupolar) 
often lead to very broad and featureless lines. However, these three interactions in solids 
are time-dependent and can be averaged by MAS. The nuclear dipole-dipole interaction, 
between magnetic moments of nuclei averages to zero only at the magic angle, θ=54.7. 
The chemical shift anisotropy, a nuclear-electron interaction, averages to a non-zero 
value. The quadrupolar interaction is only partially averaged by MAS leaving a residual 
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secondary quadrupolar interaction. In liquids, e.g. a solution of an organic compound, 
most of these interactions will average out because of the rapid time-averaged molecular 
motion that occurs. This orientation averaging in solution is mimicked by MAS of a 
solid. This causes the signal to become much narrower, giving rise to the isotropic value 
(which is of interest for structural determination of solid materials and compounds) and 
spinning sidebands which occur at multiples of the spinning speed and can be used to 
determine the chemical shift anisotropy of the nuclei. Direct NMR analysis of tissue 
samples, even when solvated, is complicated by two principal factors which can 
significantly degrade spectrum resolution 170: 
• Restricted motion of the analytes 
• Physical heterogeneity within the sample 
In a tissue sample, the restricted motion of the analytes relative to that of free molecules 
in solution may mean that dipolar couplings, D, are not fully averaged to zero. These 
have a time-averaged angular dependence: 
                                            D α r -3(3 cos2 θ - 1)  
where r is the internuclear separation and θ the angle between the static field and the 
internuclear vector. For isotropically tumbling molecules in low-viscosity solutions, the 
angular term is averaged to zero as the molecule freely rotates so dipolar couplings are 
not observed. When motion is sufficiently restricted, some residual dipolar coupling may 
be reintroduced, which will contribute to broadening of the NMR resonances. The use of 
long linker chains allows greater motion of the terminal analyte in solution and can 
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therefore reduce this effect. A potentially greater problem lies in the sample 
heterogeneity. Tissue samples suffer from local field inhomogeneity at the tissue solvent 
interfaces due to magnetic susceptibility differences and this leads to severe line 
broadening. Magnetic susceptibility has a similar angular dependence to that above, and 
line-broadening from both dipolar couplings and susceptibility discontinuities can be 
eliminated by rapid rotation of the sample about the so-called `magic angle' θ = 54.7° 
(Figure 7.), such that the above angular term becomes zero and the overall molecular 
motion emulates that in solution 170.  
                                  
Figure 7. Magic angle spinning involves rapid rotation of a sample inclined at the magic 
angle of 54.7° to the static field 170. 
 
 
The MAS spectrum shows up to three-fold signal-to-noise gain yet uses one tenth of the 
sample relative to the conventional solution spectrum, and has considerably greater 
information content. To achieve such results, samples are typically spun at rates of 1-70 
kHz, in purpose-built rotors. The rotors are made from a number of different materials 
such as ceramics e.g. zirconia, silicon nitride or polymers such as poly-methyl-
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methacrylate (PMMA), polyoxymethylene (POM). The cylindrical rotors are axially 
symmetric about the axis of rotation. Samples are packed into the rotors and these are 
then sealed with a single or double end cap. These caps are made from number of 
different materials e.g. Kel-F, Vespel, zirconia or boron nitride depending on the 
application required. The physical spinning of the sample is achieved via an air turbine 
mechanism. These turbines (or rotors) come in a variety of diameters (outside diameter), 
from 2.0-15.0 mm, and are usually spun on air or nitrogen gas. MAS needs no sample 
pre-treatment and can be done using only about 6 mg of material. The full range of high-
resolution one- and two-dimensional techniques can now be applied to tissue samples 
under MAS conditions for the complete, non-destructive identification of metabolite 
profile. This helps preserve the samples for subsequent genomic/proteomic and 
transcriptomic analysis of the samples allowing direct integration of acquired 
metabonomic data with data from these methodologies. 
 
1.9.4 NMR Pulse sequences 
NMR pulse programs control the number, duration and intensity of pulses and as well 
delay times between pulses. The simplest pulse sequence can therefore be referred to as 
‘pulse and acquire’; a single radiofrequency pulse followed by FID recording. If this 
sequence is repeated with enough time to allow relaxation and avoid saturation, the larger 
the number of repetitions, there is improvement of signal to noise upon summation of 
acquired FIDs. Various pulse sequences have been described.  
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1.9.4.1 1D experiments 
NOESYpr1D is a sequence where presaturation of the water peak allows detection of the 
rest of peaks with fairly better quality. CPMG is another sequence where signals from 
high molecular weight species such as proteins are selectively filtered out of the resulting 
spectrum by exploiting differences in relaxation times (Figure 8.). 
 
 
Figure 8. Example of 1D spectrum acquired by the author during the course of the study 
(Chemical shifts 0.6 – 2.7) 
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1.9.4.2 2D experiments 
These include J-Resolved, Correlation spectroscopy (COSY) (Figure 9.) and Total 
correlation spectroscopy (TOCSY) experiments and were done to allow detection of 
intermolecular relationships in the spectrum. 
 
 
 
Figure 9. Example of 2D spectra generated by the study via 2D spectral analysis 
 
1.9.5 Water presaturation 
As water forms the greater proportion of any biological sample, with abundance of 1H, 
peaks acquired has the highest intensity and may distort the signals received from other 
compounds of less concentration. Therefore, the application of low energy pulse 
(typically ~ 50Hz) before the main pulse will lead to acquisition of a signal that is 
lactate 
glutamate 
myoinositol 
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reduced in intensity in a discrete region of the spectrum. This ‘presaturation’ pulse, when 
applied at a frequency at which protons from water precess, can discriminately saturate 
the intensity around the water peak, thus allowing for other signals to be observed more 
easily after the main pulse. 
 
1.9.6 Biological applications of NMR spectroscopy 
To date, various studies used NMR spectroscopy for investigation of clinical problems 
using various human biological samples using both conventional and MAS NMR 
spectroscopy. Examples are summarized in table 4. 
 
Samples used Study Year 
Biofuids Tissue 
Field of study 
Martino et al. 171 1987 Bile -- Drug metabolism 
Nicholson et al. 172 1989 Urine -- Toxicology 
Ellul et al. 173 1992 Bile -- Biochemical composition 
Anthony et al.174 1992 Plasma -- Toxicology 
Koschorek et al.175 1993 CSF -- Neuropathology 
Husted et al.176 1993 -- Myelin Biochemical composition 
Nicholson et al.177 1995 Urine -- Drug metabolism 
Cheng et al.178 1996 -- Lymph nodes Oncology 
Holmes et al.179 1997 Urine -- Inborn errors of metabolism 
Liu et al.180 1997 Plasma -- Biochemical composition 
Nicolls et al.181 1997 Urine -- Drug metabolism 
Traikia et al.182 1997 -- Liposomes Membrane composition 
Humpfer et al.183 1997 -- Erythrocytes Biochemical composition 
Moka et al.184 1997 -- Renal tissue Oncology 
Cheng et al.185 1997 -- Brain tissue Oncology 
Beckwith-Hall et al.186 1998 Urine -- Toxicology 
Tomlins et al.187 1998 Semen -- Biochemical composition 
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Guo et al.188 1998 -- Atheromas Biochemical composition 
Tomlins et al.189 1998 -- Prostate tissue Oncology 
Cheng et al.190 1998 -- Breast tissue Oncology 
Meshitsuka et al.191 1999 Synovial fluid -- Arthritis 
Tkadlecova et al.192 1999 Aqueous humour -- Biochemical composition 
Millis et al.193 1999 -- Adipocyte tissue Oncology 
Garrod et al.194 1999 -- Renal tissue Biochemical composition 
Griffin et al.195 2000 -- Renal tissue Toxicology 
Brindle et al.168 2002 Plasma -- Coronary disease 
Doran et al.163 2003 -- Oesophageal tissue Oncology 
Dave et al.2 2004 -- Barrett’s mucosa Oncology 
Sitter et al.196 2004 -- Uterine cervix Oncology 
Odunsi et al.168 2004 Plasma -- Oncology 
Mun et al.197 2004 -- Gastric tissue Oncology 
Bourne et al.198 2005 -- Melanoma Oncology 
Holmes et al.199 2006 CSF -- Schizophrenia 
Bala et al.200 2006 Gut aspirate -- Biochemical composition 
Fang et al.201 2007 -- Pancreatic tissue Oncology 
Tessem et al.202 2008 -- Prostate tissue Oncology 
Jordan et al.203 2009 -- Colon tissue Oncology 
Bollard et al.204 2009 Urine, Serum Liver  Liver regeneration 
Smith et al.205 2009 Urine -- Toxicology 
 
Table 4. Examples of studies using metabonomics in literature  
 
Recently, the development of high resolution 1H magic-angle spinning (MAS) NMR 
spectroscopy has had a substantial impact on the ability to analyse intact tissue specimens 
206
. It the most widely used technique as it has the highest sensitivity considering 
abundance of 1H in biological samples; nevertheless, NMR can be employed to detect 
other biologically relevant nuclei such as 31P, 15N or 13C. 
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Progress in magnetic resonance spectroscopy techniques and data analysis have improved 
its capability to determinate the pathology of human tissues based only on their metabolic 
profiles, and this approach has been applied on many cancer tissues as shown in table 4 
above. It could even identify some stages in pathological processes before they are 
morphologically apparent e.g. be visualized by light microscopy e.g. thyroid follicular 
tumours 207,208.  
 
1.9.7 Data processing and analysis 
1.9.7.1 Chemometrics and pattern recognition (PR) 
Chemometrics is the term generally applied to describe the use of PR and related 
multivariate statistical approaches to analyse chemical numerical data 209. One of the 
problems of interpreting the data in metabonomics studies is the determination of 
significant changes in a large set of NMR spectra of a biofluid or tissue from a cohort of 
animals or humans demonstrating a variety of effects such as normal physiological 
variation that might obscure the disease process effect. This can be achieved by the use of 
PR methods. Multiparametric data can be modelled so that the class of a separate sample 
can be predicted based on a series of mathematical models derived from the original data 
or ‘training set’ 210. PR is invaluable in reducing the dimensionality of complex data sets, 
for example by 2-D or 3-D mapping procedures, thereby facilitating the visualization of 
inherent patterns in the data set. 
PR methods can be divided into two categories: ‘unsupervised’ and ‘supervised’ 
methods. Unsupervised multivariate techniques are used to establish whether any 
intrinsic clustering exists within a data set and include methods that map samples 
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according to their properties without a priori knowledge of sample class. Examples of 
unsupervised methods include principal components analysis (PCA) and clustering 
methods such as hierarchical cluster analysis. On the other hand, supervised methods of 
analysis use the class information given for a training set of sample data to optimize the 
separation between two or more sample classes. These techniques include soft 
independent modelling of class analogy (SIMCA), K-nearest neighbour analysis and 
neural networks. Supervised methods require a second independent data set to test or 
validate any class predictions made using the training set 210. Subtle biochemical changes 
in 1H NMR spectroscopic profiles of bio-fluids can be obscured in NMR PR analysis by 
interfering factors such as variations in pH, which can cause changes in NMR chemical 
shifts because of differences in the ionization state of some molecules. Minimizing effect 
of these factors have been studied and accomplished by techniques, for example, by 
adding a standard amount of buffer to the sample prior to NMR spectroscopic analysis 
211
. In addition, other methods are used as automatic data reduction techniques and 
exclusion of areas of the spectrum prior to PR analysis, as those containing water or urea, 
where the signal intensity is very variable due to water NMR peak suppression effects 212. 
In addition, after identification of regions of interest it is prudent to return to the raw 
NMR spectra for peak assignment and metabolite identification.  
 
1.9.7.2 Principal component analysis (PCA) 
PCA is a technique for finding a set of weighted linear composites of original variables 
such that each composite (a principal component) is uncorrelated with the others. It was 
originally devised by Pearson in 1901 213, though it is more often attributed to Hotelling 
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(1933) who proposed it independently 214. The first principal component is such a 
weighted linear composite of the original variables with weights chosen so that the 
composite accounts for the maximum variation in the original data. The second 
component accounts for the maximum variation that is not accounted for the first. The 
third component likewise accounts for the maximum given the first two components and 
so on.  Each PC is orthogonal and therefore independent of the other PCs.  These weights 
are found by matrix analysis that gives the weights for the original variables. This 
statistical technique has been used extensively in metabonomics. The output of the 
method results in two matrices known as scores and loadings.  
 
1.9.7.3 Scores and loadings 
Scores are the co-ordinates for the samples in the established model and may be regarded 
as the new variables. Each point represents a single NMR spectrum. The PC loadings 
define the way in which the old variables are linearly combined to form the new 
variables. The loadings define the orientation of the computed PC plane with respect to 
the original variables and indicate which variables carry the greatest weight in 
transforming the position of the original samples from the data matrix into their new 
position in the scores matrix 215.  In the loadings plot, each point represents a different 
NMR spectral region. Unsupervised methods such as PCA are useful for comparing 
pathological samples with control samples, but supervised analyses that model each class 
individually are preferred where the number of classes is large. Two common supervised 
methods are SIMCA and partial least squares (PLS) 215.  
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1.9.7.4 Soft Independent Modelling of Class Analogy (SIMCA) 
SIMCA operates by establishing the multivariate boundaries for each class in a data set. 
Based on a defined set of samples with known class identity referred to as a ‘training set’, 
statistical models are formed. A separate PCA is performed for each class of data within 
the training set, and an independent or ‘test’ set of samples is then used to examine the 
predictive ability of the models. Each sample in the test set is fitted to every class model 
and predictions are made on the quality of fit. SIMCA models are superior to some other 
supervised techniques in that a sample may be assigned to a single category, to more than 
one category or to no category at all. Therefore, it avoids forcing the sample into a given 
category. PLS is a method that relates a data matrix containing independent variables 
from a set of samples to a matrix containing dependent variables (or measurements of 
response). PLS can be used to examine the effect of time on a data set; a feature that is 
particularly useful for NMR data collected from samples taken over the course of a 
disease, therapy or toxic effect. PLS can be combined with discriminant analysis (DA) to 
establish a discriminant surface where the optimal position to place best separates 
different classes 215. 
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1.10 Study aims and objectives 
1.10.1 Overall aim 
Characterization of the metabolic profile of oesophageal cancer and investigation of its 
potential use in diagnosis and follow up.  
 
1.10.2 Detailed objectives 
1- Characterize the metabonomic profile differences in cancer tissues, especially those 
pertinent to glycolysis, glutaminolysis and choline metabolism intermediates. 
2- Investigate the field cancerization concept and test whether differences in 
metabonomic profile specific for cancer is seen even to a lesser extent in the cancer field. 
3- Qualify tissue metabolic response to chemotherapeutics based on the previous 
mentioned metabolic pathways and possible new biomarker pathways/compounds. 
 
1.10.3 Thesis layout 
• Chapter 2: will display the methodology used in samples collection, storage, 
NMR analysis, spectral data acquisition and mathematical analysis of these data 
using pattern recognition techniques and regression analysis.  
• Chapter 3: will display the design and characteristics of participants of the three 
main studies, together with the driving hypotheses and summary of observations. 
• Chapter 4: displays the actual results; it is subdivided into three sections 
corresponding to those in chapter 3. Each section will discuss the observations 
recorded in each study followed by analysis and interpretation of these results.  
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• Chapter 5: is a discussion of overall results of the three studies, putting the 
metabolic profile analysis findings in context with the corresponding clinical 
management perspectives of oesophageal cancer.  
• Chapter 6: is compilations of ideas for future research based on the findings of 
this study. Finally, the bibliography and appendices containing detailed data 
sheets. 
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2. CHAPTER 2. METHODOLOGY 
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Author statement 
This is to state that I carried out, personally, all the stages of this study including 
preparation of study protocols, ethical approval application, sample collection, coding 
and storage, sample analysis in NMR MAS spectroscopy (i.e. sample preparation, 
operating the spectroscope and optimisation of all spectral acquisition parameters), 
spectral analysis and processing, application of pattern recognition techniques and 
multivariate analysis of data, statistical analysis of results and interpretation of data and 
finally to writing up the results in this manuscript and in all the papers submitted for 
publication based on these results and data. 
 
2.1 Patients and Methods  
2.1.1 Patients 
Subjects were recruited from five hospitals across London and the surrounding boroughs: 
St Mary’s Hospital and Harley Street Clinic, London; Harefield Hospital in Middlesex, 
Watford Hospital in West Hertfordshire; Lister Hospital in East Hertfordshire. These 
were a combination of oesophageal cancer patients, gastric cancer patients, Barrett’s 
dysplasia patients and healthy control subjects. Out of this pool of patients different 
samples were employed for analysis in each study based on the suitability of the patient 
clinical and pathological criteria to each study design. In addition, sample and 
subsequently NMR spectral quality largely dictated inclusion and exclusion of patient 
subgroups in each study.  
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2.1.2 Arrangements for sample storage 
2.1.2.1  Establishment of tissue bank 
The author under supervision of Mr Hanna has established an upper GI Cancer Tissue 
bank at St Mary’s Hospital. The tissue bank is sponsored by Imperial College London, 
based at the Department of Biosurgery and Surgical Technology at St Mary’s Campus. 
Ethical approval has been granted by St Mary’s Hospital local Research Ethics 
Committee on 31/03/2005, REC Ref: 04/Q0403/119. The project was approved by St 
Mary’s Hospital Research and Development department on 03/08/2005 RE: 
04/BH/0014E (Ethical approval letter and relevant forms used is included in appendix 1). 
Samples are collected and stored according to protocols recommended by the National 
Cancer Research institute report (2004). Informed consent was obtained from all patients. 
The tissue bank followed the provisions of the Data Protection Act 1998, and the Human 
Tissue Act 2000. Samples were backed up with a database of the enrolled patients. The 
named custodian of all samples and data was registered in the data controllers register at 
the information commissioner’s office and at Imperial College London.  
 
2.1.2.2 Ethics approval for metabonomic studies 
Ethical approval for metabonomic analysis of the samples was obtained from the Royal 
Brompton and Harefield REC on 17/08/2005. REC Ref: 05/Q0404/73; extended to St 
Mary’s REC on 06/10/2005 REC Ref: 05/Q0403/165. Copy of the approval letter was 
kept with the tissue bank documents. Ethical approval letter and relevant forms used is 
included in appendix 2. 
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2.1.2.3 Establishment of patient database 
The following data was collected and stored for all patients:  
• Demographic data: age, sex, ethnic origin, weight, height, BMI, smoking and 
alcohol intake history (all to subsequently study possible isolated or confounding 
effect of these factors on metabonomic profiles of samples). 
• Medical status data: co-morbidities e.g., drug history including medications taken 
on the day of sampling in details, past medical history, ASA class 
• Chemotherapy history including type, number of cycles and date of last cycle 
• Clinical staging data, PET results and variables 
• Pathological data: pathological site, size, type, subtype, macroscopic picture, 
TNM stage, vascular, perineural or lymphatic invasion, Helicobacter pylori 
infection, Barrett’s metaplasia, regression after chemotherapy according to 
Mandard’s classification, nodes harvested/nodes with metastasis (operative 
samples). Example page of the data extraction spread sheet used is included in 
appendix 3. 
 
2.2 Sample collection 
2.2.1 Tissue samples 
2.2.1.1 Surgical samples 
The patient was approached in the night before the procedure, the project was discussed 
and a full informed consent obtained. On procedure day, once the main specimen was 
removed, pathology team was informed, specimen put in a dry bucket and was taken to 
pathology suite where one of the pathology consultants would be ready to cut out the 
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sample; this was to ensure blocking of the immediate adjacent mucosa/tumour to set the 
gold standard for sample identification and diagnosis. Cut pieces of 30-50 mg are 
obtained from the mucosa of the following sites:  normal oesophageal mucosa, normal 
proximal gastric mucosa, normal distal gastric mucosa and tumour sample. Cut pieces are 
split for the study and the other half goes to pathological confirmation. Samples are 
wrapped in an aluminium foil without washing, to prevent leakage of metabolites, and 
then stored in labelled cryo-tubes in -800c freezers. 
 
2.2.1.2 Endoscopic samples 
The night before the procedure, patient was approached, project discussed and a full 
informed consent obtained. During endoscopy, three bites out of each area as above are 
taken to collect an adequate sized sample. Care was taken to wash the biopsy forceps 
with saline rather than alcohol or formalin. Samples are wrapped and transported for 
storage. Time from sample excision in surgery / endoscopy to freezing was less than 20 
minutes for all samples. All samples are strictly mucosal with minimal submucosa. 
Normal samples were taken at least 5 centimeters away from any visible suspicious or 
malignant mucosa. Time to freezing for all surgical and endoscopic tissue samples ranged 
between three to twelve minutes with an average of six minutes. 
 
2.2.2 Blood samples 
An informed consent was obtained the night before sampling. All samples are taken at 8 
am; all patients were fasted more than 8 hours. Tubes used were red topped (plain), Blue 
topped (Na Citrate) and light Green topped (Lithium heparin) were used to collect blood 
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in an aseptic technique.  All containers are put on ice for 20-30 minutes then centrifuged 
at 1500 G. Aliquots of separated serum/plasma and urine are stored -800c. 
 
2.3 Sample preparation for NMR 
2.3.1 Tissue samples 
Sample transported to NMR suite was done in liquid nitrogen/dry ice. Tissue was thawed 
in room temperature for a maximum of two minutes, which was usually enough for 
thawing the sample owing to its small mass. The sample was then washed with 200 µL of 
95% D2O for 10 seconds maximum to prevent leakage of any solutes. The weight of the 
wet sample was recorded (Sample weights are displayed in appendix 4.), then the sample 
was loaded in a zirconium rotor, ready for NMR spectroscopy. All samples were 
preserved after NMR spectroscopy for further histological/subsequent molecular analysis.  
 
2.3.2 Blood samples 
The procedure was performed in the class II suite. Samples prepared by adding 200µL 
serum/plasma to 400µL Phosphate buffer (Na2HPO4+ NaHPO4+ 0.02%TSP+0.2% Na 
Azide in 95% D2O +5% H2O). Mixture was centrifuged at 15000 G for 5 mins. 550µL of 
this solution was pipetted into a labelled standard 5mm NMR tube, and frozen before use.  
At all times during the preparation the sample was kept on ice to avoid degradation. Only 
one freeze-thaw cycle was allowed for each aliquot and subsequent prepared NMR 
sample, again to avoid degradation of the sample.  
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2.3.3 Tissue extraction 
Tissue samples were extracted by adding 300 µL of a solvent mixture of freshly prepared 
1:2 mixture of duterated methanol:duterated chloroform in an Eppendorf tube; tissues 
were then crushed by a special plastic piston and homogenized by vortexing for one 
minute; then centrifuged at 1500 G for 5 minutes. After vortexing, 300 µL of D2O was 
added to each tube and tubes were again vortexed. Tubes were then centrifuged at 
maximum speed for 5 min. On removal from the centrifuge two layers could clearly be 
distinguished in each tube – one corresponding to the aqueous phase (the upper layer), 
with the organic phase on the bottom. Note that most of the methanol added to these 
tubes ends up in the aqueous phase. Thus the volumes of each layer are approximately 
400 µL and 200 µL in the aqueous and organic phases, respectively. Approximately 350 
µL was aspired directly from the upper layer (aqueous phase) using a Gilson p200 pipette 
and added to an NMR tube (507-HP, GOSS Scientific Instruments Ltd, Cheshire, U.K.). 
200 µL of D2O was then added to each tube so that the sample volume was sufficiently 
large for detection by receiver coils in the NMR probe. 150 µL was then withdrawn from 
the lower layer (organic phase) and added to an Eppendorf tube. This was lyophilised 
overnight. The following day some of the lyophilised organic phase extracts were 
redissolved in 550 µL of CDCl3.  
 
2.4 Sample analysis by NMR Spectroscopy 
2.4.1 Tissue 1H –MAS NMR Spectroscopy 
Metabolic profiles were generated using 1H MAS-NMR spectroscopy of intact 
oesophageal tumour tissue (‘tumour’) and of proximal histologically-normal mucosa 
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(‘PHINOM’) from cancer patients together with normal mucosa from an age-matched 
control group (‘control’), therefore, these will hereby be the names of these groups 
throughout the text. NMR spectra were acquired on a Bruker DRX600 spectrometer 
(Bruker Biospin, Rheinstetten, Germany) operating at 600. 13-MHz 1H NMR frequency 
and 283 K. Shimming was done manually for each sample. 1H NMR spectra of the 
samples were acquired using a 1D Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence 
(RD-90°-( τ -180°- τ )n-acquire). The CPMG sequence generates spectra edited by T2 
relaxation times, i.e., with reduced signals from high molecular weight species or systems 
in intermediate chemical exchange. In the experiments n = 300 and τ =400 µs, for a total 
T2 relaxation time of 240 ms. For all spectra, 256 free induction decays (FIDs) were 
collected into 32K complex data points; using a spectral width of 12 019 Hz (20 ppm), 
with a 2-s relaxation delay between pulses. A water pre-saturation pulse was applied 
throughout the relaxation delay. 
 
2.4.2 1D NMR spectroscopy for blood samples 
Prepared blood and urine samples in NMR tubes were loaded in automated sample holder 
and analysed at 298 Kelvin in a 600MHz NMR Spectrometer (Bruker, Karlsruhe, 
Germany). The pulse sequences used to profile the samples were NOESYpr1D, CPMG. 
The spectrometer was tuned and matched; Ninety degree pulse duration was calculated 
for each sample run. Shimming was optimized by gradient shimming for each sample. 
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2.5 Data processing and analysis 
Data were zero-filled by a factor of 2, and the FIDs were multiplied by an exponential 
weighting function equivalent to a line broadening of 1 Hz prior to Fourier 
transformation using XWINNMR software (Bruker Biospin, Rheinstetten, Germany). 
The acquired NMR spectra were calibrated to the lactate-CH3 resonance at 1.33 ppm and 
corrected for phase and baseline distortions. All subsequent data processing and analysis, 
unless specifically stated otherwise, was conducted using in-house software written and 
compiled in MATLAB (Mathworks) by O. Cloarec, T.M.D Ebbels and H. C. Keun.  
Spectra were interpolated from 32K to 42K data points using a cubic spline function to 
regularize the abscissa and improve calibration accuracy (final resolution 0.29 Hz/pt) 
prior to pattern recognition analysis. 
For pattern recognition analysis, spectra were divided and signal integral was computed 
in δ 0.01 intervals across the chemical shift range δ 0.24-9.96. The region δ 4.7-5.2 was 
excluded to remove variation in the presaturation of the water resonance, also regions 
δ<0.8 and δ>0.95, were excluded to avoid the effect of baseline noise. Signals from local 
anaesthetic used during endoscopy were identified by separate anaesthetic NMR analysis, 
anaesthetic peaks did not correlate or affect the rest of the spectral regions as confirmed 
by correlation analysis; yet these peaks were excluded from the analysis so they do not 
confound the mathematical model development or the final statistical analysis. Therefore, 
699 variables were left to be analysed in the following spectral regions: δ1.075-1.255, 
1.355-1.405, 2.185-2.245, 2.265-2.275, 3.335-3.395, 3.625-3.775, 4.295-4.325 and 
7.185-7.305.  Each integrated NMR spectral region was then divided by sum of the total 
remaining intensity for each spectrum in order to normalize values. The reduced and 
 85 
normalized NMR spectral data were imported into SIMCA-P (version 11, Umetrics AB, 
Umeå, Sweden) and each variable was mean-centred and Pareto scaled (divided by 
√standard deviation) prior to Partial Least Squares (PLS) regression. 
 
2.6 Pathological examination  
Samples matched to those undergoing NMR spectroscopy were subjected to staining with 
hematoxylin and eosin to ensure the benign or malignant nature of tissues. Normal 
oesophagus slides from 34 cancer patients and 50 noncancer patients underwent 
additional immuno-histochemical staining for the following markers Ki-67, P-53, 
terminal deoxynucleotidyl transferase-dUTP nick end labeling (TUNEL) and mucin 
where percentage of areas stained was accurately calculated by computational image 
analysis techniques. Two consultant pathologists (Dr Robert Goldin and Dr Josephine 
Lloyd, Department of Histopathology, St Mary’s Hospital, London), both with special 
interest in oesophageal cancer examined the slides independently.  In addition, they 
examined ten slides of each of the normal tissue from cancer and non-cancer groups 
blinded to the origin of the tissues. 
 
2.7 Validation studies: 
2.7.1 Validation of methods of tissue collection, storage and NMR processing 
Studies to verify the quality of tissue collection and analysis were done to ensure the 
resulting spectra were not affected by the mode of collection, storage or the NMR 
operator.  
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a. Samples analysed at the beginning of the study were compared to those analysed 
near the end of the study, which makes a period of about 14 months, where the 
tissue was stored in -800C. Subtle differences were found, mostly in the aromatic 
part of the spectrum, in the form of poorer quality peaks and mild elevation of the 
noise signals. None was statistically significant. 
b. Up to 10 samples were collected by a different research fellow, and analysed by a 
third one. When compared to the rest of the spectra, no apparent differences were 
found by visual examination of the spectra. 
c. Surgical specimen samples were analysed against those collected by endoscopy 
and a PCA plot was constructed and showed absence of significant clustering of 
these groups (Figure 10). However, surgical samples were found to different than 
endoscopic samples in some of the metabolites measured, this difference was 
found to be nonsignificant when examined as an independent factor in separation 
of groups. 
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Figure 10. Normal oesophagus of cancer patients taken under different anaesthetic 
conditions  
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d. Local anaesthetic used during endoscopy was found to appear as a group of 
distinct peaks on the spectrum due to the fact it coated the oesophagus during 
endoscopy and was collected with the sample. Repeat of endoscopic sample 
collection was done to get samples from patients who approved only sedation 
during their endoscopy. Comparison and OPLS models showed lack of effect of 
those peaks on the rest of the spectrum; therefore these peaks were excluded from 
the analysis and the samples were used as regular. 
 
2.7.2 Validation of statistical methods used during data processing 
Statistical advisory service at Imperial College London was consulted as for 
different statistical tests used to validate the data distribution as well as those 
methods used in the final data analysis. 
a. Normalisation methods: the data were processed by hand, by me, for: 
calibration, base line correction and normalisation of the spectra. This was 
done to assure consistency of processing, at the same time Dr Keun, the second 
supervisor would overlook processed data at regular intervals to ensure 
absence of systematic errors in processing. To ensure veracity of the 
mathematical processing, spectra were normalised to:  
• median fold changes 216 
• constant = the value 1 
• creatine peak average value 
• average of healthy oesophageal mucosa spectra.  
 88 
All normalisation methods were compared and yielded similar results in terms of 
group clustering on PCA analyses and on visual inspection of all spectral regions 
in all patient subgroups. 
 
b. Data set variable value transformation: upon analysis of the data sets by 
SIMCA, alternative methods of data transformation was attempted e.g. log 
transformation, where the residuals get bigger for bigger values of the 
dependent variable maximizing display of differences between groups 
 
c. Scaling methods: different scaling methods were tried to show maximal 
difference between data 
• Mean centering: showing actual raw changes of the data 
• Unit Variance scaling: the base weight is computed as 1/sdj, with sdj is the 
standard deviation of variable j computed around the mean. 
• Pareto Variance scaling: the base weight was computed as 1/sqrt (sdj), 
Pareto scaling was in between no scaling and UV scaling and gives the 
variable a variance equal to its standard deviation instead of unit variance. 
Different transformation and scaling methods did not change the 
observation of results significantly confirming its validity. 
•  
2.7.3 Validation of metabolic profile results 
a. Peak assignment was done by: 
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i. Hand searching of electronic metabonomic databases online in 
addition to confirmation of assignment by at least 2 published 
studies in peer reviewed journals (Figures 11-13). 
ii. Acquisition of 2 dimensional NMR experiments confirming spatial 
relations between components of the same structure (Figure 14.). 
iii. Examining the spectra against the physico-chemical structure of the 
compound in question with exclusion of assignments that defy 
well established NMR rules of spectral assignment (Figures 15-
17). 
iv. A few spiking experiments were done to emphasize the 
identification of some of the compounds where the peaks in 
question are seen to magnify upon addition of the pure compound 
material to the tissue samples. 
 
Figure 11. Assignment of spectra generated by the study (Chemical shifts 0.6 – 2.7) 
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Figure 12. Assignment of spectra generated by the study (Chemical shifts 2.75 – 4.3) 
 
 
Figure 13. Assignment of spectra generated by the study (Chemical shifts 5.3 – 9) 
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Figure 14. Assignment of spectra generated by the study via 2D spectral analysis to 
examine physical proximity of compound components confirming its identity 
 
lactate 
glutamate 
myoinositol 
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Figure 15. Confirmation of assignments via examination of chemical structure 
 
 
Lactate CH3 Alanine 
Leucine 
Isoleucine 
3 hydroxybutyrate Valine 
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Figure 16. Confirmation of assignments via examination of chemical structure 
 
Lysine Acetate 
L-glutamine D glutamate 
Glutathione 
Aspartate 
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Figure 17. Confirmation of assignments via examination of chemical structure 
 
 
 
 
 
NADP NADPH 
NAD 
NADH 
Adenine Adenosine 
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b. Tissue extraction was done to ensure findings of the intact tissue running were not 
due to compartmentalization of certain compounds that might not have been 
visible to NMR due to tissue density. Findings were almost exactly the same in 
most of the compounds studied (Figure 18.). Only the broad lipid peaks were lost 
upon extraction of the tissue. 
 
    
Figure 18. Showing similar NMR peaks and difference between tumour and normal 
tissue in intact tissue and extracted samples 
 
c. Statistical methods used to examine the data were based on optimization of choice 
of appropriate statistical tests to produce the most reliable result and confirm 
significance when present. The following are examples: 
i. The Lilliefors test was used to evaluate the hypothesis that the dataset has a 
normal distribution with unspecified mean and variance, against the alternative 
that it does not have a normal distribution. 
ii. A two-sample Kolmogorov-Smirnov test was used to compare the 
distributions of values in the two data vectors when two data sets were 
compared. The null hypothesis for this test is that X1 and X2 have the same 
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continuous distribution. The alternative hypothesis is that they have different 
continuous distributions.  
iii. Kruskal-Wallis and Wilcoxon ranksum tests are the nonparametric one-
way Analysis of Variance (ANOVA), these were used to compare samples 
from two or more groups. The choice of a critical p-value to determine 
whether the result is judged "statistically significant" is left to the researcher. It 
is common to declare a result significant if the p-value is less than 0.05 or 
0.01.  
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3. CHAPTER 3. METABONOMIC PROFILING STUDIES 
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3.1 Study I: Global metabonomic phenotyping of oesophageal and gastric cancer 
patients 
Metabonomics investigations provide a quantitative description of the low-molecular 
mass endogenous metabolites present in a biological sample giving a "metabolite 
fingerprint" of cancer and normal tissues.  
3.1.1 Hypothesis 
Oesophageal cancer tissue has metabolic markers of increased rates of glycolysis and 
glutaminolysis as compared to normal tissue.  
3.1.2 Objectives of the study 
• Characterize the metabonomic profile of malignant and normal tissue samples 
from both oesophageal and gastric cancer patients with focus on glycolytic 
intermediary compounds and glutamine metabolism intermediates. 
• Compare adenocarcinoma and squamous oesophageal cancer to normal tissue.  
3.1.1 Patients and data analysis 
Fifty seven patients were recruited in the study.  Twenty seven patients had oesophageal 
cancer, 11 with oesophago-gastric junctional cancer and 15 had gastric cancer. Three 
patients had high grade dysplasia of the lower oesophagus with no evidence of 
carcinoma. Sample collection, preparation and NMR analysis with subsequent data 
processing and statistical analysis followed the same protocol described in section 2.5., 
2.6. and 2.7). Principal component analysis (PCA) and Partial Least Squares Discriminate 
analysis (PLS-DA) was performed constructing various models. Outliers during model 
development were recorded for re-analysis and scrutiny. 
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3.2 Study II: Field effects in non-dysplastic tissue from oesophageal cancer patients 
The concept of ‘field cancerization’ was introduced by Slaughter in 1953 stating that 
tumours arise within a transformed field with an altered biochemical phenotype 78. It 
meant to describe the existence of generalized carcinogen induced early genetic changes 
in the epithelium from which multiple independent lesions occur, leading to the 
development of multifocal tumours78. In one of his earlier publications he stated: "cancer 
does not arise as an isolated cellular phenomenon, but rather as an anaplastic tendency 
involving many cells at once"76. This formed a belief that the lateral spread of tumours 
was due to progressive transformation of cells adjacent to a tumour, rather than the 
spread and destruction of the adjacent epithelium by pre-existing cancer cells77.  Ever 
since, many studies were conducted to test this hypothesis in various cancers85,87,94-101 by 
investigating the genetic and epigenetic mutations, transcriptional effects and proteomic 
profiling aspects of tumours.  With present technological advancement, including laser 
capture micro-dissection and high-throughput genomic technologies, carefully designed 
studies using appropriate control tissue will enable identification of important molecular 
signatures in these genetically transformed but histologically normal cells75.  
3.2.1 Hypothesis 
Histologically-normal mucosa from oesophageal cancer patients’ tissue has metabolic 
properties of cancer but with less scale. 
3.2.2 Objectives of the study 
• Compare the metabonomic profile of histologically-normal mucosa from 
oesophageal cancer patients tissue with that from non-diseased controls  
• Identify putative biomarkers of potential value in clinical diagnostic applications. 
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3.2.3 Patients and data analysis 
Eighty seven patients were recruited; 35 with oesophageal adenocarcinoma and 52, age-
matched, non cancer controls. Seventeen patients from the cancer group had 
chemotherapy during the course of the study, typically 3-6 courses of Cisplatin+5-
fluorouracil or Epirubicin+Capecitabin. Control samples were taken from non-cancer 
patients during endoscopy for indications other than suspicion of malignancy.  All but 21 
of these patients received local anaesthetic during their endoscopy. Another set of 
matched samples from all sampled areas were fixed in paraffin for pathological 
examination.  All samples were collected after an overnight fasting. Samples were 
annotated with full clinical details including demographic data, co-morbidities and drug 
intake.  
Sample collection, preparation and NMR analysis with subsequent data processing and 
statistical analysis followed the same protocol described in sections 2.5, 2.6 and 2.7. 
Pathological assessment was conducted as section 2.8.  Final analysis of the data in this 
study has been done in conjunction with Dr Hector Keun; where he kindly helped to 
perfect the statistical modelling and the final descriptive figure of the results. 
 
3.3 Study III: Profiling metabonomic response of oesophageal adenocarcinoma to 
chemotherapy 
Collectively, data from European and American studies suggest that administering 
systemic chemotherapy prior to surgery for oesophago-gastric cancer improves survival 
compared to surgery alone 114,116,217. The response rate to cytotoxic therapy is about 40% 
in oesophago-gastric cancer. Available evidence suggests that a favourable 
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histopathological response to cytotoxic therapy may be a useful positive predictive 
marker in oesophago-gastric cancer. However, the ability to predict tumour response in 
routine clinical practice is difficult and is an area of intense investigation. The 
predictive/prognostic significance of histopathological response to cytotoxic therapy was 
reported by Mandard et al 117 in oesophageal cancer specimens (predominantly squamous 
cell carcinomas) following neoadjuvant chemo-radiotherapy. Tumour regression grade 
(TRG) analysis, as a marker of treatment response was undertaken in that study and 
scored from complete regression (TRG1) to absent regression (TRG5). Of the 93 patients 
in that study, 42% were TRG1–2, 20% TRG3 and 33% were TRG4–5. Tumour size, 
pathological lymph node status, TRG and oesophageal wall involvement correlated 
highly with disease-free survival. On multivariate analysis, however, only TRG (TRG1–3 
vs TRG4–5) remained a significant (p=0.001) predictor of disease-free survival 117.  
 
3.3.1 Hypothesis 
Metabolic profile of oesophageal tissues vary with chemo-responsiveness in pathways 
described above as related to carcinogenesis and invasiveness. 
3.3.2 Objectives of the study 
• To observe the differences in metabolite content of tumour and normal tissue after 
chemotherapy.  
• To correlate the histo-pathological response to neo-adjuvant chemotherapy with 
metabolic tissue profiling.  
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3.3.3 Patients and data analysis 
Ninety nine patients were recruited; 47 with oesophageal adenocarcinoma and 52, age 
and sex matched, non- cancer controls. Twenty seven patients from the cancer group had 
chemotherapy in the form of 3 cycles of Cisplatin + 5-fluorouracil or Epirubicin + 
Capecitabin. The last chemotherapy dose was administered at least three weeks prior to 
sample collection. In cancer patients group, seven had complete response to 
chemotherapy; therefore tumour tissue could not be harvested. Tissues from non-cancer 
patients were used in this study as negative controls. In the non-cancer group, only 31 
patients had local anaesthetic during their endoscopy. In six of the patients, tumour and 
PHINOM samples were collected before chemotherapy, and from the same areas of 
mucosa three weeks after chemotherapy have been completed. Samples from 18 post 
chemotherapy patients were collected and graded according to their response to 
chemotherapy by Mandard’s grading system via visual histopathological as well as 
image analysis examination. All samples were collected after an overnight fasting. 
Samples were annotated with full clinical details including demographic data, co-
morbidities and drug intake.  
Sample collection, preparation and NMR analysis with subsequent data processing and 
statistical analysis followed the same protocol described in 2.5, 2.6 and 2.7. Samples 
matched to those undergoing NMR spectroscopy underwent pathological examination as 
per the protocol described in section 2.8.  
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3.3.4 Response to chemotherapy 
The response to chemotherapy was determined by histopathological assessment where 
reporting was agreed upon by two expert pathologists independently examining the 
slides. Table 5 shows Mandard grading.   
 
Tumour 
regression grade 
Histological characteristics 
1 Complete regression: no histologically identifiable residual cancer, only fibrosis 
2 Rare residual cancer cells scattered through fibrosis 
3 Increase in the number of cancer cells, but fibrosis still predominant 
4 Residual cancer outgrowing fibrosis 
5 Absence of regressive changes 
 
Table 5. Grading of tumor regression after neoadjuvant radiochemotherapy according to 
Mandard 117 
 
In addition, stained areas and percentage of fibrosis areas reflecting extent of healing 
response to chemotherapy was accurately calculated by computational image analysis 
techniques. Using the Sirius Red stained sections, the percentage fibrosis for each 
specimen was calculated using an image analysis system consisting of a light microscope 
(Olympus) with attached digital camera (Nikon BX40; Nikon, Japan) and a frame-
grabber board installed in an Intel Core based PC (Hewlett Packard) and NIS elements 
version 2.3 image analysis software (Nikon, Japan). Images of Sirius Red stained sections 
were captured at 10X magnification, digitized following interactive light intensity 
equilibration and analyzed as RGB 24-bit images. The images were captured at 2048 X 
1536 resolution at 24-bit colour depth and 300 dpi.  The 2-dimensional patterns were 
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measured by direct pixel counting on the binary images.  Five representative fields from 
each slide were assessed and an average taken. Prior to proceeding with the use of x10 
magnification for digitizing the specimens, fibrosis percentage measurements for 10 liver 
biopsies were compared using both x20 and x40 objective was chosen for scanning and 
subsequent fibrosis percentage measurement. 
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4. CHAPTER 4.  RESULTS 
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During the course of the thesis, 282 samples were collected from 144 patients recruited 
from five hospitals across London and the surrounding boroughs: St Mary’s Hospital and 
Harley Street Clinic, London; Harefield Hospital in Middlesex and Watford Hospital in 
West Hertfordshire and Lister Hospital in East Hertfordshire. These were oesophageal 
cancer patients, gastric cancer patients, Barrett’s dysplasia patients and healthy control 
subjects. Out of this pool of patients different samples were employed for analysis in 
each study based on the suitability of the patient clinical and pathological criteria to study 
design. In addition, sample and subsequently NMR spectral quality largely dictated 
inclusion and exclusion of patient subgroups in each study. Hence, throughout the results 
section, the demographic data and sample characteristics are displayed in the patients and 
methods section of each study separately. 
 
4.1  Study I: Global metabonomic phenotyping of oesophageal and gastric cancer  
4.1.1 Patients  
One hundred and thirteen samples from 56 patients were analyzed.  Twenty seven 
patients had oesophageal cancer, 11 had junctional cancer and 15 had gastric cancer. 
Three patients had high grade dysplasia of the lower oesophagus with no evidence of 
carcinoma. Patient characteristics are displayed in table 6. 
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Main study Tissue sample Pilot 
study  Cancer  Control  
Chemo-
therapy 
Yes/No 
Sex 
M/F 
Total 
Adenocarcinoma 2 19 -- 10/11 18/3 Oesophageal 
cancer Squamous -- 6 -- 1/5 4/2 
27 
Barrett’s oesophagus -- 3 -- 2/1 3/0 3 
Junctional tumours  1 10 -- 7/4 10/1 11 
Proximal gastric cancer 2 7 -- 3/6 3/6 9 
Distal gastric cancer -- 6 -- 0/6 4/2 6 
Normal oesophageal mucosa 2 28 4 14/20 23/11 34 
Normal proximal gastric 
mucosa 
2 12 3 4/13 8/9 17 
Normal distal gastric mucosa -- 4 2 1/5 3/3 6 
Totals 9 95 9   113 
       
Table 6. General characteristics of patients included in tissue analysis 
 
4.1.2 Global phenotyping 
Median CPMG spectra showed that the larger part of the spectrum to be at apparently 
consistent amplitudes among normal and cancer tissue reflecting similar structural 
qualities of mucosal tissues. This in turn emphasizes the view that different resonances 
among pathologic groups essentially reflect the disease process. Visual inspection of the 
spectra detected obvious differences between normal and malignant tissues in gastric, 
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junctional and oesophageal samples. Examples from comparison of tissue spectra are 
shown (Figures 19-22).  
 
 
Figure 19. Overlaid average 1H MAS-NMR CPMG spectra of malignant and proximal 
non-tumour oesophageal tissue. Spectra show some peaks are identical (e.g. most amino 
acids) while others which are different (higher or lower) between normal and malignant 
oesophageal tissue (e.g. lactate, lipids, glutamate) suggesting differential changes of 
various classes of metabolites involved in separate pathways are due to pathological 
effect rather than systematic error 
 
 
 
 
 
 
alanine 
lactate-CH3 
Oesophagus 
Malignant 
Normal 
 
lipids 
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Figure 20. Differences in part of the median CPMG spectra between normal and 
malignant oesophageal tissues 
 
 
 
 
 
 
Oesophagus 
Malignant 
Normal 
 
glycerophosphocholine 
phosphocholine 
glucose 
Phenylalanine 
Tyrosine 
myoinositol 
glycine creatinine 
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Figure 21. Overlaid 1H MAS-NMR CPMG spectra of oesophgeal and gastric tissue. All 
tissues were obtained prior to chemotherapy. A portion of aliphatic region shows 
systematic increase of free choline, phosphocholine, glycerophosphocholine and taurine 
in tumour compared to normal tissue 
 
 111 
               
Figure 22. Spectra of non chemotherapy-treated tissue (inclusive of oesophageal and 
gastric samples) showing systematic increase of uracil and phenylalanine in tumour 
compared to normal tissue 
 
Pattern recognition techniques were applied to investigate these differences and 
determine the main features discriminating between groups in the dataset. All tissue 
samples were included in the model as follows: oesophageal tumour tissue (squamous 
and adenocarcinoma), Barrett’s epithelium, junctional tumours, proximal and distal 
gastric tumours, together with proximal and distal normal gastric mucosa. Proximal and 
distal gastric tissues were put in the same class to test for general discrimination of 
gastric from oesophageal tissue. After exclusion of outliers, analysis of the first two 
principal components of an unsupervised PCA model showed remarkable discrimination 
Malignant 
Normal 
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between different tissues (Figure 23.). In general, oesophageal tissue could be seen 
clustered separately from gastric tissue. Normal oesophageal tissue could be seen to 
clearly separate from its malignant counterpart. Junctional tumours were scattered 
between both gastric and oesophageal tissue. Discrimination between normal and 
malignant gastric tissue could also be noted, although less clearly than in oesophageal 
samples. 
-2.00E+09
-1.00E+09
0.00E+00
1.00E+09
2.00E+09
-3.000 9 -2.000 9 -1.000 9 0.000 0 1.000 9 2.000 9 3.000 9
t[2
]
t[1]
PCA-X scores plot
CPMG spectra of all tissue samples 
t[Comp. 1]/t[Comp. 2]
R2X[1] = 0.398389            R2X[2] = 0.205639            Ellipse: Hotelling T2 (0.95) 
Oesophageal carcinoma
Normal oesophagus
Gastric carcinoma
Normal stomach
Junctional carcinoma
Barrett's dysplasia
 
Figure 23. Scores plot of a PCA model differentiating between different types of tissue 
samples 
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Figure 24. Loadings plot of PCA model differentiating between different types of tissue 
samples 
 
 
Loadings of the PCA model shows that the model clustered the groups based mainly on 
lactate and choline containing compounds’ resonances (Figure 24), where more cholines 
and lactate separated the malignant from the normal groups. A model of proximal and 
distal gastric cancers and normal tissues did show clustering of distal normal tissue from 
cancer but discrimination was less consistent for proximal tissue. Clustering was not 
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noted for any of age, sex, chemotherapy status, pathological type, subtype, grade, T or N 
stages. A separate PCA model built for proximal gastric tissue data alone failed to cluster 
malignant from normal. A supervised PLS DA model could separate the classes (data not 
shown), but with low sample numbers the reliability of these results are limited.  With 
further sample collections it will be possible to test predictive ability with greater 
accuracy. A PCA model for distal gastric tissues showed separation of normal from 
malignant, but again because of small sample numbers, these results couldn’t be 
interpreted with certainty. When a PCA model including all abnormal tissues only was 
constructed, there was no apparent differentiation between malignant samples from 
different tissues. 
 
4.1.3 Analysis of oesophageal tissue 
Oesophageal tissue was analyzed separately. Histopathological examination after H&E 
staining and immuno-histochemistry confirmed presence of adenocarcinoma in all 
tumour tissue samples. Neither of the normal tissues from cancer nor non-cancer patients 
showed evidence of malignant glands. 
All junctional adenocarcinoma samples have been classified as Seiwert type I by 
pathological examination. NMR analysis proved very subtle differences from 
oesophageal tissues; semi-quantitative comparison based on averaging relative integrals 
of NMR spectra showed no significant difference in any of the resonances in the 
spectrum in either the tumour of the normal tissues respectively. Thus, for the purpose of 
this study, junctional tumours were reclassified as oesophageal tumours. Patient 
characteristics are displayed in table 7. 
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Chemotherapy 
status 
T stage 
N 
stage 
Pathological 
grade Sample Histology 
No. Of 
patients 
Age 
range 
Sex 
M/F 
Pre Post 1/2/3/4 0/1/2 W/M/P/U 
Adeno 18 43-80 14/4 6 12 1/3/14/0 6/11/1 3/5/10/0 Oesophageal 
cancer tissues Squamous 6 50-76 4/2 5 1 1/2/3/0 3/3/0 1/3/2/0 
Junctional cancer 
tissues 
Adeno 12 33-78 10/2 5 7 1/1/8/2 1/7/4 0/2/9/1 
Adeno 19 43-80 12/7 6 13 2/2/15/0 13/6/0 3/5/11/0 Cancer patient 
blood samples Squamous 2 65-71 1/1 2 0 1/1/0/0 2/0/0 0/2/0/0 
Healthy control 
blood samples 
Normal 13 32-85 7/6 13 N/A N/A N/A N/A 
 
Table 7. Characteristics of patients included in the study. W: well differentiated, M: 
moderately differentiated, P: poorly differentiated and U: undifferentiated 
 
Comparison between spectra of oesophageal tissue, an increased abundance of 
compounds as lactate, choline, phosphocholine and glycerophosphocholine, tyrosine, 
phenylalanine and myoinositol was noted in malignant tissue as compared to normal 
oesophageal epithelium (Detailed comparison of all assigned metabolites between 
different groups of tissues can be found in appendix 5). Glucose and lipid concentrations 
were relatively higher in normal tissue, while alanine concentration did not appear to vary 
significantly across the dataset (Figures 19 and 20). Examination of extracted 
oesophageal tissue was done to avoid effect of tissue compartmentalisation on metabolite 
profile; spectra showed similar changes to intact tissue analysis further validating the 
findings reported. An example is shown in Figure 25. 
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Figure 25. Choline resonances in oesophageal tissue extracts showing similar changes to 
that of intact tissues seen in Figure 21 
 
On PCA of oesophageal tissue separately (Patient details are shown in table 7), PC1 
could discriminate between generally normal and abnormal oesophageal tissue. It could 
also discriminate between squamous and adenocarcinoma. Squamous carcinoma 
appeared between normal and adenocarcinoma samples, which might be an expected 
consequence of metabolic drift from normal oesophageal mucosal tissue composition. 
Barrett’s oesophagus appeared within adenocarcinoma samples (Figure 26); of note, 
these samples came from patients with adenocarcinoma of the oesophagus on a Barrett’s 
background. Further sub analysis of squamous versus adenocarcinoma and their normal 
counterparts is shown in Figure 27. There was no significant difference/clustering 
according to age, sex, BMI, T, or N stage. The number of samples used was not enough 
to study subgroups of N stage difference for the same T stage or other more detailed 
categorisation. 
 
Malignant 
Normal 
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Figure 26. PCA scores plot of CPMG spectra of oesophageal tissues showing 
progressive separation along the same vector between normal mucosa, squamous 
carcinoma and adenocarcinoma with Barrett’s dysplasia (R2X 0.691, Q2cum 0.541) 
 
 
Figure 27. Scores plot showing clustering of squamous and adenocarcinoma and their 
normal counter parts 
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Figure 28. Loadings line plot showing the contribution of different metabolites to 
differentiating normal and malignant clusters e.g. lactate, creatinine and intermediates of 
glucose metabolism 
 
Line loading plots identified the variable metabolites contributing to this separation 
(Figure 28); resonances from these metabolites were integrated in the raw spectra to 
allow quantitative analysis and assessment of statistical significance. Choline, 
phosphocholine and glycerophosphocholine, taurine, tyrosine, lactate, phenylalanine, 
uracil, scylloinositol and myoinositol metabolites were found to be more abundant in 
cancer tissue samples (n=24). Whereas normal tissue controls (n=38), had higher content 
of glucose, glutamine, glutathione and adenine containing compounds. All differences 
were statistically significant (Wilcoxon ranksum test P<0.05) (Figure 29 displays some of 
the relevant results). Findings were reproduced on analyzing an independent set of 
samples (n=12) validating the results (Figure 30).  
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Figure 29. Differential metabolite concentrations of glutamine, glutathione, 
scylloinositol and uracil between cancer tissue and normal tissue (n=34) 
 
 
 
 
Figure 30. Differential metabolite concentrations of glutamine, glutathione, 
scylloinositol and uracil compared in an independent set of samples (n=18) 
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4.1.4 Blood samples analysis 
Visual inspection of serum samples NMR analysis observed similar findings to tissue 
analysis data (Figure 31).   
 
 
Figure 31. 1D median spectra of serum samples showing differences which seems to be 
due to malignancy regardless chemotherapy status     
 
From a PCA model of blood samples spectral data; PC1 could moderately discriminate 
between normal and malignant samples.  Within the malignant sample group further 
differentiation between pre-chemo and post-chemo samples can be seen. The results from 
PCA analysis support the observed group differences identified by visual inspection of 
the data (Figure 32). Patterns could not at this stage be correlated to variables as sex, age, 
BMI, type of tumour, pathological grade and TNM staging. This may be due to the 
number of samples used being insufficient for sub grouping. 
----- Normal controls 
----- Malignant Pre-chemo 
----- Malignant Post-chemo 
 
Myoinositol 
glucose 
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Figure 32. PCA model of serum samples from oesophageal cancer patients vs. normal 
controls 
 
It is to be noted that analysis of serum samples was out of the scope of this study, as the 
author believe analysis of serum will have to be done in a more detailed and exhaustive 
way as it is hypothetically influenced by the health status of almost every other organ in 
the body. The small number of patients included cannot account for a statistically 
meaningful data. The analysis done hereby was executed to explore the potential of use 
of blood samples to reflect findings of the tissue analysis, thus suggesting a non-invasive 
alternative to cancer detection in these patients.  
 
4.1.5  Summary of findings 
The results of tissue analysis demonstrated differences between normal gastric and 
oesophageal tissue samples and their malignant counterpart.  Principal component 
analysis showed that normal oesophageal and normal gastric samples appeared 
● Normal controls 
● Malignant serum (pre-chemo) 
● Malignant serum (post-chemo)
 
Control patients 
Oesophageal cancer patients 
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considerably apart, while malignant oesophageal and gastric samples were closer and 
even overlapping together. Junctional tumour samples were distributed between both 
cancer groups reflecting the reported clinical and pathological dilemma whether these 
tumour arise from uppermost gastric or lowermost oesophageal mucosa.  
On PCA of oesophageal tissue separately, there is distinct difference between normal and 
cancer oesophageal tissue. It also discriminates between squamous and adenocarcinoma. 
Squamous carcinoma appeared between normal and adenocarcinoma samples. Barrett’s 
oesophagus appeared within adenocarcinoma samples. Loading plots identified the 
variable metabolites contributing to the separation between normal and cancer 
oesophageal tissues. Choline, phosphocholine and glycerophosphocholine, taurine, 
tyrosine, lactate, phenylalanine, uracil, scylloinositol and myoinositol metabolites were 
found to be significantly higher in cancer tissue samples. Whereas normal tissue controls, 
had significantly higher content of glucose, glutamine, glutathione and adenine 
containing compounds.  
The TNM stage, grade of differentiation, age, sex, BMI, comorbidity had no apparent 
effect within the sample size of this study. The sample numbers used were also not 
enough to sub-classify Barrett’s samples according to grade of dysplasia or test 
qualitative differences in their metabolic profiles. The Barrett’s tissue used, all originated 
from cancer bearing patients, and so the apparent similarity to the adenocarcinoma 
samples may be due to the effect of the nearby cancer and not just the local dysplasia. 
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4.2 Study II: Field effects in non-dysplastic tissue in oesophageal cancer patients 
4.2.1 Patients 
Eighty seven patients were recruited; 35 with oesophageal adenocarcinoma and 52, age-
matched non cancer controls. Seventeen patients from the cancer group had 
chemotherapy during the course of the study, typically 3 courses of Cisplatin+5-
fluorouracil or Epirubicin+Capecitabin. Control samples were taken from non-cancer 
patients during endoscopy for indications other than suspicion of malignancy.  All but 21 
of these patients received local anaesthetic during their endoscopy. Another set of 
matched samples from all sampled areas were fixed in paraffin for pathological 
examination.  All samples were collected after an overnight fasting. Samples were 
annotated with full clinical details including demographic data, co-morbidities and drug 
intake. Patient and sample characteristics are summarized in Table 8.  
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Control
52
56.5
Male 18
Female 34
well differentiated -
moderate -
poor -
1 -
2 -
3 -
4 -
0 -
1 -
2 -
3 -
Control PHINOM Tumor
53 38 32
Endoscopic 53 17 15
Surgical - 21 17
Chemotherapy Pre- - 24 16
Post- - 14 16
19 14 12
*All bar 14 samples were patient-matched between PHINOM and tumor g
N (training set)
18
11
19
15
1
0
3
4
27
1
5
6
35
63
Cancer
30Gender
Grade 
T Stage
N stage 
Patient Group
N (total samples)
Age (median yrs)
Sampling
N (total patients)
 Sample group
 
Table 8. Patient and sample characteristics 
 
4.2.2 NMR and histopathological testing of tissue samples  
Using 1H MAS-NMR spectroscopy of intact tissue we generated metabolic profiles of 
oesophageal tumour tissue (‘tumour’) and of proximal histologically-normal mucosa 
(‘PHINOM’) from cancer patients together with normal mucosa from an age-matched 
control group (‘control’) (n=123; Table 8; Figure 33).  Histopathological examination 
after haematoxylin and eosin staining and immuno-histochemistry confirmed presence of 
adenocarcinoma in all tumour tissue samples. Neither of the normal tissues from cancer 
nor non-cancer patients showed evidence of malignancy or dysplasia and the PHINOM 
group could not be separated from control group on blinded examination.  No significant 
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differences were observed in proliferation (Ki67) or apoptosis (TUNEL) (data can be 
seen in appendix 6).   
 
4.2.3 Metabolic profile changes progressively from tumour tissue to PHINOM to 
tissue from controls 
In order to avoid confounding variation from chemotherapy, gender and the route of 
sampling, a training set was established that contained data from samples obtained only 
from male individuals that were not receiving neoadjuvant chemotherapy, and that were 
collected by endoscopy during routine diagnostic testing or staging laparoscopy (n=45).  
From visual inspection of the profiles from the training set, several metabolites appeared 
to exhibit a progressive change in intensity from tumour tissue to PHINOM to tissue from 
controls, consistent with the hypothesis that tumours arise within a biochemically altered 
tissue field (Figure 33E).  Using partial least squares discriminant analysis (PLS-DA), a 
robust model was generated that could discriminate profiles based on the origin of the 
tissue, confirming that the metabolic profile of PHINOM is systematically different from 
that of both control and tumour tissue. (Figure 33 F-G; LV 2, Q2Y 0.46, p<0.01 by 
permutation) and (Figure 34).   
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Figure 33. Metabolic profiling by 1H-NMR MAS spectrometry with pattern recognition 
analysis reveals systematic metabolic differences in between malignant, PHINOM and 
control oesophageal tissue.  A) oesophageal cancer; B) PHINOM;C) aliphatic and D) 
aromatic regions of a typical 1H-MAS-NMR spectrum of normal oesophageal tissue; E) 
mean spectra of tissue groups indicating metabolites exhibiting systematic differences in 
a training set of 45 samples; F) Multivariate ‘scores’ from a PLS-DA model  classifying 
the tissue groups in the training set; G) Validation of the PLS-DA model by comparison 
to the classification statistics of models generated after (100) random permutations of the 
class matrix (Y) 
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PLS DA plot comparing NN Vs NM training set NM
NN
 
Figure 34. 3D PLS-DA model comparing normal tissue from cancer patients with that 
from non-cancer patients (NN=normal oesophagus healthy controls, NM=PHINOM 
group) (R2X 0.779, Q2cum 0.584)  
 
4.2.4 Surrogate biomarker metabolites identified by discriminant analysis 
To test the hypothesis further we derived two more discriminant analysis models trained 
to classify either controls from PHINOM or PHINOM from tumour.  The variances in the 
regression coefficients were estimated by cross validation (7-fold) and spectral regions 
that were significantly correlated to the presence of cancer in each model were identified 
(by T test, p<0.1).  While 26% and 12% of the spectral profile regions were uniquely 
discriminating tumour or control tissue respectively, 5% of the profile exhibited a 
significant and progressive change in signal intensity from controls to PHINOM to 
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tumour, significantly higher than expected by chance (p~10-26 assuming a binomial 
distribution, expected value 0.005%, Figure 35A).  Regions identified as showing 
progressive change were interpreted as indicating the presence of putative biomarkers for 
a field effect, and resonances indicated by these regions were integrated for further 
analysis. Several of these resonances could be assigned to specific metabolites, namely: 
phosphocholine, glutamate, myo-inositol, adenosine-containing compounds, uracil and 
inosine by reference to literature data (Table 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9. Discriminatory spectral regions 
 
Marker Region Upper ppm Lower ppm Metabolite 
A 2.18 2.1 glutamate 
B 2.51 2.4 glutamate 
C 3.16 3.09 unassigned 
D 3.21 3.2 free choline 
E 3.3 3.28 unassigned 
F 3.53 3.5 myoinositol 
G 3.57 3.55 glycine 
H 4.08 4.04 myoinositol 
I 4.22 4.15 phophocholine 
J 6.02 5.95 uridine 
K 6.13 6.17 inosine 
L 7.51 7.55 uracil 
M 7.91 7.87 tryptophan 
N 8.2 8.17 adenines 
O 8.22 8.2 adenines 
P 8.25 8.29 adenines 
Q 8.52 8.6 unassigned 
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Hierarchical clustering of these metabolites indicated that they fell into two main groups, 
those increasing or decreasing with the presence of cancer, and clustering of the samples 
showed that this panel could distinguish most control tissue from PHINOM or tumour 
tissue, in a progressive fashion (Figure 35B). In principle each metabolite cluster could 
provide complementary information for sample classification, leading to better 
discrimination.  To test if this was the case, phosphocholine/glutamate (PC/Glu) ratio was 
examined, as these metabolites were members of different clusters and both are part of 
distinct metabolic pathways that are well documented as being altered in the presence of 
malignancy.  Receiver-Operator Characteristic (ROC) analysis for the detection of cancer 
in histologically normal samples from the training set using PC/Glu gave an AUC of 
0.857 (p=0.001, std err 0.069 under non-parametric assumption) compared to AUC 
values of 0.752 (p=0.015) and 0.637 (p=0.184) for PC and Glu respectively.  The 
distribution of the PC/Glu ratio in the full sample set was examined, which included data 
from female patients and surgical excision specimens that were independent from the 
analysis thus far (n=123; Figure 35C).  PC/Glu showed a clear progression to higher 
values from control to PHINOM to tumour tissue and that the difference between 
PHINOM and tumour tissue is retained in samples obtained from surgery, despite a 
systematic difference in the PC/Glu ratio between endoscopic and surgical PHINOM 
samples (Figure 35C).  ROC analysis produced AUC values of 0.84 for control vs. 
PHINOM samples and 0.98 and 0.91 respectively for endoscopic and surgical tumour vs. 
PHINOM, demonstrating both that discriminatory ability was retained in the full sample 
set and that the PC/Glu ratio is also marker for tumourigenic progression.  The metabolic 
effect of surgical collection, presumably as a result of tissue ischemia was the only 
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apparent confounding factor of significance in our analysis.  PLS DA plot showing 
predicted PHINOM samples in the training set model is shown in (Figure 36). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Identification of spectral features defining intermediate metabolic change in 
non-tumour tissue from cancer patients. (A) Proportion of spectra area significantly 
differentiating between tissue groups based on two PLS-discriminant analysis models 
calculated as described in methods, which classified tumour from PHINOM or control 
from PHINOM.  (B) Heat map and hierarchical clustering analysis (HCA) of metabolite 
resonances occupying spectral regions exhibiting intermediate change in PHINOM in the 
training set.   Data are presented as z-scores (scaled to unit variance) and average linkage 
was used for the analysis. (C) Box plots of the phosphocholine / glutamate ratio across 
the full sample set, clustered by tissue of origin and route of sampling.  Outlying values 
>2 S.D. (full circles) and >3 S.D. (star) from the mean are indicated.  ROC AUC values 
are indicated for the classification of each group relative to the sampling route match 
PHINOM group 
Spectral area differentiating tissues
26%
12%
12%
5%
45%
PHINOM <> TUMOR
only
CONTROL <> PHINOM
only
CONTROL <> PHINOM
<> TUMOR
CONTROL > PHINOM >
TUMOR (or reverse)
not s ignificant
Intermediate change in 
proximal normal
G B A P Q J K E I H M N L C O D F
TUMTUM
TUMTUM
TUMTUM
TUM
TUM
TUM
TUMCTL
CTL
CTLCTL
CTLCTL
CTL
CTL
CTL
CTLCTL
CTLCTL
PRX
PRX
TUM
CTLCTL
CTL
PRX
PRX
PRX
CTLPRX
CTLPRX
PRX
PRX
PRX
TUMPRX
PRX
CTL
PRX
PRX
-2 1 4
Value
Color Key
Discriminating spectral regionsCONTROL     PHINOM TUMOR
A
C
B
ENDOSCOPIC
SURGICAL
AUC 
0.84
All data 
(N=123)
AUC 
0.98
AUC 
0.91
 131 
-600000000
-400000000
-200000000
0
200000000
400000000
600000000
-500000000 -400000000 -300000000 -200000000 -100000000 0 100000000 200000000 300000000 400000000
tP
S[
2]
tPS[1]
PLS-DA  Scatter plot of predictive model
R2X[1] = 0.121681              R2X[2] = 0.250704              Ellipse: Hotelling T2PS (0.95) 
NM under GA
Healthy controls
NM no GA
 
Figure 36. Prediction PLS-DA model constructed on healthy samples and normal 
oesophageal samples of cancer patients with no general anaesthetic, predicting in NM 
group. NM: PHINOM group 
 
4.2.5 Comparison of other metabolites showing similar trend 
Other metabolites as glutamine, tyrosine and glutathione showed similar progression 
between normal, PHINOM and malignant tissue samples (Figures 37, 38 and 39). These 
metabolites were compared as they belong to different metabolic pathways, also 
observation from tissue extracts are shown; where observation of differential increase or 
decrease in the compounds point out to the fact the previously observed variable values 
were not due to systematic error, processing/analysis miscalculations or compartmental 
effect on these metabolite contents as evidenced by data from tissue extracts. 
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Figure 37. Comparison of glutamine content in tissues showing progressive decrease 
from normal (NN) to PHINOM (NM) to tumour (MM) (p<0.001, Kruskal Wallis test) 
 
          
Figure 38. Comparison of glutathione content in tissues showing progressive decrease 
from normal (NN) to PHINOM (NM) to tumour (MM) (p<0.001, Kruskal Wallis test) 
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Figure 39. Comparison of tyrosine content in tissues showing progressive increase from 
normal (NN) to PHINOM (NM) to tumour (MM) (p<0.001, Kruskal Wallis test) 
 
4.2.6 Summary of findings 
By comparing histologically normal mucosa proximal to a tumour (PHINOM) with 
normal mucosa from non-diseased controls and tumour tissue, this study provides new 
evidence that field cancerization in oesophageal cancer manifests a metabolic phenotype 
and that metabolic profiling via 1H MAS-NMR is sensitive to this phenomenon.  
Moreover, metabolites were identified that show a progression in detectable levels from 
normal to PHINOM to tumour tissue. Some of these metabolites, such as phosphocholine 
(PC), are well established metabolic biomarkers for malignant potential.   
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4.3 Study III: Profiling metabonomic response of oesophageal adenocarcinoma to 
chemotherapy 
4.3.1 Patients 
Ninety nine tissue samples from 47 patients were analysed; 47 patients had lower 
oesophageal/junctional adenocarcinoma and 52, age and sex matched, non- cancer 
controls. Twenty seven patients from the cancer group had 3 cycles of Cisplatin + 5-
fluorouracil or Epirubicin + Capecitabin. Patient characteristics are displayed in table 10.  
Patient group Cancer Control 
Number 47 52 
Age (Median yrs) 62.5 56.5 
Male 30 18 Gender Female 17 34 
Well 8 - 
Moderate 21 - Grade of differentiation Poor 18 - 
1 7 - 
2 12 - 
3 26 - T stage 
4 2 - 
0 22 - 
1 18 - 
2 7 - N stage 
3 0 - 
 
Sample group Tumour PHINOM Control 
Number 49 51 52 
Surgical 29 33 - Sampling Endoscopic 20 18 52 
General 42 43 - 
Local 5 6 31 Anaesthesia 
None 2 2 21 
Pre 22 20 - Chemotherapy Post 27 31 - 
1 1 1 - 
2 2 2 - 
3 8 12 - 
4 8 9 - 
5 5 3 - 
Mandard grade 
unspecified 3 4 - 
Table 10. Patient characteristics involved in the study of the Profiling metabonomic 
response of oesophageal adenocarcinoma to chemotherapy 
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4.3.2 Demonstrating the generic effect of chemotherapy on tissues 
The NMR spectra were examined visually as well as compared mathematically by 
calculating differences in compound average values. Many non statistically significant 
differences were identified between individual metabolites among pre and post 
chemotherapy tissues. Areas where changes were noted to be similar in both normal and 
tumour tissues are suggested to be due to generic effect of chemotherapeutics on tissues. 
Examples include relative decrease in content of choline containing compounds 
(phosphocholine, glycerophosphocholine), their relation to each other and to lactate and 
also a decrease in content of other compounds such as adenine containing compounds, 
creatine and ethanolamine as shown in Figures 40, 41 and 42. 
 
   
Figure 40. Comparative changes in spectral segments occurring in both malignant and 
PHINOM after chemotherapy treatment suggesting generic effect of chemotherapy on 
both tumour and normal tissues 
 
Prechemo 
Postchemo 
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Figure 41. Comparative changes in spectral segments occurring in both malignant and 
PHINOM after chemotherapy treatment suggesting generic effect of chemotherapy on 
both tumour and normal tissues 
 
      
Figure 42. Relative ratios of lactate/cholines and phosphocholine/cholines among tumour 
and normal tissues before and after chemotherapy ratios (p<0.05, Kruskal-wallis test)  
Prechemo 
Postchemo 
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Lactate/glucose ratio which has been previously used in the literature to reflect glycolytic 
activity, showed the usual hallmark of increased glycolysis among malignant tissues as 
compared to PHINOM; however, it was not affected by chemotherapy (Figure 43). 
 
 
 
 
 
 
 
 
 
Figure 43. Lactate/glucose ratio after chemotherapy 
 
 
Principal Component Analysis of the generated spectra confirmed what was observed by 
visual examination of spectra. The first component allowed obvious clustering of tissues 
treated with chemotherapy from pre-chemotherapy tissues in addition to baseline 
separation of histological types. The vector of difference between normal and tumour 
tissue was preserved both before and after chemotherapy (Figure 44).  
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Figure 44. PCA plot showing oesophageal tissues colour coded according to 
chemotherapy status and divided by a line according to histological diagnosis 
 
4.3.3 Differential effect of chemotherapy on normal and tumour tissue 
 Analysis of the content of other metabolites such as phenyl-alanine showed increase in 
amount in both normal and malignant tissue with chemotherapy, yet only the increase in 
malignant tissue was statistically significant (p=0.014, Student t-test) (Figure 45). 
Comparison of adenine containing compounds content showed similar trend with 
significant increase after chemotherapy in tumour tissue (p-value=0.003, Student t-test), a 
finding not observed in comparable PHINOM tissue (Figure 46). 
Normal oesophagus Cancer tissue 
Prechemo 
Postchemo 
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Figure 45. Differential phenyl alanine content in different tissue types (p=0.014, 
Kruskal-Wallis test) 
 
 
Figure 46. Differential content of adenine containing compounds in different tissue types 
(p-value < 0.001, Kruskal Wallis test) 
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Tables 11 and 12 show some of comparative content of some of the metabolites 
observed comparing pre and post chemotherapy tissue; it is obvious that the 
differential compounds are not exactly the same in PHINOM as compared to tumour 
tissue signifying a different metabolic phenotype for cancer tissue that results in a 
different metabolic response to chemotherapy than normal tissue. 
 
Compound PPM range Trend p-value 
glutathione 2.54-2.58 Pre<Post 0.07 
lysine 2.99-3.025 Pre > Post 0.02 
phophocholine 3.214-2.224 Pre < Post 0.05 
glycine/ α-Glucose/α-CH 3.7-3.81 Pre > Post 0.03 
adenines 8.22-8.24 Pre < Post 0.003 
 
Table 11. Comparative content of some of the metabolites observed comparing pre and 
post chemotherapy malignant tissue 
 
 
 
Compound PPM range Trend p-value 
lactate 1.314-1.343 Post>Pre    0.04 
acetate 1.88-1.95 Pre > Post 0.04 
scyllo-inositol 3.34-3.36 Post>Pre    0.04 
phophoryl-ethanolamine 3.965-4.005 Pre > Post 0.05 
myoinositol 4.045-4.08 Post>Pre    0.03 
lactate 4.09-4.14 Post>Pre    0.05 
uroconate 7.86-7.9 Pre > Post 0.02 
 
Table 12. Comparative content of some of the metabolites observed comparing pre 
versus Post chemotherapy PHINOM 
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Relative decrease in lysine/creatine ratio was seen in malignant tissue as compared to no 
change in normal tissue was seen; yet statistical significance could not be achieved. It is 
to be noted that part of the lysine resonance is overriding a lipid resonance; this is a factor 
that could suggest studying the lipid resonances as a possible cause for changes seen in 
the lysine/ creatine ratio (Figure 47). 
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Figure 47. Lysine /creatine ratio trend after chemotherapy treatment 
 
4.3.4 Differential effect of chemotherapy on blood samples 
The 1D NMR spectroscopy of serum samples from oesophageal cancer patients and 
normal controls showed visible differences relating to disease status. Median spectra of 
all patient groups showed a greater abundance of several compounds in malignant serum 
samples irrespective of chemotherapy status as shown in study 1.  Signals of lipoproteins, 
(LDL & VLDL CH2 & CH3 groups) and cholesterol appeared to be higher in samples 
taken after chemotherapy (Figure 48).  This was a noted peak difference in chemotherapy 
 142 
treated samples irrespective of whether they were normal or malignant tissues denoting 
the possibility that this is an isolated effect of chemotherapy.  
 
 
Figure 48. 1D median spectra of serum samples showing differences which may be 
attributed to isolated effect of chemotherapy 
 
From a PCA model of these data; PC1 could moderately discriminate between normal 
and malignant samples.  Within the malignant sample group further differentiation 
between pre-chemo and post-chemo samples can be seen. The results from PCA analysis 
support the observed group differences identified by visual inspection of the data. 
Patterns could not at this stage be correlated to variables as sex, age, BMI, type of 
tumour, pathological grade and TNM staging. This may be due to the number of samples 
used being insufficient for sub grouping. 
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4.3.5 Examination of specific chemotherapy induced metabolic alterations in 
patients with matched samples 
In 6 patients where pre and post chemo samples were collected from each, a principal 
component analysis plot based on the previously described metabolite observations 
showed that both malignant and normal tissues move towards a middle metabolic 
phenotype after chemotherapy (Figure 49). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 49. PCA plot showing both tumour (thick lines) and normal (thin lines) tissues 
from the same patients, pre and post chemotherapy, move towards a common metabolic 
phenotype 
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4.3.6 Metabolic profile components of differential response to chemotherapy   
Response to chemotherapy has been histologically examined by reporting of Mandard’s 
grade for 18 tumour tissue samples, all were oesophageal adenocarcinomas. Pathological 
properties and metabolites content of analyzed samples are shown in Table 13. Image 
analysis was also conducted to assess the extent of fibrosis in these samples via 
calculation of areas stained specifically for proliferative indices, apoptosis and fibrosis. 
Image analysis was positively correlated to the histological Mandard grade assessed by 
two independent histopathologists (Spearman’s correlation coefficient 0.91). On the other 
hand, intra and inter observer reliability of pathologist grading was tested and found to  
have fair reproducibility among the same an different pathologists, this was assessed by 
Kappa statistics (data shown in appendix 7); therefore, the image analysis data were 
deemed reliable to be used for our correlation analysis. Samples were subclassified 
according to their Mandard grade, and various metabolites were compared to determine 
whether particular metabolite(s) content differed proportionally to the extent of response 
to chemotherapy. 
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Patient 
 number 
Mandard 
 class 
%  
Fibrosis 
Lactate 
 (1.315 - 1.4) 
Lysine 
 (1.64 - 1.78) 
Glutamine 
  (2.33-2.38) 
Glutathione 
 (2.54-2.58) 
Creatine 
 (3.025 - 3.045) 
Total cholines 
 (3.18 - 3.24) 
Taurine 
 (3.245-3.285) 
Scylloinositol 
 (3.34-3.36) 
Uracil 
  (5.88 - 5.93) 
Tyrosine 
 (6.87-6.93) 
Adenines 
 (8.255 - 8.275) 
P1 4 22 3329100 324140 193040 26115 113860 1181500 415250 50171 12018 22024 2929.1 
P2 1 84 1662500 368260 211220 37381 222750 820090 413440 36097 14223 27197 5269 
P3 5 12 1261600 333960 226350 34590 129730 736470 351190 38579 11708 27368 2705.1 
P4 5 11 1697000 266420 373890 35368 93947 1153400 529410 61422 24607 25578 2911.4 
P5 4 27 1673600 295760 354690 34943 140610 600410 452420 52407 23294 30153 4251 
P6 4 12 2119100 331510 274180 14659 78833 539750 371150 12524 20228 32341 5541.6 
P7 4 21 1827400 391100 187140 18665 139030 1203300 535130 41033 23099 40042 4518.6 
P8 3 33 3146800 243700 203400 53072 85647 636630 382380 43252 3892.3 17462 1239 
P9 5 11 1664800 315900 170240 11620 207300 1151300 474760 58428 25491 29372 3743.1 
P10 5 19 1146400 355130 198910 27066 136500 866170 383660 41288 33293 37623 3627.4 
P11 3 38 1725300 167760 256260 45926 270230 747450 814470 104710 9397.4 12850 2984.6 
P12 3 42 3016000 241970 196520 90478 231210 1136000 647580 66576 19562 20095 3199 
P13 3 34 2718100 223590 216180 58092 136710 935890 518350 47998 3045.2 17162 2658.3 
P14 4 21 2545700 307210 209810 67687 148150 923730 459020 45502 2729.8 25467 2685.9 
P15 2 67 3035000 232900 262370 50988 128980 1896200 643510 44311 2352.2 13076 2228.9 
P16 3 35 1727900 255170 226170 57995 162960 1049100 526390 50879 7709.6 14256 2848.7 
P17 2 49 1506700 247930 233240 61731 188710 1205200 477670 33741 4509.1 17165 2280.1 
P18 3 49 2802800 219620 294470 95362 293890 822430 597870 60614 10815 20718 1563.6 
 
Table 13. Pathological properties (Mandard’s grade of response and %fibrosis) and metabolites content (measured in average of 
relative integral values) of analyzed samples 
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It is to be noted that in the original study by Mandard et al, the multivariate analysis 
done, showed that only TRG (TRG1–3 vs. TRG4–5) remained a significant (p=0.001) 
predictor of disease-free survival (PMID: 8194005). This was taken as a guide to group 
our samples as the small number limits better informative results if the samples are to be 
divided to 5 Mandard groups. When patients were subdivided to Mandard grades 1-3 Vs 
4 and 5, and the metabolite contents were plotted, evident changes show seven 
metabolites (Lysine, Glutathione, Creatine, Taurine, Uracil, Tyrosine and to some extent 
Adenine containing compounds) suggested to be related to quality of response of tumour 
tissue to chemotherapy Table 14 and Figure 50. 
 
 
     Metabolite 
 
 
Mandard 
Lactate 
(1.315 - 
1.4) 
Lysine 
(1.64 -
1.78) 
Glutamine  
(2.33-2.38) 
Glutathione 
(2.54-2.58) 
Creatine 
(3.025 - 
3.045) 
Total 
cholines 
(3.18 - 
3.24) 
Taurine 
(3.245-
3.285) 
Scyllo 
-
inositol  
(3.34-
3.36) 
Uracil  
(5.88 - 
5.93) 
Tyrosine 
(6.87-
6.93) 
Adenines 
(8.255 - 
8.275) 
1,2,3 Vs 4,5 0.179 0.002 0.724 0.002 0.041 0.524 0.037 0.28 0.008 0.0001 0.076 
 
Table 14. Spearman’s correlation coefficients (p-values are displayed) demonstrating 
metabolites that show significant change in relation to tissue responsiveness to 
chemotherapy 
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Figure 50. Metabolite differences according to response to chemotherapy when patients 
were divided into two groups Mandard 1-3 (left column for each metabolite) vs. Mandard 
4, 5 (right column for each metabolite) 
 
 
4.3.7  Summary of findings 
This study showed that metabolic profiling can reliably discriminate chemotherapy 
treated tissue whether tumour or normal mucosa. Both generic and differential effects of 
chemotherapy were demonstrated in normal and cancer tissues. It could also display the 
correlation between variable metabolite content of malignant tissue and respective 
response to chemotherapy. Metabolites that were found to be significantly altered in 
correlation to response to chemotherapy are lysine, glutathione, creatine, taurine, uracil 
and tyrosine. Adenine containing compounds had the same trend but did not reach 
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statistical significance (p=0.07). These metabolites have been described in the literature 
as being closely related to malignant cell metabolism, proliferation and invasiveness, as 
previously discussed in the literature review section.  
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5. CHAPTER 5. FINAL DISCUSSION 
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The overall results of the study have demonstrated evidence of specific metabolic profile 
differences between three distinct groups of tissues: malignant, PHINOM and normal 
controls. It also showed characteristics of selective effect of chemotherapy on different 
tissues and correlated metabolic profile differences to chemotherapy response. This has 
been largely demonstrated in tissue analysis, and briefly cross examined in serum 
analysis. 
 
5.1 Study I: Global metabonomic phenotyping of oesophageal and gastric cancer  
The most significant global finding was that metabolic profiles of different tissues 
(oesophageal and gastric) tended to cluster closer with their new pathological designation 
(adenocarcinoma). This could be explained by the fact that malignant transformation of 
the tissue may have led to a new metabolic phenotype more or less non-specific to tissue, 
yet specific to the cancer process hypothetically transforming its phyico-chemical 
structure and mechanics. This has been clearly visualised in the PCA plots, where normal 
oesophageal and normal gastric samples appeared considerably apart, while malignant 
oesophageal and gastric samples were closer and even overlapping together.  
 
5.1.1 Component differences between cancer and normal tissues 
Glycolytic pathway compounds differentiating between benign and malignant samples 
seem to be closely related to a long known finding, originally described by Warburg in 
the 1920s, ‘aerobic glycolysis’. This the greater tendency of tumour cells to convert 
glucose to lactate in the presence of normal oxygen conditions.  Evidence suggests that 
how tumour cells glycolyse gives them selective growth advantage 23.   
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Recent research showed an increase in the GLUT-1 and GLUT-3 and GLUT-5 mRNA in 
cancers of the oesophagus, colon 218, pancreas 219, GLUT-1 and GLUT-3 mRNA were 
over expressed in the brain 220 and lung carcinomas 221, GLUT-1 protein expression in 
head and neck tumours 222, renal cell carcinoma 223, insulinomas 224 and thyroid cancers 
225; GLUT-1 and GLUT-5 over expression in breast tumours 226,227. The over expression 
of GLUT-1 and GLUT-3 is only localised in the pen-necrotic zones of the tumour, where 
the environment of the tumour cells is hypoxic. An abundance of glucose transporters 
could be an adaptation that helps the tumour cell to survive and gives it an advantage 
over normal cells under such circumstances 222. Of clinical importance is the question 
whether these changes in expression of facilitative transporters are strictly related to the 
malignant phenotype or occur at an early stage in carcinogenesis 22. Reisser et al. 228, 
found that preneoplastic lesions already showed an increased expression of GLUT-1, so 
increases in GLUT-1 expression might be used as a diagnostic tool for detection of 
preneoplastic lesions.  
Most of the tissue and plasma samples could show increase in lactate as the outcome 
product of the glycolytic pathway. This may point out to potentially, new therapeutic 
strategies in the future based on GLUT antagonization. Inhibition of GLUT-1 with 
chemicals such as phloretin, a known inhibitor of glucose membrane transport could be 
useful 229. 3-O-methylglucose could also be effective as it works via competitive 
inhibition of glucose uptake by glucose analogues 230.  
 In addition, a metabolic feature of cancer that has been characterised in probably the 
greatest detail by NMR studies is the presence of elevated choline metabolites in tumour 
cells.  This, together with a change in the phosphocholine/glycerophosphocholine ratio 
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has been shown to be a general marker for cell proliferation; and in conjunction with 
other metabolite measurements it could be predictive of the invasiveness of a tumour and 
useful in the clinical staging of disease.  It is suggested that this may be in part due to 
increased choline transport into the cell and up regulated choline kinase activity in 
response to the demand for phosphatidylcholine and membrane synthesis 50,51.  Choline 
kinase inhibition as a therapeutic strategy has been shown to be successful in animal 
models 53.  This phenomenon has been observed in tissue and bio-fluid analysis of our 
samples.  
5.1.2 Metabolic profiling of oesophageal tissue 
The main focus of the larger part of the study was on oesophageal tissues. The analysis of 
gastric samples showed less ability of differentiation between benign and malignant than 
oesophageal samples. This may be either due to the fact that gastric sample numbers were 
relatively small to attain homogenous subgroups, or that gastric tissue has a lot more 
functional and anatomical variables than oesophageal tissue. These include the presence 
of different types of cells in gastric wall, different hormonal and nervous controls and the 
common presence of Helicobacter Pylori infection the possible metabolic effects of 
which is yet to be adequately examined. Therefore, given the novelty of application of 
this methodology and the need for initial core/baseline qualification of upper gastro 
intestinal tissue metabolic profiling, oesophageal tissue was the appropriate candidate for 
various analyses carried out throughout the course of the work; gastric tissue was used 
initially as a for of positive control to compare and contrast with oesophageal tissue. 
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5.1.2.1 Junctional Tumours 
Analysis of junctional tissue proved very subtle differences from oesophageal tissues. 
During initial analysis and database construction, they have all has been classified as 
Seiwert type I by pathological examination; semi-quantitative comparison of metabolites 
on NMR spectral analysis showed no significant differences between junctional and 
oesophageal tissues, tumour or respective PHINOM.  Thus, Seiwert type I junctional 
tumours were reclassified as oesophageal tumours. Nevertheless, junctional tumour 
samples were shown on PCA plots to be distributed in the region between both 
oesophageal and gastric cancer groups reflecting the reported clinical and pathological 
dilemma whether these tumours really arise from lowermost oesophageal or uppermost 
gastric mucosa.  
5.1.2.2 Oesophageal adenocarcinoma vs. squamous carcinoma 
Cancer of the oesophagus could be clustered on principal component analysis to 
adenocarcinoma and squamous carcinoma. The differences on examining the spectra 
were minimal yet obvious, mostly in lysine and adjoining lipid resonances that were more 
prominent in adenocarcinoma. This clustering could be seen when oesophageal samples 
were plotted separately (Figure 27), different types of tumour subclass i.e. 
adenocarcinoma and squamous carcinoma could be demonstrated on separate PCA 
plotting of oesophageal tissues alone. Squamous cancer could be seen relatively separate 
from adenocarcinoma in an area in between the fully normal epithelium and the 
adenocarcinoma, having the same vector of change from normal epithelium to 
adenocarcinoma. Nevertheless, on specific semi-quantitative comparison of the 
metabolites contributing to separation, subtle differences were found not mounting to 
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statistical significance. This could have been due to the fact that only a few squamous 
carcinoma samples were available for comparison, owing to the natural higher incidence 
of adenocarcinoma in the United Kingdom, which subsequently disproportionate the 
numbers affecting statistical analysis and also undermines the veracity of representability 
of these few samples to the actual general characteristics of this tumour. Nonetheless, the 
observations of analysis of these few samples could highlight the metabolic difference 
phenomenon and promotes the need for subsequent larger scale studies to confirm and 
further explain what was observed during the course of this study. 
5.1.2.3 Barrett’s oesophagus 
The sample numbers used were not enough to sub-classify Barrett’s samples according to 
grade of dysplasia or test qualitative differences in their metabolic profiles. The Barrett’s 
tissue used, all originated from cancer bearing patients, and so the apparent similarity to 
the adenocarcinoma samples may be due to the effect of the nearby cancer and not just 
the local dysplasia. Barrett’s samples appeared within the adenocarcinoma cluster. This 
may to be due to inherent similarity between metabolism of high grade dysplasia and 
cancer in these patients who all had cancer arising on a background of Barrett’s mucosa. 
Yet again, the few number of samples analyzed was not enough for metabolite content 
comparison with either adenocarcinoma or normal mucosa. The collection of Barrett’s 
sample collection was initially planned for; the findings of cancer tissue analysis dictated 
the need of collection of large number of samples where three times as much cancer and 
samples was collected before the final census was analyzed. This was due to different 
processing and analytic sample losses. The course of the study did not allow ample time 
and patient resources for that; new ethical approval was granted for that with recruitment 
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from a renowned Barrett’s surveillance and follow up centre in London was planned, yet 
it has been deemed beyond the time scope of this study and has been incorporated in a 
future work body.  
5.1.2.4 Failure of staging correlation 
Few studies in the literature have attempted correlation of NMR data with clinical 
variables. A rather unsuccessful trial for correlation of NMR data with clinical variables 
was done in this study. The mathematical models developed could classify samples 
according to tissue of origin, oesophagus/stomach, pathological nature i.e. normal, and 
cancer. TNM stage and grade of differentiation may have been expected to affect the 
metabolic pattern as it depends on extent of genetic similarity to original cells. 
Nevertheless, correlation of tissue data with those factors could not be attained. This may 
be either due to insensitivity of the technique to these subtle differences or due to 
inaccuracy of the visual microscopic pathological grading, which is a rather subjective 
judgement of the pathologist. Other clinical variables as age, sex, BMI, co-morbidity had 
no apparent effect on the samples’ classification at this stage. This is either due to lack of 
actual differences between them or due to small number of patients.  
5.1.3 Pattern recognition validity 
Consistent clustering of samples of different origin upon pattern recognition techniques 
was done in a non-supervised learning statistical model. This validates the reliability of 
the MAS technique starting from sample collection through data analysis. It is to be noted 
that the samples were obtained both surgically and endoscopically, collected from 
different centres and NMR run on different occasions. Of interest, two of the malignant 
samples that were collected endsocopically from a visible tumour mass were 
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unexpectedly deemed ‘normal epithelium’ by pathological examination. On our models 
they were seen among the malignant group. Further analysis of repeat samples obtained 
after surgical resection of this tumour confirmed its malignant nature as supported by 
pathology reports. An argument can be made whether metabolic profiles were actually 
more sensitive in classifying the two samples than pathological examination. This can be 
further studied by NMR analysis of future disputed samples and comparing that with 
results of currently used confirmatory tests as immuno-histochemical staining. The 
sample numbers used were not enough to sub-classify Barrett’s samples according to 
grade of dysplasia or test qualitative differences in their metabolic profiles.  
 
5.2 Study II: Field effects in non-dysplastic tissue in oesophageal cancer patients 
5.2.1 Concept of ‘field cancerization’ 
This concept was introduced by Slaughter in 1953 to describe the existence of 
generalized carcinogen induced early genetic changes in the epithelium from which 
multiple independent lesions occur, leading to the development of multifocal tumours 76-
78
. This formed a belief that the lateral spread of tumours was due to progressive 
transformation of cells adjacent to a tumour, rather than the spread and destruction of the 
adjacent epithelium by pre-existing cancer cells 77.  Ever since, many studies were 
conducted to test this hypothesis in various cancers as referenced in the text; also, by 
investigating the genetic and epigenetic mutations, transcriptional effects and proteomic 
profiling aspects of tumours.  With present technological advancement, including laser 
capture micro-dissection and high-throughput genomic technologies, carefully designed 
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studies using appropriate control tissue will enable identification of important molecular 
signatures in these genetically transformed but histologically normal cells 75.  
5.2.2 Metabonomic evidence of field cancerization 
By comparing histologically normal mucosa proximal to a tumour (PHINOM) with 
normal mucosa from non-diseased controls and tumour tissue, this study provides new 
evidence that field cancerization in oesophageal cancer manifests a metabolic phenotype 
and that metabolic profiling via 1H MAS-NMR is sensitive to this phenomenon.  
Moreover, metabolites were identified that show a progression in detectable levels from 
normal to PHINOM to tumour tissue. Some of these metabolites, such as phosphocholine 
(PC), are well established metabolic biomarkers for malignant potential.  Alterations to 
choline metabolism and specifically the increase in PC have been shown to differentiate 
malignant from normal tissue in most tumours. Also, choline kinase expression which 
forms PC is increased in several cancers 50.  Normal epithelial cells transformed by 
oncoproteins or loss of tumour suppressors, also show increases in PC and conversely 
reintroduction of p53 into p53-/- HCT116 cells has been shown to decrease intracellular 
PC levels 231.  Given that loss of heterozygosity (LOH) at loci for the tumour suppressors 
p16 (9p21) and p53 (17p13) have been used to map fields in the oesophagus 232, and that 
PC levels are affected by p53 status, our observation that PC levels were elevated in 
PHINOM is consistent with the hypothesis that tumours arise within a widespread 
genetically predisposed field.  Furthermore, it has recently been shown that loss of p53 
function could directly contribute to other well established aspects of the tumour 
metabolic phenotype, such as the Warburg effect (increased glucose uptake and 
metabolism to lactate), via regulation of mitochondrial metabolism and glycolysis 23.  
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While a progressive change in lactate or glucose levels was not seen, lactate levels were 
higher in tissue from cancer patients compared to controls.  The observation that 
glutamate was progressively decreased in PHINOM and tumour may also reflect 
alterations to mitochondrial function since the increase in glutaminolysis in tumour cells 
is in part due to the consumption of glutamate via a truncated TCA cycle 233. 
The presence of field cancerization in upper gastrointestinal cancer is widely accepted, 
with well documented clonal expansion in Barrett’s dysplasia, the major pre-malignant 
lesion 80.  The results present in this report are of particular significance because the 
tissue used to define the metabolic field effect was not dysplastic nor did any of the 
patients have cancer that arose on a Barrett’s background.  This implies that metabolic 
analysis is sensitive to molecular changes that are relevant to oesophageal cancer in 
general and may relate to field related phenomena such as the well documented 
association between oesophageal and head and neck cancers; and satellite metastasis 234.  
In addition to being an alternative route to genetic measurements to assess the state of the 
cancer field, metabolic profiling has several advantageous features.  MAS-NMR profiles 
can be measured within 30 minutes of obtaining tissue from surgery or endoscopy so it 
has the potential to inform early decisions. Although histological assessment of frozen 
section can be carried out within the same time scale, MAS-NMR has the advantage of 
being able to detect changes in histologically normal tissue. Metabolic biomarkers in 
general have other advantages: as a phenotypic endpoint, these can reflect a number of 
genetic lesions that produce the same loss of function; also, a metabolite has a defined 
chemical structure and hence analytical protocol for analysis can translate across species 
and sample type.  More generally, the ability to characterize the state of the field might 
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improve accuracy of diagnosis and staging.  As noted in the first study, two of the 
samples which were collected endoscopically from a visible tumour mass were 
unexpectedly deemed ‘normal epithelium’ by pathological examination. In our model, 
they were classified as metabolically malignant, and analysis of samples obtained from 
the patient after surgical resection of those lesions confirmed its malignant nature. In an 
MAS-NMR profiling study of post-surgical prostate tissue, metabolic profiles of 
histologically-normal tissue were shown to systematically vary with stage 235.   
 
5.2.3 Clinical implication of field cancerization findings 
The most effective strategy to improve the outcome of oesophageal cancer was proven to 
be early detection 236.  Effectiveness of surveillance programmes has been disadvantaged 
by the low positive yield of endoscopic biopsies and lack of other biomarkers 237-239.In 
spite that conventional white-light endoscopy remains the gold standard surveillance 
procedure for pre-malignant conditions of the upper gastro-intestinal tract, its cost-
effectiveness is debated 238,239. The surveillance endoscopy, as mandated by the American 
College of Gastroenterology guidelines, yields about 20 biopsies, most of which are 
normal on histological assessment. Even with stepwise endoscopic biopsy in patients 
with confirmed high grade dysplasia, 41-66% of resected specimens had missed cancer 
lesions 237.  
The demonstration of metabolic field changes adjoining to oesophageal cancer in this 
study has significant clinical implications as metabonomic profiling of histologically 
normal tissue of cancer patients has the potential to predict the presence of malignancy 
within the sampled field. This would reduce the incidence of missed cancer because of 
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sampling errors with significant impact on increasing the pick up rate in diagnostic 
endoscopy. In this way, biomarkers of field effects in oesophageal and other more 
prevalent gastrointestinal malignancies, such as colorectal cancer, are important for 
improving strategies for surveillance and disease prevention and could have enormous 
benefits to health and healthcare expenditure.  Further studies are required to elucidate 
the molecular mechanisms that produce the phenomenon. 
Another surgical application to this finding would be for patients who are candidates for 
surgical resection. If it is hypothesized that this metabolic field change is partly related to 
or causative of local tumour recurrence; then metabonomic mapping of the oesophagus 
could be done preoperatively to determine the topographic extent and severity of this 
field and subsequently inform the surgical decision as to the extent of surgical resection. 
Also, metabonomic mapping of what could be considered a sentinel lymph node i.e. the 
first tier of lymph nodes draining the tumour area could be useful intra-operatively to 
inform the surgeons plan of the radicality of lymphadenectomy, an issue that has long 
been a debate among upper gastro intestinal cancer surgeons. 
 
5.3 Study III: Profiling metabonomic response of oesophageal adenocarcinoma to 
chemotherapy  
5.3.1  Metabonomic response to chemotherapy 
This study showed that metabolic profiling can reliably discriminate chemotherapy 
treated tissue whether tumour or normal mucosa. Both generic and differential effects of 
chemotherapy were demonstrated in normal and cancer tissues. It could also display the 
correlation between variable metabolite content of malignant tissue and respective 
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response to chemotherapy. Metabolites found to be significantly altered in correlation to 
response to chemotherapy are lysine, glutathione, creatine, taurine, uracil, tyrosine and to 
some extent, adenine containing compounds. These metabolites have been described in 
the literature as being closely related to malignant cell metabolism, proliferation and 
invasiveness, as previously discussed in the literature review section1, 4, 17, 23, 44, 56, 63.  
 In 6 patients where pre and post chemotherapy samples were collected, a principal 
component analysis plot based on the previously described metabolite observations 
showed that both malignant and normal tissues move towards a middle metabolic 
phenotype after chemotherapy. This may even represent formation of fibrous tissue, the 
amount of which reflects the quality of response to chemotherapy. The extent of 
movement of the tissues towards that phenotype needs to be investigated as a surrogate 
marker of response to chemotherapeutics. 
 
5.3.2 Clinical implications of metabonomic biomarkers to chemotherapy effect 
The specific metabolite alterations, which were only seen in tumour tissue and not in 
normal mucosa, suggest the differential response of cancer tissue to chemotherapy than 
the normal one.   This could be a product of the deranged metabolic pathways caused by 
perturbations inflicted by the mutated and damaged genetic structure of tumour cells. The 
question is: can this change be fixed whereas the response of the malignant cell 
metabolome to chemotherapy can be consistently qualified, in a way that can be 
examined to actually predict extent of response to chemotherapy. A factor that will 
prevent that is the genetic heterogeneity of cancer cell genomes across patients and even 
in the same tumour. On the other hand, one could argue that different tumours have well 
 162 
described clinical behaviour and pathological features that the intercellular heterogeneity 
might be a subtle effecter in the process as compared to the generic, more or less 
expected genomic and functional genomic structure of that tumour. The literature has 
scant proof of biomarkers that can be used to predict response to chemotherapy133, 136; 
this leads many patients to be managed according to current treatment strategies with 
subsequent harm to a group of patients who are resistant to chemotherapy, where by the 
time they finish their planned protocol of treatment, their tumours would have even 
grown bigger and spread further, leading to exclusion of other approaches e.g. surgery, 
which might have been feasible in the beginning of these treatment protocols145, 146. 
Whether the changes imposed by carcinogenesis were normalised by the administration 
of chemotherapy is a material for a subsequent prospective study where appropriate 
numbered samples would collected and analyzed pre-chemotherapy and followed up post 
chemotherapy administration in a temporal fashion at distinct time points to actually 
monitor the levels and ratios of metabolites measured to determine the selective effect of 
each chemotherapy regimen on cellular metabolism and the progression of this effect 
with respect to time, incidence of recurrence and distant metastasis. This could give an 
insight as to the active components of metabolic pathways in carcinogenesis, progression, 
regression and invasiveness. 
Predictive markers of response would therefore be invaluable in individualising patient 
treatment as it would enable discrimination of those patients likely to respond to 
combination therapy from those likely to be non-responsive, thus saving invaluable 
human and financial resources that is wasted otherwise. Most published studies have 
focussed on a single marker or a set of markers targeting specific pathways that may be 
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involved in cellular response to chemotherapeutics. However, it is clear that the cancer 
phenotype is a product of genetic and epigenetic alterations and, therefore, the ultimate 
response to cytotoxic therapy in cancer is also likely to be dictated by these genetic and 
epigenetic changes within the cancer genome and leading to alteration of the 
metabonomic phenotype. Thus, use of advanced metabonomic analysis exploring these 
possibilities has been demonstrated by this study 141.  
 
5.3.3 Limitations of the study 
Of the general limitations observed in this study is the relatively small sample numbers, 
where more numbers are needed to allow homogenous subgroups to study the myriad of 
variables as tumour subtypes, different schemes of chemotherapy and site specific 
subgroups of gastric cancer. Spectra of excluded outliers were examined; most of them 
had an abnormality in the form of broad peaks in some, non straight base line in another 
and poor peak expression in many. Causes of such abnormalities could be attributed to 
inadequacies in sample collection, storage, analysis or processing of data. It is to be noted 
that such exclusion decreased in the subsequent studies probably due to advancement of 
the learning curve of the author during the course of the studies.  
 
5.4 Conclusions 
The results of tissue analysis demonstrated differences between normal gastric and 
oesophageal tissue samples and their malignant counterpart.  Normal oesophageal and 
normal gastric samples appeared considerably apart, while malignant oesophageal and 
gastric samples were closer and even overlapping together. There is distinct difference 
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between normal and cancer oesophageal tissue and between squamous and 
adenocarcinoma. Variable metabolites contributing to the separation between normal and 
cancer oesophageal tissues were identified. Choline, phosphocholine and 
glycerophosphocholine, taurine, tyrosine, lactate, phenylalanine, uracil, scylloinositol and 
myoinositol metabolites were found to be significantly higher in cancer tissue samples 
whereas normal tissue controls, had significantly higher content of glucose, glutamine, 
glutathione and adenine containing compounds.  
By comparing histologically normal mucosa proximal to a tumour (PHINOM) with 
normal mucosa from non-diseased controls and tumour tissue, this study provides new 
evidence that field cancerization in oesophageal cancer manifests a metabolic phenotype 
and that metabolic profiling via 1H MAS-NMR is sensitive to this phenomenon.  
Moreover, metabolites were identified that show a progression in detectable levels from 
normal to PHINOM to tumour tissue. Some of these metabolites, such as phosphocholine 
(PC), are well established metabolic biomarkers for malignant potential.   
Both generic and differential effects of chemotherapy were demonstrated in normal and 
cancer tissues. Metabolites found to be significantly altered in correlation to response to 
chemotherapy are lysine, glutathione, creatine, taurine, uracil, tyrosine and to some extent 
adenine containing compounds. These metabolites have been described in the literature as 
being closely related to malignant cell metabolism, proliferation and invasiveness, as 
previously discussed in the literature review section.  
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6. CHAPTER 6. FUTURE STUDIES 
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6.1 Relationship between metabolic profiles and stage of cancer 
Correlation with other means of investigation will be attempted by trying to correlate 
NMR profile changes to visual enhancements on PET imaging scans and examine 
relation to cancer stage. It may be possible to correlate metabolic profile changes and 
PET scan findings e.g. standard uptake volume, mass / volume assessment by PET scan. 
Recent groups developed a prototype of endoscope mounted NMR probe which can 
provide realtime metabonomic profile for biliary ducts, this can be used for screening of 
oesophageal mucosa, this pioneering progress directs future research to translation of data 
acquired into a standard bedside screening test for oesophageal cancer 240. 
6.2 Characterization of pre-malignant tissues: 
The next step is to target premalignant conditions i.e. Barrett disease. The aim is to 
characterize Barrett epithelium in light of its pathological grading and determine whether 
there is a metabolic continuum on a scale starting at normal epithelium, passing through 
Barrett and finally cancer transformation. The following questions need to be answered: 
z Does the metabonomic profile change corresponding to degree of dysplasia in 
Barrett’s epithelium? 
z Is Barrett’s epithelium in cancer bearing oesophagus metabolically different than 
Barrett in otherwise normal oesophagus? 
z Can the potential for malignant transformation be predicted? 
z Can gene expression profiling explain metabonomic findings or direct further 
research on other metabolic pathways? 
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6.3 Effect of therapeutic modalities on body fluids metabolic profiles: 
Parallel to tissue findings, differences between malignant and benign, pre and post chemo 
serum samples were seen. The plan for the team is to address the following questions: 
z Would Radical surgery with curative intent reverse metabolic changes seen in 
cancer patients?, subsequently, can recurrence be detected and with what certainty? 
z Can the response to chemotherapy be predicted from serum metabolic profile 
changes? Can changes be seen in urine? 
 168 
 
 
 
 
 
 
 
 
 
 
7. REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 169 
 1.  Lupulescu, A. Cancer Cell Metabolism and Cancer Treatment. Harwood 
Academic Publishers, The Netherlands (2001). 
 2.  Dave, U., Taylor-Robinson, S. D., Walker, M. M., Mahon, M., Puri, B. K., 
Thursz, M. R., deSouza, N. M., Cox, I. J. In vitro 1H-magnetic resonance 
spectroscopy of Barrett's esophageal mucosa using magic angle spinning 
techniques. Eur J Gastroenterol Hepatol. 16,1199-1205 (2004). 
 3.  Jones, G. R. Cancer destruction in vivo through disrupted energy metabolism. Part 
I. The endogenous mechanism of self-destruction within the malignant cell, and 
the roles of endotoxin, certain hormones and drugs, and active oxygen in causing 
cellular injury and death. Physiol Chem. Phys. Med NMR 24, 169-179 (1992). 
 4.  Kaplan, O. & Cohen, J. S. Metabolism of breast cancer cells as revealed by non-
invasive magnetic resonance spectroscopy studies. Breast Cancer Res. Treat. 31, 
285-299 (1994). 
 5.  Lamond, A. I. & Earnshaw, W. C. Structure and function in the nucleus. Science 
280, 547-553 (1998). 
 6.  Lindon, J. C., Nicholson, J. K., Sidelmann, U. G. & Wilson, I. D. Directly 
coupled HPLC-NMR and its application to drug metabolism. Drug Metab Rev. 
29, 705-746 (1997). 
 7.  Lupulescu, A. P. Hormones, vitamins, and growth factors in cancer treatment and 
prevention. A critical appraisal. Cancer 78, 2264-2280 (1996). 
 8.  Penman, S. Rethinking cell structure. Proc. Natl. Acad. Sci. U. S. A 92, 5251-
5257 (1995). 
 9.  WARBURG, O. On respiratory impairment in cancer cells. Science 124, 269-270 
(1956). 
 10.  Nicholson, J. K., Lindon, J. C. & Holmes, E. 'Metabonomics': understanding the 
metabolic responses of living systems to pathophysiological stimuli via 
multivariate statistical analysis of biological NMR spectroscopic data. 
Xenobiotica 29, 1181-1189 (1999). 
 11.  Lindon, J. C., Nicholson, J. K. & Holmes, E. The Handbook of Metabonomics and 
Metabolomics. Elsevier, The Netherlands (2007). 
 12.  Denkert, C. et al. Mass spectrometry-based metabolic profiling reveals different 
metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. 
Cancer Res. 66, 10795-10804 (2006). 
 13.  Petrik, V., Loosemore, A., Howe, F. A., Bell, B. A. & Papadopoulos, M. C. 
OMICS and brain tumour biomarkers. Br J Neurosurg. 20, 275-280 (2006). 
 170 
 14.  Yang, J. et al. Diagnosis of liver cancer using HPLC-based metabonomics 
avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J 
Chromatogr. B Analyt. Technol. Biomed. Life Sci. 813, 59-65 (2004). 
 15.  Behl, C. et al. Neuroprotection against oxidative stress by estrogens: structure-
activity relationship. Mol. Pharmacol. 51, 535-541 (1997). 
 16.  Nguyen, T., Chin, W. C. & Verdugo, P. Role of Ca2+/K+ ion exchange in 
intracellular storage and release of Ca2+. Nature 395, 908-912 (1998). 
 17.  Bi, X. et al. Proteomic analysis of colorectal cancer reveals alterations in 
metabolic pathways: mechanism of tumorigenesis. Mol. Cell Proteomics. 5, 1119-
1130 (2006). 
 18.  Moreno, A., Rey, M., Montane, J. M., Alonso, J. & Arus, C. 1H NMR 
spectroscopy of colon tumors and normal mucosal biopsies; elevated taurine 
levels and reduced polyethyleneglycol absorption in tumors may have diagnostic 
significance. NMR Biomed. 6, 111-118 (1993). 
 19.  Longley, D. B., Allen, W. L. & Johnston, P. G. Drug resistance, predictive 
markers and pharmacogenomics in colorectal cancer. Biochim. Biophys. Acta 
1766, 184-196 (2006). 
 20.  Wallace, D. C. Mitochondria as chi. Genetics 179, 727-735 (2008). 
 21.  Selig, M., Xavier, K. B., Santos, H. & Schonheit, P. Comparative analysis of 
Embden-Meyerhof and Entner-Doudoroff glycolytic pathways in 
hyperthermophilic archaea and the bacterium Thermotoga. Arch. Microbiol. 167, 
217-232 (1997). 
 22.  Pauwels, E. K., Sturm, E. J., Bombardieri, E., Cleton, F. J. & Stokkel, M. P. 
Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical 
uptake mechanism and its implication for clinical studies. J Cancer Res. Clin 
Oncol 126, 549-559 (2000). 
 23.  Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? 
Nat. Rev. Cancer 4, 891-899 (2004). 
 24.  Warburg, O., Wind, F. & Negelein, E. Uber den Stoffwechsel von Tumourenim 
Korper. Klin Woch 5, 829-832 (1926). 
 25.  Gullino, P. M., Grantham, F. H. & Courtney, A. H. Utilization of oxygen by 
transplanted tumors in vivo. Cancer Res. 27, 1020-1030 (1967). 
 26.  Weinhouse, S. On respiratory impairment in cancer cells. Science 124, 267-269 
(1956). 
 171 
 27.  Semenza, G. L. et al. 'The metabolism of tumours': 70 years later. Novartis. 
Found. Symp. 240, 251-260 (2001). 
 28.  Nakashima, R. A., Paggi, M. G. & Pedersen, P. L. Contributions of glycolysis and 
oxidative phosphorylation to adenosine 5'-triphosphate production in AS-30D 
hepatoma cells. Cancer Res. 44, 5702-5706 (1984). 
 29.  Birnbaum, M. J., Haspel, H. C. & Rosen, O. M. Transformation of rat fibroblasts 
by FSV rapidly increases glucose transporter gene transcription. Science 235, 
1495-1498 (1987). 
 30.  Flier, J. S., Mueckler, M. M., Usher, P. & Lodish, H. F. Elevated levels of glucose 
transport and transporter messenger RNA are induced by ras or src oncogenes. 
Science 235, 1492-1495 (1987). 
 31.  Singh, M., Singh, V. N., August, J. T. & Horecker, B. L. Alterations in glucose 
metabolism in chick embryo cells transformed by Rous sarcoma virus. 
Transformation-specific changes in the activities of key enzymes of the glycolytic 
and hexose monophosphate shunt pathways. Arch. Biochem. Biophys. 165, 240-
246 (1974). 
 32.  Arora, K. K. & Pedersen, P. L. Functional significance of mitochondrial bound 
hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation 
of glucose by intramitochondrially generated ATP. J Biol. Chem. 263, 17422-
17428 (1988). 
 33.  Rempel, A., Bannasch, P. & Mayer, D. Differences in expression and intracellular 
distribution of hexokinase isoenzymes in rat liver cells of different transformation 
stages. Biochim. Biophys. Acta 1219, 660-668 (1994). 
 34.  Mathupala, S. P., Heese, C. & Pedersen, P. L. Glucose catabolism in cancer cells. 
The type II hexokinase promoter contains functionally active response elements 
for the tumor suppressor p53. J Biol. Chem. 272, 22776-22780 (1997). 
 35.  Mukhopadhyay, T., Maxwell, A. S. & Roth, J. A. p53 supppressor gene. Landes, 
Austin, Texas (1995). 
 36.  Bartrons, R. & Caro, J. Hypoxia, glucose metabolism and the Warburg's effect. J 
Bioenerg. Biomembr. 39, 223-229 (2007). 
 37.  Strauss, L. G. & Conti, P. S. The applications of PET in clinical oncology. J Nucl 
Med 32, 623-648 (1991). 
 38.  Okazumi, S. et al. Evaluation of liver tumors using fluorine-18-
fluorodeoxyglucose PET: characterization of tumor and assessment of effect of 
treatment. J Nucl Med 33, 333-339 (1992). 
 172 
 39.  Slosman, D. O., Pittet, N., Donath, A. & Polla, B. S. Fluorodeoxyglucose cell 
incorporation as an index of cell proliferation: evaluation of accuracy in cell 
culture. Eur. J Nucl Med 20, 1084-1088 (1993). 
 40.  Crippa, F. et al. Association between [18F]fluorodeoxyglucose uptake and 
postoperative histopathology, hormone receptor status, thymidine labelling index 
and p53 in primary breast cancer: a preliminary observation. Eur. J Nucl Med 25, 
1429-1434 (1998). 
 41.  Brock, C. S., Meikle, S. R. & Price, P. Does fluorine-18 fluorodeoxyglucose 
metabolic imaging of tumours benefit oncology? Eur. J Nucl Med 24, 691-705 
(1997). 
 42.  Kubota, R. et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in 
vivo: high accumulation in macrophages and granulation tissues studied by 
microautoradiography. J Nucl Med 33, 1972-1980 (1992). 
 43.  Kubota, R. et al. Microautoradiographic study for the differentiation of 
intratumoral macrophages, granulation tissues and cancer cells by the dynamics of 
fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 35, 104-112 (1994). 
 44.  Coles, N. W. & Johnstone, R. M. Glutamine metabolism in Ehrlich ascites-
carcinoma cells. Biochem. J 83, 284-291 (1962). 
 45.  Reitzer, L. J., Wice, B. M. & Kennell, D. Evidence that glutamine, not sugar, is 
the major energy source for cultured HeLa cells. J Biol. Chem. 254, 2669-2676 
(1979). 
 46.  van Acker, B. A. et al. Glutamine: the pivot of our nitrogen economy? JPEN J 
Parenter. Enteral Nutr. 23, S45-S48 (1999). 
 47.  Medina, M. A., Sanchez-Jimenez, F., Marquez, J., Rodriguez, Q. A. & Nunez, d. 
C., I Relevance of glutamine metabolism to tumor cell growth. Mol. Cell 
Biochem. 113, 1-15 (1992). 
 48.  Kuhajda, F. P. Fatty acid synthase and cancer: new application of an old pathway. 
Cancer Res. 66, 5977-5980 (2006). 
 49.  Plathow, C. & Weber, W. A. Tumor cell metabolism imaging. J Nucl Med 49 
Suppl 2, 43S-63S (2008). 
 50.  Glunde, K. & Bhujwalla, Z. M. Choline kinase alpha in cancer prognosis and 
treatment. Lancet Oncol 8, 855-857 (2007). 
 51.  Gillies, R. J. & Morse, D. L. In vivo magnetic resonance spectroscopy in cancer. 
Annu. Rev. Biomed. Eng 7, 287-326 (2005). 
 173 
 52.  Utriainen, M. et al. Evaluation of brain tumor metabolism with [11C]choline PET 
and 1H-MRS. J Neurooncol. 62, 329-338 (2003). 
 53.  Aoyama, C., Liao, H. & Ishidate, K. Structure and function of choline kinase 
isoforms in mammalian cells. Prog. Lipid Res. 43, 266-281 (2004). 
 54.  Aoyama, C., Ishidate, K., Sugimoto, H. & Vance, D. E. Induction of choline 
kinase alpha by carbon tetrachloride (CCl4) occurs via increased binding of c-jun 
to an AP-1 element. Biochim. Biophys. Acta 1771, 1148-1155 (2007). 
 55.  Cuadrado, A., Carnero, A., Dolfi, F., Jimenez, B. & Lacal, J. C. 
Phosphorylcholine: a novel second messenger essential for mitogenic activity of 
growth factors. Oncogene 8, 2959-2968 (1993). 
 56.  Aboagye, E. O. & Bhujwalla, Z. M. Malignant transformation alters membrane 
choline phospholipid metabolism of human mammary epithelial cells. Cancer 
Res. 59, 80-84 (1999). 
 57.  Ramirez de, M. A. et al. Choline kinase activation is a critical requirement for the 
proliferation of primary human mammary epithelial cells and breast tumor 
progression. Cancer Res. 64, 6732-6739 (2004). 
 58.  Bhakoo, K. K., Williams, S. R., Florian, C. L., Land, H. & Noble, M. D. 
Immortalization and transformation are associated with specific alterations in 
choline metabolism. Cancer Res. 56, 4630-4635 (1996). 
 59.  Costello, L. C. & Franklin, R. B. 'Why do tumour cells glycolyse?': from 
glycolysis through citrate to lipogenesis. Mol. Cell Biochem. 280, 1-8 (2005). 
 60.  Podo, F. Tumour phospholipid metabolism. NMR Biomed. 12, 413-439 (1999). 
 61.  Kwock, L. et al. Clinical role of proton magnetic resonance spectroscopy in 
oncology: brain, breast, and prostate cancer. Lancet Oncol 7, 859-868 (2006). 
 62.  Dowling, C. et al. Preoperative proton MR spectroscopic imaging of brain 
tumors: correlation with histopathologic analysis of resection specimens. AJNR 
Am. J Neuroradiol. 22, 604-612 (2001). 
 63.  Howe, F. A. et al. Metabolic profiles of human brain tumors using quantitative in 
vivo 1H magnetic resonance spectroscopy. Magn Reson. Med 49, 223-232 (2003). 
 64.  Chen, J., Huang, S. L., Li, T. & Chen, X. L. In vivo research in astrocytoma cell 
proliferation with 1H-magnetic resonance spectroscopy: correlation with 
histopathology and immunohistochemistry. Neuroradiology 48, 312-318 (2006). 
 65.  Jeun, S. S. et al. Assessment of malignancy in gliomas by 3T 1H MR 
spectroscopy. Clin Imaging 29, 10-15 (2005). 
 174 
 66.  Costello, L. C. & Franklin, R. B. Citrate metabolism of normal and malignant 
prostate epithelial cells. Urology 50, 3-12 (1997). 
 67.  Kurhanewicz, J., Vigneron, D., Carroll, P. & Coakley, F. Multiparametric 
magnetic resonance imaging in prostate cancer: present and future. Curr. Opin. 
Urol. 18, 71-77 (2008). 
 68.  Hricak, H. MR imaging and MR spectroscopic imaging in the pre-treatment 
evaluation of prostate cancer. Br J Radiol. 78 Spec No 2, S103-S111 (2005). 
 69.  Schoder, H. et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography 
for the detection of disease in patients with prostate-specific antigen relapse after 
radical prostatectomy. Clin Cancer Res. 11, 4761-4769 (2005). 
 70.  Hara, T., Kosaka, N. & Kishi, H. PET imaging of prostate cancer using carbon-
11-choline. J Nucl Med 39, 990-995 (1998). 
 71.  Sutinen, E. et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET 
study. Eur. J Nucl Med Mol. Imaging 31, 317-324 (2004). 
 72.  Breeuwsma, A. J. et al. In vivo uptake of [11C]choline does not correlate with cell 
proliferation in human prostate cancer. Eur. J Nucl Med Mol. Imaging 32, 668-
673 (2005). 
 73.  Giovacchini, G. et al. [(11)C]choline uptake with PET/CT for the initial diagnosis 
of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic 
therapy. Eur. J Nucl Med Mol. Imaging 35, 1065-1073 (2008). 
 74.  Scheidler, J. et al. Prostate cancer: localization with three-dimensional proton MR 
spectroscopic imaging--clinicopathologic study. Radiology 213, 473-480 (1999). 
 75.  Dakubo, G. D., Jakupciak, J. P., Birch-Machin, M. A. & Parr, R. L. Clinical 
implications and utility of field cancerization. Cancer Cell Int. 7, 2 (2007). 
 76.  Slaughter, D. P. The multiplicity of origin of malignant tumours: collective 
review. Internat Abstr Surg 79, 89-98 (1944). 
 77.  Slaughter, D. P. Multicentric origin of intraoral carcinoma. Surgery 20, 133-146 
(1946). 
 78.  Slaughter, D. P., SOUTHWICK, H. W. & SMEJKAL, W. Field cancerization in 
oral stratified squamous epithelium; clinical implications of multicentric origin. 
Cancer 6, 963-968 (1953). 
 79.  Braakhuis, B. J., Tabor, M. P., Kummer, J. A., Leemans, C. R. & Brakenhoff, R. 
H. A genetic explanation of Slaughter's concept of field cancerization: evidence 
and clinical implications. Cancer Res. 63, 1727-1730 (2003). 
 175 
 80.  Prevo, L. J., Sanchez, C. A., Galipeau, P. C. & Reid, B. J. p53-mutant clones and 
field effects in Barrett's esophagus. Cancer Res. 59, 4784-4787 (1999). 
 81.  Simon, R. et al. Cytogenetic analysis of multifocal bladder cancer supports a 
monoclonal origin and intraepithelial spread of tumor cells. Cancer Res. 61, 355-
362 (2001). 
 82.  Tabor, M. P. et al. Multiple head and neck tumors frequently originate from a 
single preneoplastic lesion. Am. J Pathol. 161, 1051-1060 (2002). 
 83.  Tabor, M. P. et al. Genetically altered fields as origin of locally recurrent head 
and neck cancer: a retrospective study. Clin Cancer Res. 10, 3607-3613 (2004). 
 84.  Sui, G. et al. Mitochondrial DNA mutations in preneoplastic lesions of the 
gastrointestinal tract: a biomarker for the early detection of cancer. Mol. Cancer 
5, 73 (2006). 
 85.  Shen, L. et al. MGMT promoter methylation and field defect in sporadic 
colorectal cancer. J Natl. Cancer Inst. 97, 1330-1338 (2005). 
 86.  Deng, G., Lu, Y., Zlotnikov, G., Thor, A. D. & Smith, H. S. Loss of 
heterozygosity in normal tissue adjacent to breast carcinomas. Science 274, 2057-
2059 (1996). 
 87.  Heaphy, C. M. et al. Telomere DNA content and allelic imbalance demonstrate 
field cancerization in histologically normal tissue adjacent to breast tumors. Int. J 
Cancer 119, 108-116 (2006). 
 88.  Ha, P. K. et al. Mitochondrial C-tract alteration in premalignant lesions of the 
head and neck: a marker for progression and clonal proliferation. Clin Cancer 
Res. 8, 2260-2265 (2002). 
 89.  Chandran, U. R. et al. Differences in gene expression in prostate cancer, normal 
appearing prostate tissue adjacent to cancer and prostate tissue from cancer free 
organ donors. BMC. Cancer 5, 45 (2005). 
 90.  Birch-Machin, M. A. The role of mitochondria in ageing and carcinogenesis. Clin 
Exp. Dermatol. 31, 548-552 (2006). 
 91.  Roesch-Ely, M. et al. Proteomic analysis reveals successive aberrations in protein 
expression from healthy mucosa to invasive head and neck cancer. Oncogene 26, 
54-64 (2007). 
 92.  Wong, D. J. et al. p16(INK4a) lesions are common, early abnormalities that 
undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res. 61, 
8284-8289 (2001). 
 176 
 93.  Kim, S. K. et al. The epigenetic silencing of LIMS2 in gastric cancer and its 
inhibitory effect on cell migration. Biochem. Biophys. Res. Commun. 349, 1032-
1040 (2006). 
 94.  Grepmeier, U. et al. Deletions at chromosome 2q and 12p are early and frequent 
molecular alterations in bronchial epithelium and NSCLC of long-term smokers. 
Int. J Oncol 27, 481-488 (2005). 
 95.  Jonason, A. S. et al. Frequent clones of p53-mutated keratinocytes in normal 
human skin. Proc. Natl. Acad. Sci. U. S. A 93, 14025-14029 (1996). 
 96.  Chu, T. Y., Shen, C. Y., Lee, H. S. & Liu, H. S. Monoclonality and surface 
lesion-specific microsatellite alterations in premalignant and malignant neoplasia 
of uterine cervix: a local field effect of genomic instability and clonal evolution. 
Genes Chromosomes. Cancer 24, 127-134 (1999). 
 97.  Rosenthal, A. N., Ryan, A., Hopster, D. & Jacobs, I. J. Molecular evidence of a 
common clonal origin and subsequent divergent clonal evolution in vulval 
intraepithelial neoplasia, vulval squamous cell carcinoma and lymph node 
metastases. Int. J Cancer 99, 549-554 (2002). 
 98.  Kakizoe, T. Development and progression of urothelial carcinoma. Cancer Sci. 
97, 821-828 (2006). 
 99.  Furlan, D. et al. The high frequency of de novo promoter methylation in 
synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res. 12, 
3329-3336 (2006). 
 100.  Kitago, M. et al. Comparison of K-ras point mutation distributions in intraductal 
papillary-mucinous tumors and ductal adenocarcinoma of the pancreas. Int. J 
Cancer 110, 177-182 (2004). 
 101.  Hanson, J. A. et al. Gene promoter methylation in prostate tumor-associated 
stromal cells. J Natl. Cancer Inst. 98, 255-261 (2006). 
 102.  Brodsky, R. A. & Jones, R. J. Riddle: what do aplastic anemia, acute 
promyelocytic leukemia, and chronic myeloid leukemia have in common? 
Leukemia 18, 1740-1742 (2004). 
 103.  Kros, J. M., Zheng, P., Dinjens, W. N. & Alers, J. C. Genetic aberrations in 
gliomatosis cerebri support monoclonal tumorigenesis. J Neuropathol. Exp. 
Neurol. 61, 806-814 (2002). 
 104.  Barrett, M. T. et al. Evolution of neoplastic cell lineages in Barrett oesophagus. 
Nat. Genet. 22, 106-109 (1999). 
 105.  Eads, C. A. et al. Fields of aberrant CpG island hypermethylation in Barrett's 
esophagus and associated adenocarcinoma. Cancer Res. 60, 5021-5026 (2000). 
 177 
 106.  Maley, C. C. et al. The combination of genetic instability and clonal expansion 
predicts progression to esophageal adenocarcinoma. Cancer Res. 64, 7629-7633 
(2004). 
 107.  Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal 
adenocarcinoma. Nat. Genet. 38, 468-473 (2006). 
 108.  Merlo, L. M., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary 
and ecological process. Nat. Rev. Cancer 6, 924-935 (2006). 
 109.  Kang, G. H. et al. Genetic evidence for the multicentric origin of synchronous 
multiple gastric carcinoma. Lab Invest 76, 407-417 (1997). 
 110.  Kim, J. S. et al. Amplification of c-erbB-2 proto-oncogene in cancer foci, 
adjacent normal, metastatic and normal tissues of human primary gastric 
adenocarcinomas. J Korean Med Sci. 12, 311-315 (1997). 
 111.  Kim, J. Y. & Cho, H. J. DNA ploidy patterns in gastric adenocarcinoma. J 
Korean Med Sci. 15, 159-166 (2000). 
 112.  Crew, K. D. & Neugut, A. I. Epidemiology of upper gastrointestinal 
malignancies. Semin. Oncol. 31, 450-464 (2004). 
 113.  Bouche, O. & Lagarde, S. [Stomach cancer]. Rev. Prat. 55, 123-130 (2005). 
 114.  Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for 
resectable gastroesophageal cancer. N. Engl. J Med 355, 11-20 (2006). 
 115.  Fareed, K. R. et al. Biomarkers of response to therapy in oesophago-gastric 
cancer. Gut 58, 127-143 (2009). 
 116.  Medical Research Council Oesophageal Cancer Working Group Surgical 
resection with or without preoperative chemotherapy in oesophageal cancer: a 
randomised controlled trial. Lancet 359, 1727-1733 (2002). 
 117.  Mandard, A. M. et al. Pathologic assessment of tumor regression after 
preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic 
correlations. Cancer 73, 2680-2686 (1994). 
 118.  Becker, K. et al. Histomorphology and grading of regression in gastric carcinoma 
treated with neoadjuvant chemotherapy. Cancer 98, 1521-1530 (2003). 
 119.  Pinedo, H. M. & Peters, G. F. Fluorouracil: biochemistry and pharmacology. J 
Clin Oncol 6, 1653-1664 (1988). 
 120.  Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-fluorouracil: mechanisms of 
action and clinical strategies. Nat. Rev. Cancer 3, 330-338 (2003). 
 178 
 121.  An, Q., Robins, P., Lindahl, T. & Barnes, D. E. 5-Fluorouracil incorporated into 
DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. 
Cancer Res. 67, 940-945 (2007). 
 122.  Venturini, M. Rational development of capecitabine. Eur. J Cancer 38 Suppl 2, 
3-9 (2002). 
 123.  Schoffski, P. The modulated oral fluoropyrimidine prodrug S-1, and its use in 
gastrointestinal cancer and other solid tumors. Anticancer Drugs 15, 85-106 
(2004). 
 124.  Deeks, E. D. & Scott, L. J. Docetaxel: in gastric cancer. Drugs 67, 1893-1901 
(2007). 
 125.  Farhat, F. S. A general review of the role of irinotecan (CPT11) in the treatment 
of gastric cancer. Med Oncol 24, 137-146 (2007). 
 126.  Shin, S. et al. An anti-apoptotic protein human survivin is a direct inhibitor of 
caspase-3 and -7. Biochemistry 40, 1117-1123 (2001). 
 127.  Nakamura, M. et al. Survivin as a predictor of cis-diamminedichloroplatinum 
sensitivity in gastric cancer patients. Cancer Sci. 95, 44-51 (2004). 
 128.  Kato, J. et al. Expression of survivin in esophageal cancer: correlation with the 
prognosis and response to chemotherapy. Int. J Cancer 95, 92-95 (2001). 
 129.  Kang, S. Y. et al. Low expression of Bax predicts poor prognosis in patients with 
locally advanced esophageal cancer treated with definitive chemoradiotherapy. 
Clin Cancer Res. 13, 4146-4153 (2007). 
 130.  Zimmermann, K. C. et al. Cyclooxygenase-2 expression in human esophageal 
carcinoma. Cancer Res. 59, 198-204 (1999). 
 131.  Mao, X. Y., Wang, X. G., Lv, X. J., Xu, L. & Han, C. B. COX-2 expression in 
gastric cancer and its relationship with angiogenesis using tissue microarray. 
World J Gastroenterol. 13, 3466-3471 (2007). 
 132.  Xi, H. et al. High cyclooxygenase-2 expression following neoadjuvant 
radiochemotherapy is associated with minor histopathologic response and poor 
prognosis in esophageal cancer. Clin Cancer Res. 11, 8341-8347 (2005). 
 133.  Boku, N. et al. Biological markers as a predictor for response and prognosis of 
unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. 
Clin Cancer Res. 4, 1469-1474 (1998). 
 134.  Okumura, H. et al. The predictive value of p53, p53R2, and p21 for the effect of 
chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer 
92, 284-289 (2005). 
 179 
 135.  Akamatsu, M. et al. c-erbB-2 oncoprotein expression related to 
chemoradioresistance in esophageal squamous cell carcinoma. Int. J Radiat. 
Oncol Biol. Phys. 57, 1323-1327 (2003). 
 136.  Sarbia, M., Ott, N., Puhringer-Oppermann, F. & Brucher, B. L. The predictive 
value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated 
squamous cell carcinoma of the oesophagus. Br J Cancer 97, 1404-1408 (2007). 
 137.  Gibson, M. K. et al. Epidermal growth factor receptor, p53 mutation, and 
pathological response predict survival in patients with locally advanced 
esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res. 
9, 6461-6468 (2003). 
 138.  Izzo, J. G. et al. Association of activated transcription factor nuclear factor 
kappab with chemoradiation resistance and poor outcome in esophageal 
carcinoma. J Clin Oncol 24, 748-754 (2006). 
 139.  Harris, A. L. Hypoxia--a key regulatory factor in tumour growth. Nat. Rev. 
Cancer 2, 38-47 (2002). 
 140.  Boku, N., Ohtsu, A., Nagashima, F., Shirao, K. & Koizumi, W. Relationship 
between expression of vascular endothelial growth factor in tumor tissue from 
gastric cancers and chemotherapy effects: comparison between S-1 alone and the 
combination of S-1 plus CDDP. Jpn J Clin Oncol 37, 509-514 (2007). 
 141.  Chin, L. & Gray, J. W. Translating insights from the cancer genome into clinical 
practice. Nature 452, 553-563 (2008). 
 142.  van't Veer, L. J. & Bernards, R. Enabling personalized cancer medicine through 
analysis of gene-expression patterns. Nature 452, 564-570 (2008). 
 143.  Luthra, R. et al. Gene expression profiling of localized esophageal carcinomas: 
association with pathologic response to preoperative chemoradiation. J Clin 
Oncol 24, 259-267 (2006). 
 144.  Luthra, M. G. et al. Decreased expression of gene cluster at chromosome 1q21 
defines molecular subgroups of chemoradiotherapy response in esophageal 
cancers. Clin Cancer Res. 13, 912-919 (2007). 
 145.  Ashida, A. et al. Expression profiling of esophageal squamous cell carcinoma 
patients treated with definitive chemoradiotherapy: clinical implications. Int. J 
Oncol 28, 1345-1352 (2006). 
 146.  Duong, C. et al. Pretreatment gene expression profiles can be used to predict 
response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann. Surg 
Oncol 14, 3602-3609 (2007). 
 180 
 147.   Union Internationale Contre le Cancer. TNM classification if malignant tumours. 
6th ed. New York: Wiley-Liss. 2002. 
 148.  Moehler, M., Lyros, O., Gockel, I., Galle, P. R. & Lang, H. Multidisciplinary 
management of gastric and gastroesophageal cancers. World J Gastroenterol. 14, 
3773-3780 (2008). 
 149.  Denzer, U. et al. Minilaparoscopy in the diagnosis of peritoneal tumor spread: 
prospective controlled comparison with computed tomography. Surg Endosc. 18, 
1067-1070 (2004). 
 150.  Dehdashti, F. & Siegel, B. A. Neoplasms of the esophagus and stomach. Semin 
Nucl Med 34, 198-208 (2004). 
 151.  Fitzgerald, R. C. Review article: Barrett's oesophagus and associated 
adenocarcinoma--a UK perspective. Aliment. Pharmacol. Ther. 20 Suppl 8, 45-49 
(2004). 
 152.  Weber, W. A. & Ott, K. Imaging of esophageal and gastric cancer. Semin. Oncol. 
31, 530-541 (2004). 
 153.  Hambraeus, G. M. et al. Prognostic factors influencing survival in combined 
radiotherapy and surgery of squamous cell carcinoma of the esophagus with 
special reference to a histopathologic grading system. Cancer 62, 895-904 (1988). 
 154.  Lewinski, T., Morysinski, T., Pietrow, D. & Sikora, K. Preoperative radiotherapy 
combined with resection of squamous cell carcinoma of the mid-thoracic 
oesophagus. Does a histopathological malignancy grading system assess actual 
survival? Eur. J Surg Oncol 17, 571-574 (1991). 
 155.  Siewert, J. R. et al. Gastric Cancer. Curr. Probl. Surg 34, 835-939 (1997). 
 156.  Schuhmacher, C. P. et al. Neoadjuvant therapy for patients with locally advanced 
gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results 
after 5 years of follow-up. Cancer 91, 918-927 (2001). 
 157.  Tytgat, G. N. et al. Cancer of the esophagus and gastric cardia: recent advances. 
Dis. Esophagus. 17, 10-26 (2004). 
 158.  Sato, T. & Lizuka, T. Color Atlas of Surgical Anatomy for Esophageal Cancer. 
Springer-Verlag, Tokyo (1992). 
 159.  Akiyama, H., Tsurumaru, M., Udagawa, H. & Kajiyama, Y. Radical lymph node 
dissection for cancer of the thoracic esophagus. Ann. Surg 220, 364-372 (1994). 
 160.  Millikan, K. W. et al. A 15-year review of esophagectomy for carcinoma of the 
esophagus and cardia. Arch. Surg. 130, 617-624 (1995). 
 181 
 161.  Hulscher, J. B. et al. Extended transthoracic resection compared with limited 
transhiatal resection for adenocarcinoma of the esophagus. N. Engl. J. Med. 347, 
1662-1669 (2002). 
 162.  Lerut, T. et al. Extended surgery for cancer of the esophagus and 
gastroesophageal junction. Journal of Surgical Research 117, 58-63 (2004). 
 163.  Doran, S. T. et al. Pathology of Barrett's esophagus by proton magnetic resonance 
spectroscopy and a statistical classification strategy. Am. J. Surg. 185, 232-238 
(2003). 
 164.  Spechler, S. J. Barrett's Oesophagus. Semin Gastroeintest Dis 7, 51-60 (1996). 
 165.  Waters, M. D., Selkirk, J. K. & Olden, K. The impact of new technologies on 
human population studies. Mutat. Res. 544, 349-360 (2003). 
 166.  Lenz, E. M., Bright, J., Wilson, I. D., Morgan, S. R. & Nash, A. F. A 1H NMR-
based metabonomic study of urine and plasma samples obtained from healthy 
human subjects. J. Pharm. Biomed. Anal. 33, 1103-1115 (2003). 
 167.  Bell, J. D., Bhakoo, K. K. Metabolic changes underlying 31P MR spectral 
alterations in human hepatic tumours. NMR Biomed. 11(7), 354-9 (1998). 
 168.  Odunsi, K. et al. Detection of epithelial ovarian cancer using 1H-NMR-based 
metabonomics. Int. J. Cancer 113, 782-788 (2005). 
 169.  de Certaines, J. D. Is biomedical nuclear magnetic resonance limited by a 
revisitable paradigm in physics? Cell Mol. Biol. (Noisy. -le-grand) 51, 655-661 
(2005). 
 170.  Claridge, T. D. W. High-Resolution NMR Techniques in Organic Chemistry. 
Elsevier Ltd., Oxford (1999). 
 171.  Martino, R., Bernadou, J., Malet-Martino, M. C., Roche, H. & Armand, J. P. 
Excretion of doxifluridine catabolites in human bile assessed by 19F NMR 
spectrometry. Biomed. Pharmacother. 41, 104-106 (1987). 
 172.  Nicholson, J. K., Higham, D. P., Timbrell, J. A. & Sadler, P. J. Quantitative high 
resolution 1H NMR urinalysis studies on the biochemical effects of cadmium in 
the rat. Mol. Pharmacol. 36, 398-404 (1989). 
 173.  Ellul, J. P., Murphy, G. M., Parkes, H. G., Slapa, R. Z. & Dowling, R. H. Nuclear 
magnetic resonance spectroscopy to determine the micellar cholesterol in human 
bile. FEBS Lett. 300, 30-32 (1992). 
 174.  Anthony, M. L., Gartland, K. P., Beddell, C. R., Lindon, J. C. & Nicholson, J. K. 
Cephaloridine-induced nephrotoxicity in the Fischer 344 rat: proton NMR 
spectroscopic studies of urine and plasma in relation to conventional clinical 
 182 
chemical and histopathological assessments of nephronal damage. Arch. Toxicol. 
66, 525-537 (1992). 
 175.  Koschorek, F. et al. High-resolution 1H NMR spectroscopy of cerebrospinal fluid 
in spinal diseases. Neurosurg. Rev. 16, 307-315 (1993). 
 176.  Husted, C., Montez, B., Le, C., Moscarello, M. A. & Oldfield, E. Carbon-13 
"magic-angle" sample-spinning nuclear magnetic resonance studies of human 
myelin, and model membrane systems. Magn Reson. Med. 29, 168-178 (1993). 
 177.  Nicholson, J. K., Foxall, P. J., Spraul, M., Farrant, R. D. & Lindon, J. C. 750 
MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal. Chem. 
67, 793-811 (1995). 
 178.  Cheng, L. L. et al. Enhanced resolution of proton NMR spectra of malignant 
lymph nodes using magic-angle spinning. Magn Reson. Med. 36, 653-658 (1996). 
 179.  Holmes, E. et al. 750 MHz 1H NMR spectroscopy characterisation of the 
complex metabolic pattern of urine from patients with inborn errors of 
metabolism: 2-hydroxyglutaric aciduria and maple syrup urine disease. J. Pharm. 
Biomed. Anal. 15, 1647-1659 (1997). 
 180.  Liu, M., Nicholson, J. K., Parkinson, J. A. & Lindon, J. C. Measurement of 
biomolecular diffusion coefficients in blood plasma using two-dimensional 1H-
1H diffusion-edited total-correlation NMR spectroscopy. Anal. Chem. 69, 1504-
1509 (1997). 
 181.  Nicholls, A. W. et al. NMR spectroscopic studies on the metabolism and futile 
deacetylation of phenacetin in the rat. Xenobiotica 27, 1175-1186 (1997). 
 182.  Traikia, M., Langlais, D. B., Cannarozzi, G. M. & Devaux, P. F. High-resolution 
spectra of liposomes using MAS NMR. The case of intermediate-size vesicles. J. 
Magn Reson. 125, 140-144 (1997). 
 183.  Humpfer, E., Spraul, M., Nicholls, A. W., Nicholson, J. K. & Lindon, J. C. Direct 
observation of resolved intracellular and extracellular water signals in intact 
human red blood cells using 1H MAS NMR spectroscopy. Magn Reson. Med. 38, 
334-336 (1997). 
 184.  Moka, D. et al. Biochemical classification of kidney carcinoma biopsy samples 
using magic-angle-spinning 1H nuclear magnetic resonance spectroscopy. J. 
Pharm. Biomed. Anal. 17, 125-132 (1998). 
 185.  Cheng, L. L. et al. Quantitative neuropathology by high resolution magic angle 
spinning proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U. S. A 
94, 6408-6413 (1997). 
 183 
 186.  Beckwith-Hall, B. M. et al. Nuclear magnetic resonance spectroscopic and 
principal components analysis investigations into biochemical effects of three 
model hepatotoxins. Chem. Res. Toxicol. 11, 260-272 (1998). 
 187.  Tomlins, A. M. et al. High resolution 1H NMR spectroscopic studies on dynamic 
biochemical processes in incubated human seminal fluid samples. Biochim. 
Biophys. Acta 1379, 367-380 (1998). 
 188.  Guo, W., Morrisett, J. D., Lawrie, G. M., DeBakey, M. E. & Hamilton, J. A. 
Identification of different lipid phases and calcium phosphate deposits in human 
carotid artery plaques by MAS NMR spectroscopy. Magn Reson. Med. 39, 184-
189 (1998). 
 189.  Tomlins, A. M. et al. High-resolution magic-angle spinning 1H nuclear magnetic 
resonance analysis of intact prostatic hyperplastic and tumour tissues. Analytical 
Communications 35, 113-115 (1998). 
 190.  Cheng, L. L., Chang, I. W., Smith, B. L. & Gonzalez, R. G. Evaluating human 
breast ductal carcinomas with high-resolution magic-angle spinning proton 
magnetic resonance spectroscopy. J. Magn Reson. 135, 194-202 (1998). 
 191.  Meshitsuka, S. et al. Nuclear magnetic resonance studies of synovial fluids from 
patients with rheumatoid arthritis and osteoarthritis. Clin. Chim. Acta 281, 163-
167 (1999). 
 192.  Tkadlecova, M., Havelcek, J., Volka, K., Soucek, P. & Karel, I. Study of aqueous 
humour by 1H NMR spectroscopy. Journal of Molecular Structure 480, 601-605 
(1999). 
 193.  Millis, K. et al. Classification of human liposarcoma and lipoma using ex vivo 
proton NMR spectroscopy. Magn Reson. Med. 41, 257-267 (1999). 
 194.  Garrod, S. et al. High-resolution magic angle spinning 1H NMR spectroscopic 
studies on intact rat renal cortex and medulla. Magn Reson. Med. 41, 1108-1118 
(1999). 
 195.  Griffin, J. L. et al. The initial pathogenesis of cadmium induced renal toxicity. 
FEBS Lett. 478, 147-150 (2000). 
 196.  Sitter, B. et al. Cervical cancer tissue characterized by high-resolution magic 
angle spinning MR spectroscopy. MAGMA. 16, 174-181 (2004). 
 197.  Mun, C. W. et al. Ex vivo proton MR spectroscopy (1H-MRS) for evaluation of 
human gastric carcinoma. Magn Reson. Imaging 22, 861-870 (2004). 
 198.  Bourne, R. M. et al. In vivo and ex vivo proton MR spectroscopy of primary and 
secondary melanoma. Eur. J. Radiol. 53, 506-513 (2005). 
 184 
 199.  Holmes, E. et al. Metabolic Profiling of CSF: Evidence That Early Intervention 
May Impact on Disease Progression and Outcome in Schizophrenia. PLoS. Med. 
3, (2006). 
 200.  Bala, L. et al. Malabsorption syndrome with and without small intestinal bacterial 
overgrowth: a study on upper-gut aspirate using 1H NMR spectroscopy. Magn 
Reson. Med. 56, 738-744 (2006). 
 201.  Fang, F. et al. Discrimination of metabolic profiles of pancreatic cancer from 
chronic pancreatitis by high-resolution magic angle spinning 1H nuclear magnetic 
resonance and principal components analysis. Cancer Sci. 98, 1678-1682 (2007). 
 202.  Tessem, M. B. et al. Evaluation of lactate and alanine as metabolic biomarkers of 
prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson. 
Med 60, 510-516 (2008). 
 203.  Jordan, K. W. et al. Metabolomic characterization of human rectal 
adenocarcinoma with intact tissue magnetic resonance spectroscopy. Dis. Colon 
Rectum 52, 520-525 (2009). 
 204.  Bollard, M. E. et al. NMR-based metabolic profiling identifies biomarkers of liver 
regeneration following partial hepatectomy in the rat. J Proteome. Res. (2009). 
 205.  Smith, L. M. et al. Large-scale human metabolic phenotyping and molecular 
epidemiological studies via 1H NMR spectroscopy of urine: investigation of 
borate preservation. Anal. Chem. 81, 4847-4856 (2009). 
 206.  Delikatny, E. J. et al. Proton MR and human cervical neoplasia: ex vivo 
spectroscopy allows distinction of invasive carcinoma of the cervix from 
carcinoma in situ and other preinvasive lesions. Radiology 188, 791-796 (1993). 
 207.  Russell, P. et al. Proton magnetic resonance and human thyroid neoplasia. I: 
Discrimination between benign and malignant neoplasms. Am. J. Med. 96, 383-
388 (1994). 
 208.  Lean, C. L. et al. Diagnosis of follicular thyroid lesions by proton magnetic 
resonance on fine needle biopsy. J. Clin. Endocrinol. Metab 80, 1306-1311 
(1995). 
 209.  Sharaf, M. A., Illman, D. L. & Kowalski, B. R. Chemometrics. (Chichester:J. 
Wiley and Sons), (1986). 
 210.  Lindon, J. C., Holmes, E. & Nicholson, J. K. Pattern recognition methods and 
applications in biomedical magnetic resonance. Progress in NMR Spectroscopy 
39, 1-40 (2001). 
 185 
 211.  Holmes, E. et al. Development of a model for classification of toxin-induced 
lesions using 1H NMR spectroscopy of urine combined with pattern recognition. 
NMR Biomed. 11, 235-244 (1998). 
 212.  Brown, T. R. & Stoyanova, R. NMR spectral quantitation by principal-component 
analysis. II. Determination of frequency and phase shifts. J. Magn Reson. B 112, 
32-43 (1996). 
 213.  Pearson, K. On lines and planes of closest fit to systems of points in space. 
Philosophical Magazine 2, 559-572 (1901). 
 214.  Hotelling, H. Analysis of a complex of statistical variables into principal 
components. Journal of Educational Psychology 24, 417-441 (1933). 
 215.  Lindon, J. C., Holmes, E. & Nicholson, J. K. So what's the deal with 
metabonomics? Anal. Chem. 75, 384A-391A (2003). 
 216.  Dieterle, F., Ross, A., Schlotterbeck, G. & Senn, H. Probabilistic quotient 
normalization as robust method to account for dilution of complex biological 
mixtures. Application in 1H NMR metabonomics. Anal. Chem. 78, 4281-4290 
(2006). 
 217.  Kelsen, D. P. et al. Chemotherapy followed by surgery compared with surgery 
alone for localized esophageal cancer. N. Engl. J Med 339, 1979-1984 (1998). 
 218.  Mesonero, J., Matosin, M., Cambier, D., Rodriguez-Yoldi, M. J. & Brot-Laroche, 
E. Sugar-dependent expression of the fructose transporter GLUT5 in Caco-2 cells. 
Biochem. J 312 ( Pt 3), 757-762 (1995). 
 219.  Yamamoto, T. et al. Over-expression of facilitative glucose transporter genes in 
human cancer. Biochem. Biophys. Res. Commun. 170, 223-230 (1990). 
 220.  Nishioka, T. et al. Distribution of the glucose transporters in human brain tumors. 
Cancer Res. 52, 3972-3979 (1992). 
 221.  Younes, M., Brown, R. W., Stephenson, M., Gondo, M. & Cagle, P. T. 
Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is 
associated with poor survival. Cancer 80, 1046-1051 (1997). 
 222.  Mellanen, P., Minn, H., Grenman, R. & Harkonen, P. Expression of glucose 
transporters in head-and-neck tumors. Int. J Cancer 56, 622-629 (1994). 
 223.  Nagase, Y. et al. Immunohistochemical localization of glucose transporters in 
human renal cell carcinoma. J Urol. 153, 798-801 (1995). 
 224.  Boden, G., Murer, E. & Mozzoli, M. Glucose transporter proteins in human 
insulinoma. Ann. Intern. Med 121, 109-112 (1994). 
 186 
 225.  Haber, R. S., Weiser, K. R., Pritsker, A., Reder, I. & Burstein, D. E. GLUT1 
glucose transporter expression in benign and malignant thyroid nodules. Thyroid 
7, 363-367 (1997). 
 226.  Brown, R. S. & Wahl, R. L. Overexpression of Glut-1 glucose transporter in 
human breast cancer. An immunohistochemical study. Cancer 72, 2979-2985 
(1993). 
 227.  Zamora-Leon, S. P. et al. Expression of the fructose transporter GLUT5 in human 
breast cancer. Proc. Natl. Acad. Sci. U. S. A 93, 1847-1852 (1996). 
 228.  Reisser, C., Eichhorn, K., Herold-Mende, C., Born, A. I. & Bannasch, P. 
Expression of facilitative glucose transport proteins during development of 
squamous cell carcinomas of the head and neck. Int. J Cancer 80, 194-198 
(1999). 
 229.  Miller, J. H., Mullin, J. M., McAvoy, E. & Kleinzeller, A. Polarity of transport of 
2-deoxy-D-glucose and D-glucose by cultured renal epithelia (LLC-PK1). 
Biochim. Biophys. Acta 1110, 209-217 (1992). 
 230.  Hwang, Y. Y., Kim, S. G., Evelhoch, J. L. & Ackerman, J. J. Nonglycolytic 
acidification of murine radiation-induced fibrosarcoma 1 tumor via 3-O-methyl-
D-glucose monitored by 1H, 2H, 13C, and 31P nuclear magnetic resonance 
spectroscopy. Cancer Res. 52, 1259-1266 (1992). 
 231.  Glunde, K., Jie, C. & Bhujwalla, Z. M. Molecular causes of the aberrant choline 
phospholipid metabolism in breast cancer. Cancer Res. 64, 4270-4276 (2004). 
 232.  Galipeau, P. C., Prevo, L. J., Sanchez, C. A., Longton, G. M. & Reid, B. J. Clonal 
expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant 
esophageal (Barrett's) tissue. J Natl. Cancer Inst. 91, 2087-2095 (1999). 
 233.  Mazurek, S. & Eigenbrodt, E. The tumor metabolome. Anticancer Res. 23, 1149-
1154 (2003). 
 234.  Ferlito, A. et al. "Skip metastases" from head and neck cancers. Acta Otolaryngol. 
122, 788-791 (2002). 
 235.  Cheng, L. L. et al. Metabolic characterization of human prostate cancer with 
tissue magnetic resonance spectroscopy. Cancer Res. 65, 3030-3034 (2005). 
 236.  Lerut, T. et al. Three-field lymphadenectomy for carcinoma of the esophagus and 
gastroesophageal junction in 174 R0 resections: impact on staging, disease-free 
survival, and outcome: a plea for adaptation of TNM classification in upper-half 
esophageal carcinoma. Ann. Surg 240, 962-972 (2004). 
 187 
 237.  Falk, G. W., Rice, T. W., Goldblum, J. R. & Richter, J. E. Jumbo biopsy forceps 
protocol still misses unsuspected cancer in Barrett's esophagus with high-grade 
dysplasia. Gastrointest. Endosc. 49, 170-176 (1999). 
 238.  Sampliner, R. E. Updated guidelines for the diagnosis, surveillance, and therapy 
of Barrett's esophagus. Am. J Gastroenterol. 97, 1888-1895 (2002). 
 239.  Lovat, L. B. et al. Elastic scattering spectroscopy accurately detects high grade 
dysplasia and cancer in Barrett's oesophagus. Gut 55, 1078-1083 (2006). 
240. Cox, I. J., Sharif, A., Cobbold, J. F., Thomas, H. C., Taylor-Robinson, S. D. 
Current and future applications of in vitro magnetic resonance spectroscopy in 
hepatobiliary disease. World J Gastroenterol. 12(30), 4773-83 (2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 188 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. APPENDIX 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 189 
Appendix 1. Letters and forms relevant to establishment of 
tissue bank 
 
1. Establishment of tissue bank ethics approval letter 
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2. Research and Development approval letter 
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3. Patient information sheet 
 
 
\             Division of Surgery, Anaesthetics & Intensive care 
 Department of Surgical Oncology and Technology 
         Imperial College London 
 10th Floor, QEQM Building 
 St Mary’s Hospital 
 Praed Street, London  W2 1NY 
        Tel: +44(0)20 7886 2125   
 Fax: +44(0)20 7413 0470 
 
        
 
      Mr George Hanna PhD, FRCS 
                 Senior Lecturer and Consultant Surgeon 
  g.hanna@imperial.ac.uk 
                                       www.imperial.ac.uk 
 
 
TISSUE BANK PATIENT INFORMATION LEAFLET  
 
 
Academic Surgical Unit - St Mary’s Hospital  
Upper Gastro-Intestinal Tissue Bank 
REC Ref. no. 04/Q0403/119 
 
Department of Surgical Oncology and Technology 
Mr George Hanna PhD, FRCS 
Senior Lecturer/Consultant Upper GI Surgeon and named custodian of the tissue bank 
 Date:     /       /                      
 
Dear Sir/Madam 
 You are being invited to take part in the tissue bank project.  Before you 
decide it is important for you to understand why the tissue bank is being 
established and what it will involve.  Please take time to read the following 
information carefully and discuss it with others if you wish.  Ask us if there is 
anything that is not clear or if you would like more information.  Take time to 
decide whether or not you wish to take part.  Thank you for reading this 
information sheet. 
 
What is a tissue bank? 
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A tissue bank is a collection of tissue samples being stored long term that will be 
used to assist in future research into a specific disease or group of diseases or 
investigate disease processes and their treatment. Tissue banks are a valuable 
research resource and are increasingly being established at local, regional and 
national level.  
What will the tissues in the tissue bank be used for? 
The tissues will be used to help our understanding of Oesophageal and Gastric 
cancer.  We will be looking at how tumours grow, why some tumours spread and 
trying to find new treatments for these types of cancer. 
Tissue and blood samples might be used for DNA and/or protein analysis or 
other molecular biology studies in a way to identify mechanisms of development 
of this disease as well as effect of different treatments on the course of these 
tumours. 
Tissues may also be used in unforeseen research projects in the future. None of 
these will allow linking of the specimens for identification of patients they were 
taken from. 
Why have I been chosen? 
You have been chosen because you are undergoing treatment of oesophageal or 
gastric cancer. 
Do I have to take part? 
Taking part in the research is entirely voluntary. It is up to you to decide whether 
or not to take part.  If you do decide to take part you will be given this information 
sheet to keep and be asked to sign a consent form. If you decide to take part you 
are still free to withdraw at any time and without giving a reason.  A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of 
care you receive. 
What do I have to do? 
Nothing, except to approve of giving your tissues to be stored in the tissue bank, 
and to keep a copy of your hospital records containing details of your blood tests 
results, radiography reports and other documents explaining your condition. 
How much of my tissues will be taken? 
Before your operation a blood sample among the samples taken for your routine 
assessment will be taken. Also any tissue biopsies taken in the course of 
diagnosis of your disease will be taken. During the course of your operation the 
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tumour and tumour related tissue removed, will be conserved in the tissue bank. 
No additional tissue will be taken beyond that clinically needed. These tissues 
are to be used in future research. 
After your operation another blood sample will be taken again among the 
samples taken for your routine assessment will be taken. 
What will happen to the tissues? 
Tissues will be preserved in the tissue bank for an indefinite period of time. The 
specimens will remain the property of the Academic Surgical Unit - St Mary’s 
Hospital Upper Gastro-Intestinal Tissue Bank. The principal investigator Mr GB 
Hanna is the named custodian of all tissue specimens. Sections of the 
specimens may be used for future research purposes.   
Will I be contacted again in the future? 
You need to indicate in the consent form whether or not you would like to be 
contacted should the result of any research carried out on your tissue yield new 
findings that may have an impact on your care; This information can be 
discussed with you either by your hospital Consultant or General Practitioner. 
The, information about your tissues will be available for you at any time through 
contacting the Tissue Bank Custodian, Mr Hanna.  
What if something goes wrong? 
We do not believe you will be harmed by donating tissue to the Academic 
Surgical Unit – St Mary’s Hospital Upper Gastro-Intestinal Tissue Bank. There is 
no additional intervention or change in your treatment plan implemented if you 
choose to participate.  
If you wish to complain, or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms should be available to you. 
Who will have access to my tissue and how will confidentiality be 
maintained? 
Access to your tissue samples will be only available through the Academic 
Surgical Unit – St Mary’s Hospital Upper Gastro-Intestinal Tissue Bank, 
controlled by Imperial College London.  The named custodian is Mr George 
Hanna will hold responsibility of storage and management of your tissue samples 
as well as your records.  
Researchers under Mr George Hanna’s direct supervision or after his approval 
may also have access to the tissue samples. 
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The handling of your tissue samples will be treated with the usual degree of 
confidentiality under the data protection act. All samples will be coded and 
pseudonomised before transfer to other research partners - you will not be 
identified in any way from your tissue sample. 
He will be responsible for keeping proper records of all uses that have been 
made of the material, whether by himself or by others. Users of pseudonomised 
samples will be required undertake not to attempt to identify individual research 
participants. Where linked pseudonomised samples are provided to a third party, 
the custodian. The stored data will not be linked with you. It will be coded. 
Nevertheless, you or your legal representative can gain access to these 
information through writing to Mr Hanna, the named custodian of the Tissue Bank 
and guardian of the codes, who will break the code and present the information, 
if so required.    
The custodian will be formally responsible for the safe keeping, control of use 
and disposal of tissue samples in accordance with the consent you give. He will 
be officially responsible to ensure that procedures and security arrangements are 
sufficient to prevent breaches of confidentiality. Data that has not been 
pseudonomised will not be transferred without informed consent from you or from 
your next of kin or legal representative in case you cannot consent. 
All future research projects which wish to use tissue from the tissue bank will 
need the approval of an NHS Research Ethics Committee. Copies of such 
approvals will be kept and archived for reference. 
All research that involves NHS patients or staff, information from NHS medical 
records or uses NHS patients or staff, information from NHS medical records or 
uses NHS premises or facilities must be approved by an NHS Research Ethics 
Committee before it goes ahead.  Approval does not guarantee that you will not 
come to any harm if you take part.  However, approval means that the 
Committee is satisfied that your rights will be respected, that any risks have been 
reduced to a minimum and balanced against possible benefits and that you have 
been given sufficient information on which to make an informed decision to take 
part or not. 
Will I receive payment for the tissue that I donate to the tissue bank? 
You will not receive any payment for the tissue.  The tissue is a gift - neither you 
nor your relatives will benefit from any inventions that result from the use of the 
tissue. 
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What happens if I wish to have my tissue removed from the tissue bank? 
If you no longer wish your tissues to be held in the tissue bank you may withdraw 
them at any time, without justifying your decision and your future treatment will 
not be affected in any way. 
If you wish to have your tissue removed from the tissue bank please contact Mr 
George Hanna for suitable arrangements. 
Who is organising and funding body of the tissue bank? 
The Academic Surgical Unit, St Mary’s hospital, Praed street, London W2 1NY 
Who has reviewed the establishment of the bank? 
The St Mary’s Hospital Local Research Ethics Committee.  
Thank you for reading this information leaflet. 
Correspondence for further information: 
Mr George B Hanna 
Senior Lecturer/Consultant Upper GI Surgeon  
Academic Surgical Unit 
10th Floor, QEQM Building 
St Mary’s Hospital 
Praed street,  
London   W2 1NY 
Tel:  0207 886 2124 
Fax: 0207 886 1810 
E-mail: g.hanna@imperial.ac.uk 
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Patient name, address, DOB (or ID label) 
4. Consent form 
 
 
 Division of Surgery, Anaesthetics & Intensive care 
 Department of Surgical Oncology and Technology 
         Imperial College London 
 10th Floor, QEQM Building 
 St Mary’s Hospital 
 Praed Street, London  W2 1NY 
        Tel: +44(0)20 7886 2125   
 Fax: +44(0)20 7413 0470 
 
        
 
      Mr George Hanna PhD, FRCS 
                 Senior Lecturer and Consultant Surgeon 
  g.hanna@imperial.ac.uk 
                                       www.imperial.ac.uk 
 
TISSUE BANK CONSENT FORM 
 
 
 
 
 
 
 
 
 
Title of Tissue Bank:   
Academic Surgical Unit – St Mary’s Hospital Upper Gastro-Intestinal Tissue Bank 
REC Ref. no. 04/Q0403/119 
 
Principal Investigator and named Custodian of Tissue Bank: 
Mr George Hanna PhD, FRCS 
Senior Lecturer/Consultant Upper GI Surgeon  
 Please initial boxes as applicable 
I confirm that I have read and understand the information leaflet sheet dated 
...../....../.............  for the above Tissue Bank and have had the opportunity to 
ask questions. 
F 
I understand that I may withdraw my consent to my tissue being included in 
the tissue bank at any time without justifying my decision and without 
affecting my normal care and medical management. 
F 
I agree to donate the tissue samples as detailed below and allow their use in 
medical research as described in the Patient Information Leaflet.   F 
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I understand that sections of any of my medical notes may be looked at by 
responsible individuals from the research team, or from regulatory authorities 
where it is relevant to my taking part in research.  I give permission for these 
individuals to have access to my records. 
F 
I do /do not give consent to the use of my tissue in future research projects if 
an unanticipated use emerges in the future, which is not described in this 
information leaflet (delete as applicable) 
 
F 
I understand that tissue samples will not be used to undertake any genetic 
tests whose results may have adverse consequences on my or my families 
insurance or employment.  
F 
I agree / do not agree to my tissue samples being used to undertake genetic 
research (delete as applicable) F 
I understand that if research using my tissues produces information, which 
has immediate clinical relevance to me, I would/ would not like to be 
informed by my hospital consultant or GP and be given an opportunity to 
discuss the results. I realise that these information will be readily available to 
me upon requesting it from the Tissue bank Custodian. (delete as applicable) 
 
F 
I understand that the tissue is a gift and that I will not benefit from any 
intellectual property that results from the use of the tissue. F 
The samples which I hereby consent to donate are:  
. Pre and postoperative blood samples.  
. Preoperative tissue biopsy samples produced along the course of my 
assessment and diagnosis plan.  
. Intra-operatively removed surgical specimen containing tumour or tumour 
invaded tissues e.g. lymphatics, lymph nodes and metastases…etc.which 
are removed as  a part of the surgical operation planned for my treatment.  
 
 
F 
________________________ ________________                  ____________________ 
Name of Patient  DateSignature 
________________________ ________________                  ____________________ 
Name of Parent/guardian/ DateSignature 
legal representative (If applicable) 
_________________________ ________________     ___________________ 
Researcher Date Signature 
 
Original for researcher / tissue bank, 1 copy for patient, 1 copy for hospital notes 
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Patient name, address, DOB (or ID label) 
5. Tissue information form 
 
 
 Division of Surgery, Anaesthetics & Intensive care 
 Department of Surgical Oncology and Technology 
         Imperial College London 
 10th Floor, QEQM Building 
 St Mary’s Hospital 
 Praed Street, London  W2 1NY 
        Tel: +44(0)20 7886 2125   
 Fax: +44(0)20 7413 0470 
 
 
 
Academic Surgical Unit – St Mary’s Hospital Upper Gastro-
Intestinal Tissue Bank 
REC Ref. no. 04/Q0403/119 
Named Custodian: Mr GB Hanna PhD FRCS 
Tissue information form 
Patient details: 
 
 
 
 
 
 
Centre name:      Date:  
Patient Number:    Diagnosis: 
Tissue bank code:        Pathology request number:  
Specimen details: 
 
Serial no. Type Time to freezing 
(min) 
Amount 
in stock 
1    
2    
3    
4    
5    
6    
7    
8    
Time tissue rendered ischemic (roughly):  Time of excision:   
Time of start cutting up:      Time freezing completed:  
Method of freezing:       Isopentane  LN2 
Method of transport to tissue bank:  
Time of transport to tissue bank after freezing:  
 
-------------------- -             ----------------------------------              ----------------------------- 
Researcher name     Date     Signature 
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Appendix 2. Letters and forms relevant to conduct of 
metabonomic analysis 
 
1. Ethical approval letter 
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2. Research and Development approval letter 
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3. Patient information sheet 
 
             Division of Surgery, Anaesthetics & Intensive care 
 Department of Biosurgery and Surgical Technology 
        Imperial College London 
 10th Floor, QEQM Building 
 St Mary’s Hospital 
 Praed Street, London  W2 1NY 
        Tel: +44(0)20 7886 2125   
 Fax: +44(0)20 7413 0470 
 
        
 
      Mr George Hanna PhD, FRCS 
                 Reader and Consultant Surgeon 
  g.hanna@imperial.ac.uk 
                                       www.imperial.ac.uk 
 
 
PATIENT INFORMATION LEAFLET 
 
 
Title of Project: 
Metabonomic Profiling of Gastric and Oesophageal Cancer 
REC Ref. 05/Q0404/73 
Version: 2 
 
Principal investigator: 
Mr GB Hanna PhD FRCS MErgS 
Reader and Consultant Upper GI Surgeon 
Imperial College London, St Mary’s Hospital, London. 
Co-investigator: 
Mr Danny Yakoub MSc MRCSEd 
Clinical Research Fellow, Imperial College London 
  
 
Date:     /       /                      
Dear Sir/Madam 
 You are being invited to take part in the Metabonomic Profiling of Gastric 
and Oesophageal Cancer project. Please take time to read the following 
information carefully and discuss it with others if you wish.  Ask us if there is 
anything that is not clear or if you would like more information.  Take time to 
decide whether or not you wish to take part.  Thank you for reading this 
information sheet. 
 
What are the details of the project? 
 
The study involves collecting tissue, blood and urine samples to be analysed 
using special imaging techniques, in order to detect compounds specific to 
gastric and oesophageal cancer. 
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What will the tissues be used for? 
 
The tissues will be used to help our understanding of oesophageal and gastric 
cancer.  We will be looking at compounds released by tumours in order to 
understand how these tumours grow, why some tumours spread and trying to 
find new treatments for these types of cancer. 
 
Why have I been chosen? 
You have been chosen because you are undergoing treatment for oesophageal or gastric 
cancer. 
 
Do I have to take part? 
Taking part in the research is entirely voluntary. It is up to you to decide whether 
or not to take part.  If you do decide to take part you will be given this information 
sheet to keep and be asked to sign a consent form. If you decide to take part you 
are still free to withdraw at any time and without giving a reason.  A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of 
care you receive, now or in the future. 
 
What do I have to do? 
Nothing, except to agree to make a gift to us of specimens of tissue removed 
during your operation which would otherwise be destroyed, or tissue obtained 
during endoscopy, in addition to blood and urine samples. We also need your 
permission to keep a copy of your hospital records containing details of your 
blood tests results, radiography reports and other documents explaining your 
condition. 
 
How much of my tissues will be taken? 
 
Before your operation, blood and urine samples (15-20 mls, about the volume of 
2 table spoons) will be taken along with your routine assessment samples. No 
extra needle pricks or vein punctures are required. Also part of tissue biopsied 
during endoscopy will be taken. 
  
We will also take tumour sample and tissue around it (40-100 mg, about the size 
of a pea) removed in the surgical specimen and otherwise would have been 
destroyed. No additional tissue will be taken beyond that needed for your 
treatment. After your operation, blood and urine samples will be taken again 
along with the samples taken for your routine assessment. 
 
What will happen to the tissues? 
 
Tissues will first be preserved in the tissue bank. Then they will be processed 
and prepared for analysis through the use of a magnetic resonance device to 
define types and amounts of compounds within the tissues. After the completion 
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of the study, we would like to retain the blood/tissue samples for possible future 
research at a future date, when new tests/techniques may be available. We 
would not contact you again for further permission before doing this. If you agree 
to take part in this study, you will also be giving consent for possible future use of 
the sample; this is why we ask you to make a gift of them. Samples will remain 
the property of the Academic Surgical Unit - St Mary’s Hospital Upper Gastro-
Intestinal Tissue Bank.  
 
Specimens that have not been used in the study or stored in the tissue bank will 
be decently disposed of in light of the provisions of the Human Tissue Act 2004, 
and through the regulations of the Human Tissue authority established in the Act 
to oversee such arrangements. No genetic, HIV, Hepatitis B or other 
communicable disease testing will be done on the specimens collected. The 
principal investigator Mr GB Hanna is the named custodian of all tissue 
specimens. Sections of the specimens may be used for future research 
purposes.  
 
Will I be contacted again in the future? 
 
You need to indicate in the consent form whether or not you would like to be 
contacted should the result of any research carried out on your tissue yield new 
findings that may have an impact on your care; This information can be 
discussed with you by your hospital Consultant. The, information about your 
tissues will be available for you at any time through contacting the Tissue Bank 
Custodian, Mr Hanna.  
 
What if something goes wrong? 
 
We do not believe you would be harmed by donating tissue to the study. There is 
no additional intervention or change in your treatment plan implemented if you 
choose to participate.  
If you wish to complain, or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms would be available to you. 
 
Who will have access to my tissue and how will confidentiality be 
maintained? 
 
Tissues and samples will be stored in the Academic Surgical Unit – St Mary’s 
Hospital Upper Gastro-Intestinal Tissue Bank and access to your tissue samples 
will be only available through it. The named custodian is Mr George Hanna, who 
is also the chief investigator in this study will hold responsibility of storage and 
management of your tissue samples as well as your records.  
 
Researchers under Mr George Hanna’s direct supervision or after his approval 
may also have access to the tissue samples. 
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The handling of your tissue samples will be treated with strict confidentiality 
under the Data Protection Act. All samples will be coded and pseudonymised 
before transfer to other research partners, so that you cannot be identified from 
your tissue sample. 
 
The custodian will be responsible for keeping proper records of all uses that have 
been made of the material, whether by himself or by others. Users of 
pseudonymised samples will not attempt to identify individual research 
participants. The stored data will be coded. Nevertheless, you or your legal 
representative can access this information by writing to Mr Hanna, the custodian 
of the Tissue Bank and guardian of the codes, who will break the code and 
present the information if so required.    
 
For tissues that has not been used in the study, and stored in the tissue bank, 
future research projects will need the approval of an NHS Research Ethics 
Committee. Copies of such approvals will be kept and archived for reference. 
 
All research that involves NHS patients or staff, information from NHS medical 
records or uses NHS patients or staff, information from NHS medical records or 
uses NHS premises or facilities must be approved by an NHS Research Ethics 
Committee before it goes ahead.  Approval does not guarantee that you will not 
come to any harm if you take part. However, approval means that the Committee 
is satisfied that your rights will be respected, that any risks have been reduced to 
a minimum and balanced against possible benefits and that you have been given 
sufficient information on which to make an informed decision to take part or not. 
 
Will I receive payment for the tissue that I donate to the tissue bank or the 
study? 
 
No, we shall treat your samples as a gift to the Imperial College Upper GI Cancer 
Tissue Bank at St Mary’s Hospital, London, and you would thus relinquish any 
interest in it. 
 
What happens if I wish to have my tissue removed from the tissue bank or 
the study? 
 
If you no longer wish your tissues to be held in the tissue bank you may withdraw 
them at any time, without justifying your decision and your future treatment will 
not be affected in any way. If you wish to have your tissue removed from the 
tissue bank please contact Mr George Hanna for suitable arrangements. 
 
Who is organising and funding body of the tissue bank and the study? 
 
The Academic Surgical Unit, Imperial College London, St Mary’s hospital, Praed 
street, London W2 1NY 
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Who has reviewed the establishment of the bank? 
 
The St Mary’s Hospital Local Research Ethics Committee.  
 
Who has reviewed the ethical considerations of the study? 
 
Brompton, Harefield and NHLI Local Research Ethics Committee 
 
Thank you for reading this information leaflet. 
 
 
Correspondence for further information: 
 
Mr George B Hanna 
Reader/Consultant Upper GI Surgeon  
Department of Biosurgery and Surgical Technology 
10th Floor, QEQM Building 
St Mary’s Hospital, London 
Praed Street,  
London   W2 1NY 
Tel:  0207 886 2124 
Fax: 0207 886 1810 
E-mail: g.hanna@imperial.ac.uk 
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Patient name, address, DOB (or ID label) 
4. Patient consent form 
 
Division of Surgery, Anaesthetics & Intensive care 
                Department of Biosurgery and Surgical Technology 
       Imperial College London 
10th Floor, QEQM Building 
St Mary’s Hospital 
Praed Street, London  W2 1NY 
       Tel: +44(0)20 7886 2125   
Fax: +44(0)20 7413 0470 
 
        
 
      Mr George Hanna PhD, FRCS 
                 Reader and Consultant Surgeon 
  g.hanna@imperial.ac.uk 
                                       www.imperial.ac.uk 
 
PATIENT CONSENT FORM 
 
 
 
 
 
 
 
 
Title of Project: 
Metabonomic Profiling of Gastric and Oesophageal Cancer 
REC Ref. 05/Q0404/73  
Version: 2 
Principal investigator: 
Mr GB Hanna PhD FRCS MErgS 
Reader and Consultant  Upper GI Surgeon 
Imperial College London, St Mary’s Hospital. 
Assistant: 
Mr Danny Yakoub MSc MRCSEd 
Clinical Research Fellow, Imperial College London 
 
I confirm that I have read and understood the information leaflet dated 
...../....../.............  for the above study and have had the opportunity to ask 
questions. 
F   F 
YES         NO 
I understand that I may withdraw consent to my tissue being included in 
the study at any time without justifying my decision and without affecting 
my normal care and medical management. 
F   F 
YES         NO 
I agree to donate the tissue samples as detailed below and allow their 
use in the medical research as described in the Patient Information 
Leaflet.   
F   F 
YES         NO 
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I understand that sections of any of my medical records may be looked at 
by responsible individuals from the research team, or from regulatory 
authorities where it is relevant to my taking part in research.  I give 
permission for these individuals to have access to my records. 
F   F 
YES         NO 
I give consent to the use of my tissues in future research projects if an 
unanticipated use emerges, which is not described in this information 
leaflet  
 
F   F 
YES         NO 
I understand that tissue samples will not be used to undertake any 
genetic tests, results of which may have adverse consequences on my or 
my family’s insurance or employment.  
F   F 
YES         NO 
I agree on the use of my tissue samples in genetic research.  F   F 
YES         NO 
I understand that the tissue is a gift and that I will not benefit from any 
intellectual property privilege that results from the use of the tissues in 
research studies. 
 
I would like to be contacted should the result of any research carried out 
on my tissue yield new findings that may have an impact on my care 
 
F   F 
YES         NO 
 
F   F 
YES         NO 
 
The samples which I hereby consent to donate are:  
a. Pre-operative blood and urine samples 
 
b. Pre-operative tissue biopsy samples produced along the course of my 
assessment and diagnosis plan including endoscopic biopsies.              
 
c. Intra-operatively removed surgical specimen containing tumour or 
tumour invaded tissues, which are removed as a part of the surgical 
operation planned for my treatment.                                                               
d. Post operative blood and urine samples during the course of my follow 
up.                                                                                   
 
F   F 
YES         NO 
 
F   F 
YES         NO 
 
F   F 
YES         NO 
F   F 
YES         NO 
 
_______________________ ________________                  ____________________ 
Name of Patient  Date Signature 
 
________________________ ________________                  ____________________ 
Researcher Date Signature 
 
Original for researcher / tissue bank, 1 copy for patient, 1 copy for hospital notes 
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5. Control candidate information sheet 
 
             Division of Surgery, Anaesthetics & Intensive care 
 Department of Biosurgery and Surgical Technology 
        Imperial College London 
 10th Floor, QEQM Building 
 St Mary’s Hospital 
 Praed Street, London  W2 1NY 
        Tel: +44(0)20 7886 2125   
 Fax: +44(0)20 7413 0470 
 
        
 
      Mr George Hanna PhD, FRCS 
                 Reader and Consultant Surgeon 
  g.hanna@imperial.ac.uk 
                                       www.imperial.ac.uk 
 
 
CONTROL CANDIDATE INFORMATION LEAFLET 
 
Title of Project: 
Metabonomic Profiling of Gastric and Oesophageal Tissues 
REC Ref. 05/Q0403/165 
Version 3 
 
Principal investigator: 
Mr GB Hanna PhD FRCS MErgS 
Reader and Consultant Upper GI Surgeon 
Imperial College London, St Mary’s Hospital, London. 
Co-Investigator: 
Mr Danny Yakoub MSc MRCSEd 
Clinical Research Fellow, Imperial College London 
  
Date:     /       /                      
 
Dear Sir/Madam 
 You are being invited to take part in our study titled: “Metabonomic 
Profiling of Gastric and Oesophageal Tissues”. Please read the following 
information carefully and discuss it with others if you wish.  Ask us if there is 
anything that is not clear or if you would like more information.  Take time to 
decide whether or not you wish to participate.  Thank you for reading this 
information sheet. 
 
What are the details of the project? 
The study involves collecting tissue, blood and urine samples to be analysed 
using special devices, in order to detect compounds specific to gastric and 
oesophageal tissues. This is planned to be done through comparison between 
patients with various upper GI diseases and those who do not have it as a control 
group from which you are a candidate. Samples will be stored in a tissue bank 
and later processed in our research project.  
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What will be the use of the collected samples? 
As a control candidate, your tissues and other samples will be compared with 
those of other diseases patients’ samples, to detect these compounds specific to 
each disease. This will help our understanding of oesophageal and gastric 
diseases and trying to find new treatments. Also it might be used as a potential 
tool for diagnosis in the future.  
 
Why have I been chosen? 
You have been chosen because you are having a diagnostic upper GI 
endoscopy. 
 
Do I have to take part? 
Taking part in the research is entirely voluntary. It is up to you to decide whether 
or not to take part.  If you do decide to take part you will be given this information 
sheet to keep and be asked to sign a consent form. If you decide to take part you 
are still free to withdraw at any time and without giving a reason.  A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of 
care you receive, now or in the future. 
 
What do I have to do? 
Nothing, except to agree to make a gift to us of two specimens of tissue obtained 
during your endoscopy, in addition to blood and urine samples. And also permit 
us to keep a copy of your hospital records containing details of your blood tests 
results, radiography reports and other documents explaining your condition. 
 
How much of my tissues will be taken? 
A spoon-full of blood, ½ a cup of urine and bits of tissue in the size of a pin head. 
  
What will happen to the tissues? 
Tissues will first be preserved in the tissue bank. Then they will be processed 
and prepared for analysis through the use of a magnetic resonance device to 
define types and amounts of compounds within the tissues. After the completion 
of the study, we would like to retain the blood/tissue samples for possible future 
research at a future date, when new tests/techniques may be available. We 
would not contact you again for further permission before doing this. If you agree 
to take part in this study, you will also be giving consent for possible future use of 
the sample; this is why we ask you to make a gift of them. Samples will remain 
the property of the Academic Surgical Unit - St Mary’s Hospital Upper Gastro-
Intestinal Tissue Bank.  
No genetic, HIV, Hepatitis B or other communicable disease testing will be done 
on the specimens collected. The principal investigator Mr GB Hanna is the 
named custodian of all tissue specimens. Sections of the specimens may be 
used for future research purposes.  
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Will I be contacted again in the future? 
You need to indicate in the consent form whether or not you would like to be 
contacted should the result of any research carried out on your tissue yield new 
findings that may have an impact on your care; This information can be 
discussed with you by your hospital Consultant. The, information about your 
tissues will be available for you at any time through contacting the Tissue Bank 
Custodian, Mr Hanna. 
 
What if something goes wrong? 
We do not believe you would be harmed by donating tissue to the study. There is 
no additional intervention or change in your treatment plan implemented if you 
choose to participate. If you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms would be 
available to you. 
 
Who will have access to my tissue and how will confidentiality be 
maintained? 
Samples will be stored in the Academic Surgical Unit – St Mary’s Hospital Upper 
Gastro-Intestinal Tissue Bank and access to your samples will be only available 
through it. The named custodian is Mr George Hanna, who is also the chief 
investigator in this study will hold responsibility of storage and management of 
your samples as well as your records. Researchers under Mr George Hanna’s 
direct supervision or after his approval may also have access to the tissue 
samples. The handling of your tissue samples will be treated with strict 
confidentiality under the Data Protection Act. All samples will be coded and 
pseudonymised before transfer to other research partners, so that you cannot be 
identified from your tissue sample. The custodian will be responsible for keeping 
proper records of all uses that have been made of the material, whether by 
himself or by others. Users of pseudonymised samples will not attempt to identify 
individual research participants. The stored data will be coded. Nevertheless, you 
or your legal representative can access this information by writing to Mr Hanna, 
the custodian of the Tissue Bank and guardian of the codes, who will break the 
code and present the information, if so required.    
 
For samples that have not been used in the study, and stored in the tissue bank, 
future research projects will need the approval of an NHS Research Ethics 
Committee. Copies of such approvals will be kept and archived for reference. All 
research that involves NHS patients or staff, information from NHS medical 
records or uses NHS patients or staff, information from NHS medical records or 
uses NHS premises or facilities must be approved by an NHS Research Ethics 
Committee before it goes ahead which means that the Committee is satisfied that 
your rights will be respected, that any risks have been reduced to a minimum and 
balanced against possible benefits and that you have been given sufficient 
information on which to make an informed decision to take part or not. 
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Will I receive payment for the tissue that I donate to the tissue bank or the 
study? 
No, we shall treat your samples as a gift to the Imperial College Upper GI  Tissue 
Bank at St Mary’s Hospital, London, and you would thus relinquish any interest in 
it. 
 
What happens if I wish to have my tissue removed from the tissue bank or 
the study? 
If you no longer wish your tissues to be held in the tissue bank, you may 
withdraw them at any time, without justifying your decision and your future 
treatment will not be affected in any way. If you wish to have your tissues 
removed from the tissue bank please contact Mr George Hanna for suitable 
arrangements. 
 
Who is organising and funding body of the tissue bank and the study? 
 
The Academic Surgical Unit, Imperial College London, St Mary’s hospital, Praed 
street, London W2 1NY 
 
Who has reviewed the establishment of the bank? 
 
The St Mary’s Hospital Local Research Ethics Committee.  
 
Who has reviewed the ethical considerations of this study? 
 
Brompton, Harefield and NHLI Local Research Ethics Committee 
 
Thank you for reading this information leaflet. 
 
If you agree to participate, please bring the signed consent form along with 
you on the day of your planned endoscopy. 
 
Correspondence for further information: 
 
Mr George B Hanna 
Reader/Consultant Upper GI Surgeon  
Department of Biosurgery and Surgical Technology  
10th Floor, QEQM Building 
St Mary’s Hospital, London 
Praed street,  
London   W2 1NY 
Tel:  0207 886 2124 
Fax: 0207 886 1810 
E-mail: g.hanna@imperial.ac.uk 
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Patient name, address, DOB (or ID label) 
6. Control candidate consent form 
 
Division of Surgery, Anaesthetics & Intensive care 
                Department of Biosurgery and Surgical Technology 
       Imperial College London 
10th Floor, QEQM Building 
St Mary’s Hospital 
Praed Street, London  W2 1NY 
       Tel: +44(0)20 7886 2125   
Fax: +44(0)20 7413 0470 
 
        
 
      Mr George Hanna PhD, FRCS 
                 Reader and Consultant Surgeon 
  g.hanna@imperial.ac.uk 
                                       www.imperial.ac.uk 
 
CONTROL CANDIDATE CONSENT FORM 
 
 
 
 
 
 
 
 
 
Title of Project: 
Metabonomic Profiling of Gastric and Oesophageal Tissues 
REC Ref. 05/Q0403/165 
Version: 3 
 
Principal investigator: 
Mr GB Hanna PhD FRCS MErgS 
Reader and Consultant Upper GI Surgeon 
Imperial College London, St Mary’s Hospital, London. 
Co-investigator: 
Mr Danny Yakoub MSc MRCSEd 
Clinical Research Fellow, Imperial College London 
 
 Please initial boxes as applicable 
I confirm that I have read and understood the information leaflet 
dated...../....../.............  for the above study and have had the opportunity to 
ask questions. 
F   F 
YES         NO 
I understand that I may withdraw consent to my tissue being included in the 
study at any time without justifying my decision and without affecting my 
normal care and medical management. 
F   F 
YES         NO 
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I agree to donate the tissue samples as detailed below and allow their use 
in the medical research as described in the Information Leaflet.   F   F 
YES         NO 
I understand that sections of any of my medical records may be looked at 
by responsible individuals from the research team or from regulatory 
authorities where it is relevant to my taking part in research.  I give 
permission for these individuals to have access to my records. 
F   F 
YES         NO 
I give consent to the use of my tissues in future research projects if an 
unanticipated use emerges, which is not described in this information 
leaflet  
 
F   F 
YES         NO 
I understand that tissue samples will not be used to undertake any genetic 
tests, results of which may have adverse consequences on my or my 
family’s insurance or employment.  
F   F 
YES         NO 
  
I understand that the tissue is a gift and that I will not benefit from any 
intellectual property privilege that result from the use of the tissues in 
research studies. 
 
I would like to be contacted should the result of any research carried out on 
my tissue yield new findings that may have an impact on my care 
 
F   F 
YES         NO 
 
F   F 
YES         NO 
 
The samples which I hereby consent to donate are:  
 
a. Pre-endoscopy blood and urine samples 
 
b. Endoscopy tissue biopsy samples produced along the course of my 
  assessment and diagnosis plan.              
 
 
 
F   F 
YES         NO 
 
F   F 
YES         NO 
 
 
________________________ ________________                  ____________________ 
Name of Patient  Date Signature 
 
________________________ ________________                  ____________________ 
Researcher Date Signature 
 
Original for researcher / tissue bank, 1 copy for patient, 1 copy for hospital notes 
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Appendix 3. Snap shot of the extraction table used to 
summarize the data before analysis 
 
Sample number 1 2 3 
Patient number 29 120 1 
Sample Bank code M-29-1 H1-9-1 M-1-1 
MatLab code 10102 20201 10201 
SIMCA code OSCRG_001 JACSG_002 OACSG_003 
Sample type (tumour=1, N Prox st=2, N dis st=3, N 
oes=4) 1 1 1 
Chemo state   (0=nochemo,  1=post chemo) 0 1 1 
Pathological type of ptnt(0=none, 1=Ad, 2=Sq) 2 1 1 
Class in field study (MM=1,  NM=2, NN=3, OTHER =4) 4 1 1 
Included in field study (0=No, 1=Yes) 0 1 1 
Surgical/endoscopic (endosc=0, surgical =1) 0 1 0 
Anaesthetic (0=none, 1=LA, 2=GA) 2 2 2 
T Stage 2 2 3 
N stage 0 0 0 
Grade  (Well=1, Moderate=2, Poor=3, undiff=4) 2 3 2 
Age 65 51 70 
Sex (0=F,   1=M) 1 1 1 
sample weight (mg) 18.1 18.1 29.9 
 
   
 
   
Metabolites 
   
Lactate (1.315 - 1.4) 1.51E+06 3.33E+06 1.66E+06 
Lysine (1.64 - 1.78) 2.81E+05 3.24E+05 3.68E+05 
Glutamine  (2.33-2.38) 2.06E+05 1.93E+05 2.11E+05 
Glutathione (2.54-2.58) 1.42E+05 26115 37381 
Creatine (3.025 - 3.045) 1.74E+05 1.14E+05 2.23E+05 
Total cholines (3.18 - 3.24) 3.99E+05 1.18E+06 8.20E+05 
Taurine (3.245-3.285) 3.81E+05 4.15E+05 4.13E+05 
Scylloinositol (3.34-3.36) 23186 50171 36097 
Uracil  (5.88 - 5.93) 11317 12018 14223 
Tyrosine (6.87-6.93) 23272 22024 27197 
Adenines (8.255 - 8.275) 3663.5 2929.1 5269 
    
    
Bucketed data 
   
0.80487 1944.2 5675.1 4880.2 
0.81488 2503.5 5805.1 5779.7 
0.82488 3387.2 6704.7 7342.2 
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Appendix 4. Table 15. Sample weights in sequence of analysis 
Sample 
No. 
Weight
(mg) 
Sample 
No. 
Weight
(mg) 
Sample 
No. 
Weight
(mg) 
Sample 
No. 
Weight
(mg) 
Sample 
No. 
Weight
(mg) 
Sample 
No. 
Weight
(mg) 
1 18.1 53 36.3 105 31.2 157 27.5 209 49.1 261 53.2 
2 18.1 54 40.2 106 69.3 158 35 210 38.4 262 57.5 
3 29.9 55 51.7 107 30.4 159 22.2 211 27 263 43.9 
4 29.9 56 44.2 108 33.7 160 39 212 34.7 264 48.4 
5 31.6 57 38.7 109 11 161 16.8 213 53 265 58.5 
6 23.8 58 33.2 110 48.7 162 32.2 214 37.6 266 58.5 
7 30.3 59 21.7 111 39.7 163 45.7 215 44.7 267 60 
8 37.8 60 17.7 112 42.7 164 49.8 216 34.1 268 54.1 
9 35.7 61 54.7 113 34.2 165 28.2 217 33.2 269 40.4 
10 30.5 62 24.7 114 27.7 166 59.1 218 49.8 270 25.2 
11 31.2 63 38.7 115 44.6 167 37.4 219 57 271 36.4 
12 37.8 64 47.3 116 32.6 168 47.2 220 22.5 272 53.2 
13 31.2 65 56.7 117 22.6 169 31 221 48 273 55.8 
14 49.6 66 41.2 118 30.2 170 36.2 222 53.6 274 47.8 
15 57.4 67 41.2 119 39.7 171 58.4 223 49.1 275 41.8 
16 29.7 68 26.7 120 33.3 172 28 224 42.7 276 45.8 
17 38.4 69 27.7 121 30.5 173 41.9 225 42.9 277 42.2 
18 27.7 70 47.7 122 27.7 174 38.6 226 50.5 278 48.8 
19 38.6 71 58.2 123 31 175 29.2 227 31.9 279 40.3 
20 48.6 72 43.2 124 66.2 176 43.6 228 35.7 280 63.1 
21 21.1 73 32.2 125 31.2 177 39.2 229 56.8 281 53.5 
22 38.2 74 26.3 126 42.2 178 31.2 230 42.7 282 55.4 
23 26.9 75 40 127 49.7 179 45.3 231 43.8   
24 24.4 76 35.7 128 11.8 180 23 232 48.3   
25 35.6 77 23.5 129 33.2 181 23.4 233 41.9   
26 33.4 78 46 130 39.2 182 20.4 234 42.4   
27 27.7 79 38.7 131 29.2 183 22.3 235 48.8   
28 23.6 80 32.5 132 24.9 184 19.6 236 45.3   
29 28.7 81 47 133 44.4 185 18.9 237 49.4   
30 22.2 82 44.3 134 29.6 186 17.7 238 47.4   
31 29.4 83 39.7 135 31.7 187 17.2 239 68.6   
32 28.2 84 53.9 136 43.4 188 16.5 240 43.2   
33 35 85 33.1 137 32 189 17.5 241 53.2   
34 35.1 86 27 138 37.9 190 19.5 242 53.2   
35 38.3 87 24.8 139 44.7 191 20 243 58.7   
36 38.1 88 20.4 140 34.4 192 19.6 244 49.4   
37 25.6 89 24.8 141 31.4 193 18 245 48.8   
38 24.6 90 24.2 142 42.3 194 22.3 246 37.2   
39 20.8 91 20.4 143 31.7 195 26 247 53.2   
40 24.4 92 29.5 144 36.9 196 24.3 248 41.6   
41 41.2 93 43.2 145 49.9 197 24.3 249 48.4   
42 26.6 94 25.8 146 39.9 198 22.1 250 57.2   
43 35.2 95 34.8 147 38 199 23.3 251 47.1   
44 26.2 96 32.7 148 39.5 200 38 252 35.9   
45 28.7 97 30.2 149 32.8 201 33.4 253 43.7   
46 42.5 98 32.5 150 41.2 202 30.2 254 51.2   
47 36.7 99 27.9 151 28.4 203 40.3 255 49   
48 54.2 100 6.4 152 44.2 204 34.1 256 64.9   
49 36.5 101 17.6 153 52.1 205 28.2 257 57.2 Average 36.9 
50 42.6 102 6.9 154 8 206 58.2 258 29.4 Range 6.4 - 
51 42.6 103 8.2 155 24.9 207 33.4 259 43.8  69.3 
52 44.2 104 18.7 156 32.1 208 58.1 260 50.6   
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Appendix 5. Semiquantitative comparison of metabolites in 
oesophageal sample groups 
 
Table 16. All carcinoma tissue versus all normal oesophageal tissues 
Peak centre PPM 
range 
Peak shape Compound Trend in spectra P-value 
0.09 0.85-0.93 Multiplet (broad) CH3 lipids Nor = cancer 0.64 
0.96, 0.91, 
1.01 
0.94-1.02 Triplet, 2 doublets A Acids(Isoleu,Leu) Cx > Nor 0.04 
1.043 1.03-1.075 Doublet Amino Acids(val,pro) Nor = cancer 0.11 
1.2 1.19-1.21 Doublet A-hydroxy-butyrate Nor = cancer 0.2 
1.305 1.26-1.312 Singlet (broad) Ch2 lipids Nor = cancer 0.72 
1.33 1.314-
1.343 
Doublet Lactate Cx>Nor <0.001 
1.47 1.465-
1.492 
Doublet alanine Nor = cancer 1.0 
1.72 1.65-1.78 Multiplet (broad) CH2-lipids Nor = cancer 0.13 
1.92 1.88-1.95 Singlet acetate Nor = cancer 0.64 
2.05 2-2.09 Multiplet (broad) lipids Nor = cancer 0.18 
2.14 2.1-2.19 Multiplet (broad) lipids Nor > Cx 0.04 
2.353 2.3-2.39 Multiplet/quartet glutamine Nor > Cx 0.01 
2.56 2.54-2.58 Multiplet/triplet glutathione Nor > Cx 0.02 
2.801 2.78-2.81 Doublet ?δ-amino-levul Cx > Nor 0.095 
2.83 2.81-2.845 Multiplet ?aspartate Cx > Nor 0.085 
2.96 2.93-2.98 Multiplet Asparatate/Α-keto glutarate Nor = cancer 0.13 
3.01 2.99-3.025 Singlet lysine Nor = cancer 0.81 
3.04 3.028-
3.046 
Singlet creatine Cx > Nor 0.07 
3.204 3.19-3.21 Singlet Free choline Cx > Nor 0.002 
3.223 3.214-
2.224 
Singlet Phophocholine Cx > Nor 0.03 
3.23 3.2245-
3.24 
Singlet Glycerophophocholine Cx > Nor 0.02 
3.263 3.24-3.3 Triplet Taurine+Myoinositol Nor = cancer 0.53 
3.426 3.4-3.6 Doublet Scylloinositol Cx > Nor 0.03 
3.525, 3.542 3.51-3.55 Double doublets Myoinositol Cx > Nor 0.049 
3.56 3.55-3.565 Singlet glycine Nor = cancer 0.93 
3.606 3.585-
3.615 
Singlet Glyceraldehyde/β-glucose Nor = cancer 0.24 
3.779 3.73-3.8 Triplet (broad) Glycine/ α-Glucose/α-CH Nor = cancer 0.26 
3.933 3.925-3.94 Singlet creatine Nor > Cx 0.06 
3.986 3.965-
4.005 
Multiplet (broad) Phophoryl-ethanolamine Nor = cancer 0.26 
4.06 4.045-4.08 Singlet/triplet(broad) choline/myoinositol Nor = cancer 0.56 
4.118 4.09-4.14 Quartet lactate Nor > Cx 0.002 
4.17 4.15-4.2 Singlet (broad) ?β-OH-butyrte Nor = cancer 0.98 
4.66 4.63-4.68 Doublet β -glucose Nor >cancer 0.05 
5.232 5.22-5.245 Doublet α-glucose Nor >cancer 0.046 
5.33 5.28-5.38 Multiplet broad Fatty acids Nor = cancer 0.93 
5.42 5.395-5.44 Multiplet α -Glu-1-X Nor = cancer 0.15 
5.797 5.785-5.81 Doublet Uracil Cx > Nor 0.053 
5.9 5.88-5.93 2 Singlets, Doublet Uracil Cx > Nor 0.03 
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5.98 5.96-6 Multiplets ?cytosine Nor = cancer 0.24 
6.521 6.51-6.53 Singlet Fumarate Nor = cancer 0.4 
6.891 6.87-6.91 Doublet Tyrosine Cx > Nor 0.02 
7.187 7.15-7.2 Doublet Tyrosine Nor = cancer 0.31 
7.376 7.355-
7.395 
Doublet Phenyl alanine Cx > Nor 0.005 
7.423 7.405-
7.435 
Doublet/triplet tryptophan Cx > Nor 0.01 
7.53 7.515-7.54 Doublet Tryptophan/tryptamine Cx > Nor 0.04 
7.888 7.86-7.9 Doublet uroconate Nor = cancer 0.64 
7.965 7.94-7.99 Multiplet ?guanosine Nor = cancer 0.64 
8.186,208,239 8.17-
8.24,8.36 
3 singlets adenine Nor > Cx 0.002 
Nor=normal mucosa from cancer patients, Cx=tumour tissue 
 
 
 
Table 17. All oesophageal versus junctional cancer tissues 
Peak centre PPM 
range 
Peak shape Compound Trend in 
spectra 
P-value 
0.09 0.85-0.93 Multiplet (broad) CH3 lipids variable 0.32 
0.96, 0.91, 
1.01 
0.94-1.02 Triplet, 2 doublets A Acids(Isoleu,Leu) Oes = Jun 0.66 
1.043 1.03-1.075 Doublet Amino Acids(val,pro) Oes = Jun 0.93 
1.2 1.19-1.21 Doublet A-hydroxy-butyrate Oes = Jun 0.12 
1.305 1.26-1.312 Singlet (broad) Ch2 lipids variable 0.42 
1.33 1.314-
1.343 
Doublet lactate variable 0.9 
1.47 1.465-
1.492 
Doublet alanine Oes = Jun 0.79 
1.72 1.65-1.78 Multiplet (broad) CH2-lipids Oes = Jun 0.66 
1.92 1.88-1.95 Singlet acetate Oes = Jun 1.0 
2.05 2-2.09 Multiplet (broad) lipids Jun > Oes 0.052 
2.14 2.1-2.19 Multiplet (broad) lipids variable 0.19 
2.353 2.3-2.39 Multiplet/quartet glutamine variable 0.25 
2.56 2.54-2.58 Multiplet/triplet glutathione Oes = Jun 0.66 
2.801 2.78-2.81 Doublet ?δ-amino-levul variable 0.66 
2.83 2.81-2.845 Multiplet ?aspartate variable 0.66 
2.96 2.93-2.98 Multiplet Asparatate/Α-keto glutarate Jun > Oes 0.08 
3.01 2.99-3.025 Singlet lysine variable 0.9 
3.04 3.028-
3.046 
Singlet creatine variable 0.9 
3.204 3.19-3.21 Singlet Free choline Oes = Jun 0.66 
3.223 3.214-
2.224 
Singlet Phophocholine Oes = Jun 1.0 
3.23 3.2245-
3.24 
Singlet Glycerophophocholine Oes = Jun 0.79 
3.263 3.24-3.3 Triplet Taurine+Myoinositol Oes = Jun 0.54 
3.426 3.4-3.6 Doublet Scylloinositol variable 0.12 
3.525, 3.542 3.51-3.55 Double doublets Myoinositol Oes = Jun 0.43 
3.56 3.55-3.565 Singlet glycine variable 0.54 
3.606 3.585-
3.615 
Singlet Glyceraldehyde/β-glucose Oes = Jun 1.0 
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3.779 3.73-3.8 Triplet (broad) Glycine/ α-Glucose/α-CH variable 0.66 
3.933 3.925-3.94 Singlet creatine Oes = Jun 0.4 
3.986 3.965-
4.005 
Multiplet (broad) Phophoryl-ethanolamine Oes = Jun 0.33 
4.06 4.045-4.08 Singlet/triplet(broad) choline/myoinositol Oes = Jun 0.33 
4.118 4.09-4.14 Quartet lactate Oes = Jun 0.9 
4.17 4.15-4.2 Singlet (broad) ?β-OH-butyrte Oes = Jun 0.54 
4.66 4.63-4.68 Doublet β -glucose Oes = Jun 0.66 
5.232 5.22-5.245 Doublet α-glucose Oes = Jun 0.79 
5.33 5.28-5.38 Multiplet broad Fatty acids variable 0.9 
5.42 5.395-5.44 Multiplet α -Glu-1-X variable 0.66 
5.797 5.785-5.81 Doublet Uracil variable 0.43 
5.9 5.88-5.93 2 Singlets, Doublet Uracil variable 0.08 
5.98 5.96-6 Multiplets ?cytosine Oes = Jun 0.66 
6.521 6.51-6.53 Singlet Fumarate Oes > Jun 0.052 
6.891 6.87-6.91 Doublet Tyrosine Oes = Jun 1.0 
7.187 7.15-7.2 Doublet Tyrosine Oes = Jun 1.0 
7.376 7.355-
7.395 
Doublet Phenyl alanine variable 0.66 
7.423 7.405-
7.435 
Doublet/triplet tryptophan Oes = Jun 0.79 
7.53 7.515-7.54 Doublet Tryptophan/tryptamine Oes = Jun 0.54 
7.888 7.86-7.9 Doublet uroconate Oes = Jun 0.54 
7.965 7.94-7.99 Multiplet ?guanosine Oes = Jun 0.43 
8.186,208,239 8.17-
8.24,8.36 
3 singlets adenine Oes = Jun 0.66 
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Appendix 6. Immuno-histochemical comparison between 
healthy controls and normal mucosa from cancer patients 
 
Healthy 
patients 
% 
positive 
% 
positive 
% 
positive 
% 
positive  
Cancer 
patients 
% 
positive 
% 
positive 
% 
positive 
% 
positive 
n = 54 ki-67 TUNEL mucin p53  n = 34 ki-67 TUNEL mucin p53 
1 2.2 1.1 0 0  1 3.1 3 0 0 
2 3.3 2.5 0 0  2 2.3 2.3 0 0 
3 1 1.8 0 0  3 4.5 1.3 0 0 
4 4.9 3.7 0 0  4 5.4 3.8 0 0 
5 7.1 3.3 0 0  5 3.6 3.6 0 0 
6 1.9 3.8 0 0  6 3.5 5 0 0 
7 2.2 5.8 0 0  7 2.4 1.1 0 0 
8 3.8 4.6 0 0  8 1.1 0.5 0 0 
9 4.9 4.4 0 0  9 5.2 4.3 0 0 
10 2.9 2.8 0 0  10 5.3 3.7 0 0 
11 6.7 2.2 0 0  11 6.2 5.2 0 0 
12 4.4 0 0 0  12 3.4 1.9 0 0 
13 3.3 0.9 0 0  13 4.8 1.1 0 0 
14 3.2 1.3 0 0  14 4.9 1.5 0 0 
15 4.9 3.3 0 0  15 3.7 1.8 0 0 
16 1.1 5.1 0 0  16 5.1 2.5 0 0 
17 3.5 0.8 0 0  17 5 3.6 0 0 
18 3.9 1.5 0 0  18 3.4 4.6 0 0 
19 4.8 3.1 0 0  19 2.3 2.1 0 0 
20 5.1 2 0 0  20 8.1 1.9 0 0 
21 4.1 4.1 0 0  21 5.3 2.1 0 0 
22 3.2 1.6 0 0  22 4.5 4.2 0 0 
23 3.3 6.1 0 0  23 6.7 3.8 0 0 
24 4.6 3.6 0 0  24 5.9 1.8 0 0 
25 5.1 3.6 0 0  25 6.1 1.6 0 0 
26 4.4 1.9 0 0  26 4.9 2.6 0 0 
27 1.4 1.1 0 0  27 0.6 2.2 0 0 
28 2.6 0 0 0  28 4.1 2.8 0 0 
29 4.9 2.6 0 0  29 3.6 5.1 0 0 
30 7.1 3.3 0 0  30 3.4 3.8 0 0 
31 5.5 0.8 0 0  31 4.4 3.3 0 0 
32 1.8 3.3 0 0  32 3.1 1.1 0 0 
33 4.2 2.6 0 0  33 5.3 3.7 0 0 
34 3.9 0.2 0 0  34 4.7 0 0 0 
35 4.4 4.4 0 0  Average 4.29 2.73 0 0 
36 4.9 3 0 0       
37 5.1 0.5 0 0       
38 3.9 0.7 0 0       
39 4.4 4.4 0 0       
40 4.8 2.7 0 0       
41 4.4 4.1 0 0       
42 4.9 3.9 0 0   Marker Ki67 TUNEL  
43 6.2 1.8 0 0   p-value 0.33 0.82  
44 2.8 0 0 0       
45 7.5 2.6 0 0       
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46 4.4 3.8 0 0       
47 4 2.2 0 0       
48 2.8 3.3 0 0       
49 1.9 4.6 0 0       
50 2.5 4.4 0 0       
51 1.8 1.8 0 0       
52 2.6 3.2 0 0       
53 4.6 3.6 0 0       
54 4.9 0 0 0       
Average 3.96 2.66 0 0       
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Appendix 7. Intra and inter observer reliability testing among 
pathologists for determination of Mandard grading of tissue 
response to chemotherapy 
 
Pathologist Kappa Standard error 
Pathologist 1 0.45 0.066 
Pathologist 2 0.48 0.064 
Pathologist 3 0.49 0.062 
Pathologist 4 0.47 0.065 
Table 18. Intraobserver agreement on Mandard regression grading (MRG) after 
neoadjuvant therapy  
 
As shown from Table 16 the level of reproducibility as for the intraobserver variation, 
ranged between 0.45 – 0.49, which indicated only a fair agreement according to the 
Kappa classification, with the standard error between 0.062 – 0.065.  
 Test 1  Test 2  
Pathologists Kappa Standard error Kappa Standard error 
Pathologist 1 vs. 2 0.33 0.069 0.38 0.066 
Pathologist 1 vs. 3 0.32 0.066 0.27 0.066 
Pathologist 1 vs. 4 0.31 0.066 0.33 0.066 
Pathologist 2 vs. 3 0.44 0.064 0.31 0.065 
Pathologist 2 vs. 4 0.36 0.067 0.32 0.067 
Pathologist 3 vs. 4 0.37 0.064 0.27 0.064 
Table 19. Interobserver reproducibility Mandard regression grading (MRG) after 
neoadjuvant therapy 
 
As for the level of agreement when the results were compared again among the 4 
pathologists using Weighted Kappa statistics, the range of agreement went from a 
minimum of 0.27, which is considered a weak agreement, up to 0.44, which is again 
considered fair agreement, with the range of standard error between 0.064 – 0.069. 
